TRICYCLICAL PYRROL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND USE AS KINASE INHIBITORS

专利摘要:
tricyclic pyrrole derivatives, process for their preparation and their use as kinase inhibitors. The present invention relates to tricyclic pyrrole derivatives of formula (I) which modulate protein kinase activity and therefore are useful in the treatment of diseases caused by unregulated protein kinase activity. the present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising such compounds, and methods for treating diseases using such compounds or pharmaceutical compositions.
公开号:BR112013018515B1
申请号:R112013018515-5
申请日:2012-01-19
公开日:2021-06-29
发明作者:Marina Caldarelli；Mauro Angiolini；Italo Beria；Maria Gabriella Brasca；Francesco Casuscelli；Roberto d'Alessio；Andrea Lombardi Borgia
申请人:Nerviano Medical Sciences S.R.I；
IPC主号:

专利说明:

The present invention relates to tricyclic pyrrole derivatives, a process for their preparation, pharmaceutical compositions comprising them and their use as therapeutic agents, particularly in the treatment of cell proliferative disorders and cancer.
The compounds of this invention, therefore, are useful in treating diseases caused by unregulated protein kinase activity. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising such compounds, and methods for treating diseases using pharmaceutical compositions comprising such compounds.
Malfunctioning protein kinases (PKs) is the hallmark of numerous diseases. A large part of the oncogenes and proto-oncogenes are involved in the human cancer code for PKs. The marked activities of PKs are also implicated in many non-malignant diseases, such as benign prostatic hyperplasia, familial adenomatosis polyposis, neurofibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis, glomerulonephritis and postpartum stenosis and restenosis. -surgical.
PKs also imply inflammatory conditions and the multiplication of viruses and parasites. PKs may also play an important role in the pathogenesis and development of neurodegenerative diseases.
For a general reference to the malfunction or dysregulation of PKs, see, for example, Current Opinion in Chemical Biology 1999, 3, 459-465 and carcinogenesis 2008, 29, 1087-1091.
The use of mitotic inhibitors in cancer therapy is a widely accepted clinical strategy for the treatment of a wide range of human tumors. Taxanes (paclitaxel and docetaxel) and vinca alkaloids (vincristine and vinblastine) work by stabilizing or destabilizing microtubules with catastrophic consequences in cells that progress through mitosis. They are first-line therapeutics for many types of tumors and second-line for cancers of the ovaries, breast, lung, bladder and esophagus refractory to cisplatin (taxanes). However, due to the role of microtubules in processes such as cell movement, phagocytosis and axonal transport, certain toxicities such as peripheral neuropathy are often observed with these agents. Progression through mitosis is a requirement of all proliferating cells, and consequently cancer therapies that target mitosis are generally applicable to a wide range of tumor types. Several protein kinases play key roles in orchestrating the cell cycle and some of these are already undergoing targeted treatments in oncology adjustment including CDK-2 and Aurora-A. The fidelity of mitoses is of prime importance and there are several "checkpoints" in normal cells to maintain chromosome integrity during the cell cycle.
The spindle checkpoint (SAC) is specifically required for proper chromosomal segregation in two daughter cells in cell division. It ensures that sister chromatids aligned on the metaphase plate do not separate prior to bipolar attachment of all duplicated chromosomes to the mitotic spindle (Reviewed in Musacchio A. and Salmon D. Nat Rev Mol Cell Biol, 8 May(5): 379 -93, 2007).
Even a single misaligned chromosome is enough to trigger the SAC signal, it is a well-regulated pathway that ultimately results in inhibition of the anaphase or cyclosome promoter complex (APC/C) mediated by polyubiquitination and degradation of two major mitotic components: cyclin BI and securin. Securin is specifically required to achieve anaphase separation and transition of the sister chromatids, instead, cyclin BI inactivates the CDK1 master mitotic kinase by promoting mitotic exit. (Reviewed in Musacchio A. and Salmon D. Nat Rev Mol Cell Biol, May 8(5); 379-93, 2007).
A large group of proteins have already been identified to play a role in SAC functions: human MPS1 kinase (monopolar spindle 1) (also known as TTK) certainly plays a more important role. MPS1 is a well-preserved dual serine/threonine tyrosine kinase from yeast to mammals. The human genome encodes only one member of the MPS1 gene family, which does not have great sequence similarities with other protein kinases.
MPS1 is a cell cycle-regulating enzyme that is up-regulated and activated in mitosis after phosphorylation (Stucke VM, et al., Embo J. 21(7): 1723, 2002).
In Saccharomyces cerevisiae, MPS1 controls bipolar spindle body duplication (Winey M. et al., 114:745 J. Cell Biol, 1991), spindle assembly (Jones, MH et al. Curr. Biol 15:160, 2005 ) and the spindle checkpoint (Weiss and Winey, J. Cell. Biol 132:111, 1996). Rather than eukaryotes superior to MPS1 kinase activity is primarily involved in the functions and regulations of SAC (Jelluma, N. et al., Cell 132:233, 2008).
Experiments in RNA interference indicate that, in the absence of MPS1, SAC functions are compromised: mitotic length is reduced and cells divide rapidly without metaphase plate alignment, which ultimately causes aberrant aneuploidization, mitotic catastrophe, and it is no longer compatible with cell survival (Jelluma s. et al., Cell 132:233, 2008; Tighe A. et al., J Cell Biol 2008; Jelluma N. et al., Pios ONE 3 (6): e2415 , 2008) . Furthermore, to support these results, a small molecule ATP-competitor MPS1 inhibitor has been described and despite its unclear selectivity profile, has been shown to be able to disable SAC functions, inactivate onocodazole, and capture and promote death of taxol-mediated mitotic cell, mainly in tumorigenic cell lines (Schmidt et al., EMBO Rep, 6(9): 866, 2005).
Although most tumors are neuploid, MPS1 has never mutated into cancer, instead it has proliferated into several tumors of different origins, such as bladder, anaplastic, thyroid, breast, and prostate cancer (Yuan B. et al, Clin Cancer Res , 12(4): 1121, 2006). Furthermore, it was found in the signature of the 25 major genes expressed in CIN and aneuploid tumors that predict clinical outcomes in breast and lung cancer, medulloblastoma, glioma, mesothelioma and lymphoma (Carter SL et al., Nat Genet. 38(9): 1043. 2006). Finally, it is highly elevated in metastatic tumors and has been seen expressed in p53 mutated breast cancers (Bertheau P. et al., Pios Med 4 (3): e90, 2007).
Along with the fact that also other SAC components such as MAD2, BUBR1 or BUB1 have been found in different tumors (deCarcer G. et al. Curr Med Chem 14(9): 969, 2007), it appears that SAC functions might be needed and essential to maintain highly aneuploid tumor cells capable of secreting, and tumor selectivity of SAC inhibitors is predicted particularly in highly aneuploid tumors such as colon, lung and breast carcinomas (Kops GJ et al., NAT. Rev cancer, 5 :773, 2005).
Finally, induction of massive aneuploidy and SAC deregulation have been shown to reduce tumorigenesis in tumor-prone mice, supporting the hypothesis that SAC inhibition could confer tumor growth inhibition (Weaver et al., Cancer Cell 11 (1): 25, 2007). Thus, for these reasons, pharmacological attenuation of MPS1 function may have a therapeutic benefit in the treatment of various types of cancers.
Originally identified as genes activated by proviral mutagenesis in a mouse model of lymphoma, PIMs (PIM1, PIM2 and/or PIM-3 throughout this report) are serine/threonine protein kinases. PIN kinases are poorly expressed in normal tissues and highly expressed or even mutable in a discrete number of human cancers, including lymphoma, leukemia, prostate, pancreas, and gastric cancers [Shah et al. Eur. J. Cancer, 44, 2144-51, (2008)].
PIM kinases are constitutively active and their activity supports tumor cell growth in vitro and in vivo and survive by modifying an increasing number of common substrates as well as isoform-specific substrates, including various cell cycle regulators and mediators of apoptosis . PIM1 but not PIM2 also appears to mediate the addressing and migration of normal and malignant hematopoietic cells by regulating surface expression of the chemokine receptor [Brault et al. 95 Haematologica 95 1004-1015 (2010)].
There is growing evidence that PIM1 and PIM2 kinases may be involved in mediating the oncogenic effects of some oncogenes associated with acute myeloid leukemias (AML). In particular, the oncogenic role of FLT3 mutations (ITD and KD mut., present in 30% of AMLs) and/or translocations involving the MLL gene (occurring in 20% of AMLs), [Kumar, et al. J. Mol Biol 348, 183-193, (2005)]. PIM1 is more expressed in FLT3-ITD-transformed AML cells than in WT bone marrow cells. Data suggest that PIM1 as well as PIM2 inhibition may mediate the FLT3ITD-dependent killing of AML cells. Interestingly, cells transformed by FLT3 mutations conferring resistance to small molecule tyrosine kinase inhibitors were also sensitive to knockdown of PIM2, or PIM-1 and PIM-2 by RNAi [ Kim et al., Blood 105, 1759-67 , (2005)].
In addition, PIM2 has been reported to be over-expressed and associated with the progression of various malignant neoplasms that originate from the B cell lineage, such as chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (LDGCB), lymphoma. mantle cells (MCL) or myeloma [Cohen et al. Leuk. Lynphoma 94 51 2004, Huttmann et al Leukemia 20 1774 (2006)].
Interestingly, PIM and AKT/PKB appear to play partly redundant roles in mediating hematopoietic cell growth and survival, probably due to overlapping substrates such as BAD, p21WAF1/clp', p27KIP1 or Cot/Tpl-2 [Choudhary et al ., Mol Cell. 36 326-39 (2009)].
PIM kinases have been shown to control the resistance, proliferation and survival of mTOR (rapamycin) inhibition. Therefore, a combination of small molecule inhibitors targeting several surviving kinases may be essential for a powerful cancer therapeutic platform [Amaravadi R., et al. J. Clin. Invest. 2005, 115 (10) 2618-24]. Synthesis of oncogenic proteins through elF4E that binds to protein 1 (4E-BP1) appears to be independent of mTOR and controlled by PIM-2. These observations suggest that the oncogenic elF4F translation initiation complex can be blocked with small molecule PIM-2 inhibitors [Tamburini J. et al. Blood 2009, 114(8), 1718-27 and Brault L. et al. Haematologica 2010, 95 (6) 1004-1015].
Tetrahydrobenzocycloheptane derivatives known in the art as immunosuppressive agents and in the treatment and prevention of inflammatory diseases, allergic and immunological diseases are disclosed in W02009/089305. Tetrahydrocycloheptapyrimidine derivatives known in the art as protein kinase inhibitors are disclosed in WO2005/037843.
Tricyclicindole derivatives that have kinase inhibitory activity were disclosed in WO2008/065054, on behalf of the Applicant itself, some specific compounds mentioned above in document W02008/065054 are excluded from the present general formula. Despite these developments, there is still a need for effective agents to said diseases.
The present inventors have now realized that the compounds of formula (I), described below, are kinase inhibitors and therefore are useful in therapy as antitumor agents and do not have, in terms of toxicity and side effects, the aforementioned drawbacks associated with currently available antitumor drugs.
In this sense, a first objective of the present invention is to provide a substituted tricyclic compound of the formula (I) Formula (I):
where R1 is hydrogen, halogen or a linear or branched group, optionally substituted, selected from amino, C1 -C6 alkyl, C3 -C7 cycloalkyl, cycloalkyl-alkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl1; R2 is a group selected from -NR "R"', -N(OR"')R" and OR", where R" and R'" are each independently hydrogen or an optionally substituted linear or branched group selected from C1-6 alkyl. Cθ, C3-C7 cycloalkyl, cycloalkyl-alkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, or together with the nitrogen atom to which they are may form a 5- or 6-membered heteroaryl or heterocyclyl group, optionally containing an additional selected heteroatom between N, 0 and S;R3 is hydrogen or a linear or branched, optionally substituted group selected from C1 -C6 alkyl, C3 -C7 cycloalkyl, cycloalkyl-alkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl; R1 is hydrogen or a group linear or branched, optionally substituted, selected from C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, cycloalkyl-alkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl; X is a single bond or a divalent radical selected from -NR'-, -CONR'-, -NH-CO- NH-, -O-, -S-, -SO2- and -OSO2-, where R' is hydrogen or a linear or branched, optionally substituted group selected from C1-6 alkyl, C3-C7 cycloalkyl, cycloalkyl-alkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl or together with the nitrogen atom to which they are attached, RI and R' can form a 5- or 6-membered heteroaryl or a heterocyclyl group optionally containing an additional heteroatom selected from N, 0 and S; A is a group selected from -CH2-, -(CH2)2-, -(CH2)3-, -CH=CH-, -C(CH3)2-CH2- and -CH2-C(CH3)2;or a pharmaceutically acceptable salt thereof, with the proviso that the following compounds are excluded: 2-amino-9-methyl-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxylate,2-acid amino-9-methyl-6,9-dihydro-5H-pyrrole[3,2-h]quinazoline- 7-carboxylic,2-amino-9-methyl-6,9-dihydro-5H-pyrrole[3,2-h]quinazoline-7-carboxamide,ethyl 2-amino-8-phenyl-9H-pyrrole[3.2 -h]quinazoline-7-carboxylate,2-amino-8-phenyl-9H-pyrrole[3,2-h]quinazoline-7-carboxamide,2-amino-9-methyl-8-phenyl-9H-pyrrole[3 ,2-h]quinazoline-7-carboxamide, e2-amino-9-methyl-8-phenyl-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxamide.
The present invention also provides methods of synthesizing substituted tricyclics, represented by formula (I), prepared through a process consisting of standard synthetic transformations, isomers, tautomers, hydrates, solvates, complexes, metabolites, prodrugs, vehicles and N -oxides.
The present invention also provides a method for treating diseases caused by or associated with dysregulation of protein kinase activity, particularly ABL, ACK1, AKT1, ALK, AUR1, AUR2, BRK, BUB1, CDC7/DBF4, CDK2/CYCA, CHK1, CK2, EEF2K, EGFR1, EphA2, EphB4, ERK2, FAK, FGFR1, FLT3, GSK3beta, Haspin, IGFR1, IKK2, IR, JAK1, JAK2, JAK3, KIT, LCK, LYN, MAPKAPK2, MELK, MET, MNK2, MPS1, MST4, NEK6NIM1, P38alpha, PAK4, PDGFR, PDK1, PERK, PIM1, PIM2, PIM3, PKAalpha, PKCbeta, PLK1, RET, ROS1, SULU1, Syk, TLK2, TRKA, TYK, VEGFR2, VEGFR3, ZAP70, more particularly MPS1, PIM1, PIM2, PIM3 .
A preferred method of the present invention is to treat a disease caused by and/or associated with dysregulated protein kinase activity selected from the group consisting of cancer, cell proliferation disorders, viral infections, autoimmune and neurodegenerative diseases.
Another preferred method of the present invention is to treat certain types of cancer, including, but not limited to: carcinomas such as bladder, breast, colon, kidney, liver, lung, including small cell lung cancer, esophagus, gallbladder. , ovary, pancreas, stomach, neck, thyroid, prostate and skin, including squamous cell carcinoma, hematopoietic tumors of lymphoid lineage, including leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hair cell lymphoma, and Burkett's lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, myelodysplastic syndrome, and promyelocytic leukemia; tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcona; central and peripheral nervous system tumors, including astrocytoma and neuroblastoma, glioma and schwannomas; other tumors, including melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratocanthoma, thyroid follicular cancer and Kaposi's sarcoma, and mesothelioma, highly aneuploid tumors and tumors expressing the mitotic checkpoint.
Another preferred method of the present invention is for treating certain cell proliferative disorders, such as, for example, benign prostatic hyperplasia, familial adenomatosis polyposis, neurofibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis, glomerulonephritis and postsurgical stenosis and restenosis.
Another preferred method of the present invention is to treat diseases and disorders associated with autoimmune cells and disorders such as autoimmune and inflammatory diseases, for examples, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease (IBD), Crohn's disease, irritable bowel syndrome , pancreatitis, ulcerative colitis, diverticulosis, myasthenia gravis, vasculitis, psoriasis, scleroderma, asthma, allergies, systemic sclerosis, vitiligo, arthritis such as osteoarthritis, juvenile rheumatoid arthritis, ankylosing spondylitis.
Another preferred method of the present invention is to treat viral infections, in particular the prevention of AIDS developed in HIV-infected individuals.
Another preferred method of the present invention is to treat neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease.
In addition, the method of the present invention also provides tumor angiogenesis and metastasis inhibition, as well as the treatment and rejection of transplanted organs, disease due to graft versus host.
The present invention further provides for a pharmaceutical composition comprising a compound of formula (I), in combination with known anticancer treatments such as radiation therapy or chemotherapy regimen in combination with cytostatic or cytotoxic agents, antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon-like agents, cyclooxygenase inhibitors (eg, COX-2 inhibitors), metalomatrixprotease inhibitors, telomerase inhibitors, tyrosine kinase inhibitors, anti-growth factor receptor agents, anti-HER agents, agents anti-EGFR, anti-angiogenesis agents, farnesyl transferase inhibitors, ras-raf signal transduction pathway inhibitors, cell cycle inhibitors, other cdks inhibitors, tubulin binding agents, topoisomerase I inhibitors, topoisomerase II inhibitors, and similar.
Furthermore, the invention provides an in vitro method for inhibiting protein kinase activity which comprises contacting the kinase with an effective amount of a compound of formula (I) as defined above. Furthermore, the invention provides a product or kit which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined above, or pharmaceutical compositions thereof and one or more chemotherapeutic agents, as preparation for simultaneous, separate or sequential use in anticancer therapy.
Another aspect of the invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined above, for use as a medicine.
Furthermore, the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt, as defined above, in the manufacture of a medicine with anticancer activity.
Finally, the invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined above, for use in a method of treating cancer.
Unless otherwise specified, when referring to the compounds of formula (I) themselves, as well as any pharmaceutical composition thereof, or any therapeutic treatment comprising them, the present invention includes all isomers, tautomers, hydrates, solvates, complexes, metabolites, prodrugs, carriers, N-oxides and pharmaceutically acceptable salts of the compounds of the present invention.
In other words, if easily obtainable from compounds of formula (I) as defined above, also their tautomeric isomers, hydrates, solvates, complexes, metabolites, prodrugs, vehicles, N-oxides are object of the present invention.
A metabolite of a compound of formula (I) is any compound to which this same compound of formula (I) is converted in vivo, for example upon administration to a mammal in need thereof. Normally, however, without representing a limiting example, upon administration of the compound of formula (I), same derivative can be converted into a variety of compounds, for example, including more soluble derivatives such as hydroxylated derivatives, which are easily excreted. Thus, depending on the metabolic pathway thus occurring, any of these hydroxylated derivatives can be considered as a metabolite of the compounds of formula (D -
Prodrugs are any covalently linked compounds that release in vivo the active drug according to formula (I).
N-oxides are compounds of the formula (I), where nitrogen and oxygen are held together via a dative bond. If a stereogenic center or other form of an isomeric center is present in a compound of the present invention, all forms of such an isomer or isomers, including enantiomers and diastereomers, are intended to be covered by them. Compounds containing a stereogenic center can be used as a racemic mixture, an enantiomerically enriched mixture, or the racemic mixture can be separated using well known techniques and a single enantiomer can be used alone. In cases where the compounds have unsaturated carbon-carbon double bonds, both the cis (Z) and trans (E) isomers are within the scope of the present invention.
In cases where the compounds may exist in tautomeric forms, such as keto-enol tautomers, each tautomeric form is considered to be part of this invention if it exists predominantly in one form or in equilibrium.
With the term "aryl" includes carbocyclic or heterocyclic groups containing 1 to 2 ring moieties, either fused or linked together by a single bond, where at least one of the rings is aromatic, when present, heterocyclic aromatic rings also referred to as a heterogroup aryl, comprising a 5 to 6-membered ring containing 1 to 3 heteroatoms selected from N, O or S.
Examples of aryl groups according to the invention are, for example, phenyl, biphenyl, α- or β-naphthyl, dihydronaphthyl, thienyl, benzothiophenyl, furyl, benzofuranyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyridyl , pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, isoindolyl, purinyl, quinolyl, isoquinolyl, dihydroquinolinyl, quinoxalinyl, benzodioxolyl, indanyl, indenyl, triazolyl, and the like.
By the term "heterocyclic" (also known as "heterocycloalkyl") we mean a 3- to 7-membered carbocyclic ring, saturated or partially unsaturated when one or more carbon atoms are replaced by heteroatoms, such as nitrogen, oxygen, and sulfur. Non-limiting examples of the heterocyclic group are, for example, pyrane, pyrrolidine, pyrroline, imidazoline, imidazolidine, pyrazolidine, pyrazoline, thiazoline, thiazolidine, dihydrofuran, tetrahydrofuran, 1,3-dioxolane, piperidine, piperazine, morpholine and the like.
By the term "C3-C7 cycloalkyl" it is our intention to refer to, unless otherwise noted, monocyclic carbon rings of 3 to 7 elements all of carbon elements that may contain one or more double bonds but do not have an n-system fully conjugated electron. Examples and cycloalkyl groups, without limitation, are cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexene and cyclohexadiene, cycloeptan, cycloeptene and cycloeptadiene.
With the term "linear or branched C 1 -C 6 alkyl", then comprised of C 1 -C 4 alkyl, we mean any of the groups, such as, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl , sec-butyl, n-pentyl, n-hexyl, and the like.
By the term "linear or branched C2-C6 alkenyl" we mean any of the groups, such as, for example, vinyl, allyl, 1-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-pentenyl, 1 -hexenyl, and the like
By the term "linear or branched C2-C6 alkynyl" we mean any of the groups, such as, for example, ethynyl, 2-propynylbutyl, 4-pentynyl, and the like.
In accordance with the present invention, and unless otherwise specified, any of the groups R1, R2, R3, R', R" and R'" may optionally be substituted, in any of their free positions, by one or more groups, by example, groups from 1 to 6, independently selected from: halogen, nitro, oxo groups (=0), cyano, C1 -Cg alkyl, polyfluorinated alkyl, polyfluorinated alkoxy, alkenyl, alkynyl, hydroxyalkyl, aryl, arylalkyl, heterocyclic, C3 cycloalkyl -C7, hydroxy, alkoxy, aryloxy, heterocyclicoxy, methylenedioxy, alkylcarbonyloxy, arylcarbonyloxy, cycloalkenyloxy, heterocycliccarbonyloxy, alkylideneaminooxy, carboxy, alkoxycarbonyl, aryloxycarbonyl, cycloalkyloxycarbonyl, heterocyclicoxy-cyclyl, amino, amino, diamino, dialkylamino, dialkylamino , alkylcarbonylamino, arylcarbonylamino, heterocyclic-carbonylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, arylaminocarbonyl, heterocyclic-aminocarbonyl, alc oxycarbonylamino, hydroxyaminocarbonyl, alkoxyamino, alkylsulfonylamino, arylsulfonylamino, heterocyclicsulfonylamino, formyl, alkylcarbonyl, arylcarbonyl, cycloalkylcarbonyl, heterocycliccarbonyl, alkylsulfonyl, arylsulfonyl, aminosulfonyl, alkylaminosulfonyl, alkylaminosulfonyl, dialkylaminoalkylsulfonyl, alkylaminothiosulfonyl, dialkylaminoalkylsulfonyl, arylthiosulfonyl.
In turn, when applicable, each of said substituents can be further substituted by one or more of the groups mentioned above.
In this respect, with the term halogen we intend a 5 atom of fluorine, chlorine, bromine or iodine. With the term cyan we intend a residue -CN. With the term nitro we intend a group -NO2.
By the term alkenyl or alkynyl we mean any of the aforementioned linear or branched C 2 -C 6 alkyl groups plus 10 having a double or triple bond. Not limited to these examples, the alkenyl or alkynyl groups of the invention are, for example, vinyl, allyl, 1-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-pentenyl, 1-hexenyl, ethynyl , 2-propynylbutyl, 4-pentynyl, and the like. By the term polyfluorinated alkyl or alkoxy we mean any of the above linear or branched alkoxy or C1 -C6 alkyl groups which are substituted by more fluorine atom, such as, for example, trifluoromethyl, trifluoroethyl, 1, 1,1,3,3,3-hexafluoropropyl, trifluoromethoxy and the like.
By the term alkoxy, aryloxy, heterocyclicoxy and derivatives we mean any of the above heterocyclic, aryl, C 1 -C 6 alkyl, or groups attached to the rest of the molecule through an oxygen atom (-O-).
In view of the above, it is evident to a person skilled in the art that any group whose name is a compound name, such as, for example, arylamino must be intended as conventionally interpreted by the parties from which it comes, for example, by an amino group that is also substituted for aryl, where aryl is as defined above.
Likewise, any of the terms, such as, for example, alkylthio, alkylamino, dialkylamino, alkoxycarbonyl, alkoxycarbonylamino, heterocycliccarbonyl, heterocycliccarbonylamino, cycloalkyloxycarbonyl and the like, including groups where alkyl, aryl, alkoxy, the heterocyclic and C3-C7 cycloalkyl portions , are as defined above.
Pharmaceutically acceptable salts of compounds of formula (I) include acid addition salts with organic or inorganic acids, for example nitric, hydrochloric, hydrobromic, sulfuric, perchloric, phosphoric, acetic, trifluoroacetic, propionic, glycolic, lactic, oxalic, malonic, malic, maleic, tartaric, citric, benzoic, cinnamic, mandelic, methanesulfonic, isethionic and salicylic. Preferably, the acid addition salt of the compounds of the invention is selected from the hydrochloride or mesylate salt.
The pharmaceutically acceptable salts of the compounds of formula (I) also include salts with organic or inorganic bases, for example alkali or alkaline earth metals, especially sodium, potassium, calcium or magnesium ammonium hydroxide, carbonates and bicarbonates, amines, ethylamine, diethylamine, triethylamine, piperidine and the like.
Preferred compounds of formula (I) are those compounds wherein X is a group -NR'-and R2 is a group selected from -NHR" and -N(OR"')R", wherein R" is hydrogen or a optionally substituted linear or branched group selected from C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, cycloalkyl-alkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl; and R', R1", R1, R3, R4 and A are defined as above.
Other preferred compounds are those compounds of formula (I) wherein X is a -0- group and R2 is a group selected from -NHR" and -N(OR"')R" wherein R" is hydrogen or a group linear or branched, optionally substituted, selected from C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, cycloalkyl-alkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl; and R'", R1, R3, R4 and A are defined as above.
Other preferred compounds are those compounds of formula (I) wherein X is an -S- group and R2 is a group selected from -NHR" and -N(OR"')R" wherein R" is hydrogen or a group linear or branched, optionally substituted, selected from C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, cycloalkyl-alkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl; and R'", R1, R3, R4 and A are defined as above.
Other preferred compounds are those compounds of formula (I) wherein X is a single bond and R2 is a group selected from -NHR" and -N(OR"')R", wherein R" is orramified hydrogen, optionally substituted, selected from C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, cycloalkyl-alkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl; and R'", R1, R3, R4 and A are defined as above.
Other preferred compounds are those compounds of formula (I) wherein X is a -NR'- group; R2 is a -NHR" or -N(OR"')R" group, wherein R" is hydrogen or an optionally substituted group selected from a linear or branched C1-C4 alkyl and aryl group; and R 1 is a linear or branched, optionally substituted group selected from C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, cycloalkyl-alkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl; and R', R'", R3, R4 and A are defined as above.
Other preferred compounds are those compounds of formula (I) wherein X is an -O- group; R2 is a -NHR" or -N(OR"')R" group, wherein R" is hydrogen or a linear or branched, optionally substituted group selected from a C1-C4 alkyl and aryl group; and R1 is an optionally substituted linear or branched group selected from C1 -C6 alkyl, C3 -C7 cycloalkyl, cycloalkyl-alkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl; and R'", R3, R4 and A are defined as above.
Other preferred compounds are those compounds of formula (I) wherein X is an -S- group; R2 is a -NHR" or -N(OR"')R" group, wherein R" is hydrogen or a linear or branched, optionally substituted group selected from a C1-C4 alkyl and aryl group; and R1 is an optionally substituted linear or branched group selected from C1 -C6 alkyl, C3 -C7 cycloalkyl, cycloalkyl-alkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl; and R'", R3, R4 and A are defined as above.
Other preferred compounds are those compounds of formula (I) wherein X is a single bond; R2 is a group -NHR" or -N(OR"')R", wherein R" is hydrogen or a linear or branched, optionally substituted group selected from a C1-C4 alkyl and aryl group; and R1 is a linear or branched, optionally substituted group selected from C1 -C6 alkyl, C3 -C7 cycloalkyl, cycloalkyl-alkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl; and R'", R3, R4 and A are defined as above.
Specific preferred compounds of formula (I) or a salt thereof are the compounds listed below: 1) N-(2,6-diethylphenyl)-9-(methoxymethyl)-2-{[2-methoxy-4-(4- methylpiperazin-1-yl)phenyl]amino}-8-methyl-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxamide,2) 2-[(4-bromo-2-methoxyphenyl )amino]-N-(2,6-diethylphenyl)-8,9-dimethyl-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxamide,3) N-(2,6- -diethylphenyl)-2-({2-methoxy-4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl}amino)-8,9-dimethyl-6,9-dihydro-5H-pyrrole [3,2-h]quinazoline-7-carboxamide,4) N-(2,6-diethylphenyl)—2—({4—[4—(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino) -8,9-dimethyl-6,9-dihydro-5H-pyrrole[3,2-h]quinazoline-7-carboxamide,5) N-(2,6-diethylphenyl)-2-{[2-methoxy-4 -(4-methylpiperazin-1-yl)phenyl]amino}-8,9-dimethyl-6,9-dihydro-5H-pyrrole [3,2 —h]quinazoline-7-carboxamide,6) N-(2, 6-diethylphenyl)-2-({4-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methoxyphenyl}amino)-8,9-dimethyl-6,9-dihydro-5H-pyrrole[3 ,2-h]quinazoline-7-carboxamide,7) 2-{[2-methoxy -4-(4-methylpiperazin-1-yl)phenyl]amino}-8,9-dimethyl-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxamide,8) 2-[ (4-bromo-2-methoxyphenyl)amino]-N-(2,β-diethyl-phenyl)-9-methyl-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxamide, 9) N-(2,6-diethylphenyl)-2-{[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]amino}-9-methyl-6,9-dihydro-5H-pyrrolo[ 3,2-h]quinazoline-7-carboxamide,10}N-(2,6-diethylphenyl)-2-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)- 9-methyl-6,9-dihydro-5H-pyrrole[3,2-h]quinazoline-7-carboxamide,11) N-(2,6-diethylphenyl)-2-({2-methoxy-4-[4] -(pyrrolidin-1-yl}piperidin-1-yl]phenyl]amino)-9-methyl-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxamide,12) N-( 2,6-diethylphenyl)-2-[(4-{[3-(dimethylamino)propyl](methyl)amino}-2-methoxyphenyl)amino]-9-methyl-6,9-dihydro-5H-pyrrole[3 ,2-h]quinazoline-7-carboxamide,N-(2,6-diethylphenyl)-2-({4-[4-(2-hydroxyethyl) piperazin-1-yl]-2-methoxyphenyl}amino)-9 -methyl-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxamide,14) 2-[(4-bromo-2-methoxyphenyl)ami no]-N-[(IS)—2—(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-phenylethyl]-9-methyl-6,9-dihydro-5H -pyrrole[3,2-h]quinazoline-7-carboxamide,15) 2-[(4-bromo-2-methoxyphenyl)amino]-N-(2,6-diethylphenyl)-10-methyl-5,6, 7,10-tetrahydropyrrole[3', 2':6,7]cyclohepta[1,2-d]pyrimidine-8-carboxamide,16) N-(2,6-diethylphenyl)-2-{[2-methoxy- 4-(4-methylpiperazin-1-yl)phenyl]amino}-10-methyl-5,6,7,10-tetrahydropyrrole [3',2':6,7]cyclohepta[1,2-d]pyrimidine- 8-carboxamide,17) N-(2,6-diethylphenyl)-2-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-10-methyl-5,6, 7,10-tetrahydropyrrole [3',2': 6,7]cyclohepta[1,2-d]pyrimidine-8-carboxamide,18) N-(2,6-diethylphenyl)-2-({2-methoxy- 4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl}amino)-10-methyl-5,6,7,10-tetrahydropyrrole[3',26.7]cyclohepta[1,2- d] pyrimidine-8-carboxamide,19) 8-methyl-2-(methylsulfanyl)-9-(propan-2-yl)-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7- carboxamide,20) 8-methyl-2-(methylsulfanyl)-6,9-dihydro-5H-pyrrole[3,2-h]quinazoline-7-carboxamide)21) 2-(m ethylsulfanyl)-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxamide,22) 2-(methylsulfanyl)-9-(propan-2-yl)-6,9-dihydro-5H - pyrrole[3,2-h]quinazoline-7-carboxamide, 23) 2-(dimethylamino)-8-methyl-β,9-dihydro-5H-pyrrole[3,2-h]quinazoline-7-carboxamide,24 ) 9-(2-hydroxyethyl)-8-methyl-2-(methylsulfanyl)-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxamide,25) 9-(2-hydroxyethyl) -2-(methylsulfanyl)-6,9-dihydro-5H-pyrrole[3,2-h]quinazoline-7-carboxamide,26) 2-(dimethylamino)-8-methyl-9H-pyrrole[3,2-h ]quinazoline-7-carboxamide,27) 9-methyl-2-(methylsulfanyl)-9H-pyrrole[3,2-h]quinazoline-7-carboxamide),28) 8-methyl-2-(methylsulfanyl)-9H- pyrrole[3,2-h]quinazoline-7-carboxamide),29) 9-(2-hydroxyethyl)-8-methyl-2-(methylsulfanyl)-9H-pyrrole[3,2-h]quinazoline-7-carboxamide ,30) 8-methyl-2-(methylsulfanyl)-9-(propan-2-yl)-9H-pyrrole [3,2-h]quinazoline-7-carboxamide,31) 9-ethyl-2-(methylsulfanyl) -9H-pyrrole[3,2-h]quinazoline-7-carboxamide,32) 2-(methylsulfanyl)-9-(piperidin-4-yl)-6,9-dihydro-5H-pyrrole[3,2-h ]quinazoline-7-chlor carboxamide ete,33) 9-(cis-4-aminocyclohexyl)-2-(methylsulfanyl)-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxamide chloride,34) 9- (cis-4-aminocyclohexyl)-2-(methylsulfanyl)-9H-pyrrolo[3,2-h]quinazoline-7-carboxamide,35) 2-(methylsulfanyl)-9-(piperidin-4-yl)-9H- pyrrolo[3,2-h]quinazoline-7-carboxamide, 36) 2-(methylsulfanyl)-9H-pyrrolo[3,2-h]quinazoline-7-carboxamide,37) 2-methyl-6,9-dihydro- 5H-pyrrole[3,2-h]quinazoline-7-carboxamide,38) 9-(3-amino-2,2-dimethylpropyl)-2-(methylsulfanyl)-9H-pyrrole[3,2-h]quinazoline- 7-carboxamide hydrochloride, e39) 9-(azepan-3-yl)-2-(methylsulfanyl)-9H-pyrrolo[3,2-h]quinazoline-7-carboxamide hydrochloride.
By reference to any of the specific compounds of formula (I) of the invention, optionally in the form of a pharmaceutically acceptable salt, see the section on experiments and claims.
The present invention also provides a process for preparing the compounds of formula (I), as defined above, using the reaction routes and synthetic schemes described below, employing techniques available in the art and available starting materials. The preparation of certain embodiments of the present invention is described in the examples which follow, but those skilled in the art will recognize that the described preparations can be readily adapted to prepare other embodiments of the present invention. For example, the synthesis of non-examplified compounds according to the invention can be accomplished by modifications apparent to those skilled in the art, for example, adequately protecting interfering groups, switching to other appropriate reagents known in the art, or making routine modifications to the reaction conditions . Alternatively, other reactions referred to herein or known in the art will be recognized as having adaptability for the preparation of other compounds of the invention. Scheme 1 reported shows the preparation of a compound of formula (I).

In the above scheme 1, X is a single bond or a divalent radical selected from -NR', -0- and -S-; R2 is an optionally substituted alkoxy; A is defined in formula (I) except -CH=CH-; R 1 , R 3 , R 4 and R 1 are as defined in formula (I) and R 5 is an optionally substituted C 1 -C 6 alkyl.
All those of ordinary skill in the art will appreciate that any transformation performed in accordance with such methods may require standard modifications such as, for example, protecting interfering groups, switching to other appropriate reagents known in the art, or making routine modifications to the conditions of reaction. Likewise, a process of the present invention comprises the following steps: Step A) reacting a compound of formula (II).
where A is as defined in claim 1, except -CH=CH- and R5 is C1 -C6 alkyl optionally substituted with a compound of formula (III)
where R2 is an optionally substituted alkoxy;
Step B) reacting the resulting compound of formula (IV):
where R 2 is an optionally substituted alkoxy, R 5 is optionally substituted C 1 -C 6 alkyl and is defined in claim 1, except -CH=CH-, with toluenesulfonylmethyl isocyanate in the presence of a strong base;
Step C) selectively hydrolyze under acidic or basic conditions the resulting compound of formula (V)
where R 3 and R 4 are hydrogen, A is as defined in claim 1, except -CH=CH-, R 2 is an optionally substituted alkoxy and R 5 is optionally substituted C 1 -C 6 alkyl to give a compound of formula (VI)
where R3 and R4 are hydrogen, A is as defined in claim 1, except -CH=CH-, and R2 is an optionally substituted alkoxy;
Step Ca) a compound of formula (VI), where R3 is hydrogen, R4 is as defined in claim 1, except hydrogen, A is as defined in claim 1, except -CH=CH-, and R2 is an optionally substituted alkoxy, can be obtained by reacting a compound of formula (VII)
where A is as defined in claim 1, except -
CH=CH- with a compound of formula (VIII)
where R2 is an optionally substituted alkoxy and R4 is as defined in claim 1, except hydrogen;
Step D) cyclizing the resulting compound of formula (VI) where R2 is an optionally substituted alkoxy, R3 is hydrogen, R4 is as defined in claim 1 and A is as defined in claim 1, except -CH=CH-, under conditions such as to obtain a compound of formula (IX)
where R2 is an optionally substituted alkoxy, R3 is hydrogen, R4 is as defined in claim 1 and A is defined in claim 1, except -CH=CH-; if necessary or desired, Step E) alkylating a compound of formula (IX) , where R3 is hydrogen, with a compound of formula (X):
where L is an appropriate leaving group such as mesyl, tosylate, halogen atom, and R3 is as defined in claim 1, except hydrogen;
Step F) reacting the resulting compound of formula (IX)
where R 2 is an optionally substituted alkoxy, R 3 and R 4 are as defined in claim 1 and A is defined in claim 1, except -CH=CH-, with an N,N-dimethylformamide derivative;
Step G) reacting the resulting compound of formula (XI)
where R2 is an optionally substituted alkoxy, R3 and R4 are defined in claim 1 and A is defined in claim 1, except -CH=CH-, with a compound of formula (XII)
wherein X is a single bond or a bivalent radical selected from -NR', -O- and -S-; and R1 and R' are as defined in claim 1, so as to obtain a compound of formula (I)
wherein X is a single bond or a bivalent radical selected from -NR', -O- and -S-; R2 is an optionally substituted alkoxy; A is defined in claim 1, except -CH=CH-; and R1, R3, R4 and R' are as defined in claim 1; optionally converting a compound of formula (I) into another compound other than formula (I) and, if desired, converting a compound of formula (I) into a pharmaceutically acceptable salt thereof or converting a salt into a free compound (I).
As stated above, the compounds of the formula (I), which are prepared according to the process object of the invention, can be conveniently converted into other compounds of the formula (I), operating in accordance with well-known synthetic conditions, in the following examples of possible conversions: conv.1) conversion of a compound of formula (I) where R3 is a protecting group P, such as methoxymethylphenol or p-methoxybenzylic and into the corresponding compound of formula (I) where R3 is the hydrogen atom in acidic or basic conditions:

Conv.2) conversion of a compound of formula (I) where R3 is hydrogen into the corresponding compound of formula (I) where R3 is defined in formula (I) but not hydrogen, through reaction with the compound of formula R3-L ( X) where L is OH or a group which, optionally, after activation, can function as an appropriate leaving group such as iodine, bromine, chlorine or sulfonate group (eg -OS(0)2CF3, -OS(0) 2CH3 or -OS(0)2PhMe) and R3 is as defined above, but not the hydrogen atom:

Conv.3) conversion of a compound of formula (I) wherein R 2 is OR 5 , where R 5 is a C 1 -C 6 alkyl optionally substituted in the corresponding compound of formula (I) wherein R 2 is hydroxy or a corresponding salt thereof , through acidic or basic hydrolysis:

Conv.4) conversion of a compound of formula (I) wherein R2 is hydroxy or a corresponding salt thereof, into the corresponding compound of formula (I) wherein R2 is a -NR"R" or -N( OR"')R" where R" and R'" are defined in formula (I), by reaction with a derivative of formula R"R"'NH (XIII) or R"NHOR" 1 (XIV) where R" and R'" are as defined above under basic conditions and in the presence of a suitable condensing agent; Alternatively a compound of formula (I) wherein R2 is hydroxy may first be converted to the corresponding chloride derivative using a chlorinating agent and then reacting the resulting compound with a derivative of the formula R"R"'NH (XIII) or R"NHOR" 1 (XIV) where R" and R'" are as defined above under basic conditions, so as to to obtain a compound of the formula I), where R2 is a group -NR"R"' or -N(OR"')R":

Conv.5) conversion of a compound of formula (I) wherein R 2 is OR 5 wherein R 5 is an optionally substituted C 1 -C 6 alkyl to the corresponding compound of formula (I) wherein R 2 is a group -NR"R"' or - N(OR"')R", wherein R" and R'" are defined in formula (I), by reaction with a derivative of formula R"R"'NH (XIII) or R"NHOR"' (XIV ), where R" and R'" are as defined above:

Conv.6) conversion of a compound of formula (I) wherein X is defined in formula (I) except SO2 and -OSO2- and R1 is an aryl, i.e. phenyl, substituted by bromine, into the compound of formula (I ) wherein R1 is an aryl, i.e. phenyl, substituted by the corresponding NR'R"', by treatment with an amine, deformula R"R'"-NH(XIII):
where Ra and Rb are independently halogen atom, except bromine, hydrogen, nitro, cyano, C1 -C6 alkyl, polyfluorinated alkyl, polyfluorinated alkoxy, alkenyl, alkynyl, hydroxyalkyl, aryl, arylalkyl, heterocyclic, C3-C7 cycloalkyl, hydroxy, alkoxy , aryloxy, heterocyclicoxy, methylenedioxy, alkylcarbonyloxy, arylcarbonyloxy, cycloalkenyloxy, heterocycliccarbonyloxy, alkylideneaminooxy, carboxy, alkoxycarbonyl, aryloxycarbonyl, cycloalkyloxycarbonyl, heterocyclicoxycarbonyl, amino,ureido, alkylamino, dialkylaminoalkylaminocarbonyl, heterocyclylaminoalkylaminocarbonyl, heterocyclylaminoalkylaminocarbonyl, heterocyclic, arylaminocarbonyl -carbonylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, arylaminocarbonyl, heterocyclicaminocarbonyl, alkoxycarbonylamino, hydroxyaminocarbonyl, alkoxyamino, alkylsulfonylamino, arylsulfonylamino, heterocyclicsulfonylamino, formyl, alkylcarbonyl, arylcarbonyl, cycloalkylcarbonyl, heterocycyloxy nyl, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, arylaminosulfonyl, heterocyclicaminosulfonyl, arylthio, alkylthio, phosphonate and alkylphosphonate;
Conv.7) conversion of a compound of formula (I) where X is -NH- and R1 is hydrogen, into the corresponding compound of formula (I) where R1 is hydrogen, into the corresponding compound of formula (I) where R1 in an aryl, ie, phenyl, substituted
where Ra, Rb and Rc are independently hydrogen, nitro, cyano, C1 -C6 alkyl, polyfluorinated alkyl, polyfluorinated alkoxy, alkenyl, alkynyl, hydroxyalkyl, aryl, arylalkyl, heterocyclic, C3 -C7 cycloalkyl, hydroxy, alkoxy, aryloxy, heterocyclicoxy, methylenedioxy, alkylcarbonyloxy, arylcarbonyloxy, cycloalkenyloxy, heterocycliccarbonyloxy, alkylideneaminooxy, carboxy, alkoxycarbonyl, aryloxycarbonyl, cycloalkyloxycarbonyl, heterocyclicoxy-carbonyl, amino, ureido, alkylamino, dialkylamino, arylamino, diarylamino, heterocyclylamino, alkylaminocycloalkylaminocarbonylamino, heterocyclic alkylaminocarbonyl, carbonyl,dialkylaminocarbonyl, arylaminocarbonyl, heterocyclicaminocarbonyl,alkoxycarbonylamino, hydroxyaminonyl, alkoxyamino, alkylsulfonylamino, arylsulfonylamino, heterocyclicsulfonylamino, formyl, alkylcarbonyl, arylcarbonyl, cycloalkylcarbonyl, heterocycliccarbonyl, alkylsulfonyl, alkylsulfonyl, arylsulfonyl 1phonyl, dialkylaminosulfonyl, arylaminosulfonyl, heterocyclicaminosulfonyl, arylthio, alkylthio, phosphonate and alkylphosphonate; by treatment with an iodine derivative of the formula (XV)
where Ra, Rb and Rc are as defined above, in the presence of palladium;
Conv.8) conversion of a compound of formula (I) wherein X is defined in formula (I) except SO2 and -OSO2-, and R1 is an aryl, ie phenyl, substituted by -COOPg, where Pg is a appropriate protecting group, in the corresponding compound of formula (I) wherein R 1 is an aryl, i.e. phenyl, substituted by -COOH, via conditions well known in the literature (see TeodoraW. Green PereG. M.Wuts):
where Ra and Rb are independently halogen atom, hydrogen, nitro, cyano, C1 -C6 alkyl, polyfluorinated alkyl, polyfluorinated alkoxy, alkenyl, alkynyl, hydroxyalkyl, aryl, arylalkyl, heterocyclic, C3-C7 cycloalkyl, hydroxy, alkoxy, aryloxy, heterocyclicoxy, methylenedioxy, alkylcarbonyloxy, arylcarbonyloxy, cycloalkenyloxy, heterocycliccarbonyloxy, alkylideneaminooxy, carboxy, alkoxycarbonyl, aryloxycarbonyl, cycloalkyloxycarbonyl, heterocyclicoxy-carbonyl, amino, ureido, alkylamino, dialkylamino, arylamino, diarylaminocarbonyl, heterocyclylamino, heterocyclicamino carbonylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, arylaminocarbonyl, heterocyclicaminocarbonyl, alkoxycarbonylamino, hydroxyaminocarbonyl, alkoxyamino, alkylsulfonylamino, arylsulfonylamino, heterocyclicsulfonylamino, formyl, alkylcarbonyl, arylcarbonyl, cycloalkylcarbonyl, arylsulfonylamino, arylsulfonylamino sulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, arylaminosulfonyl, heterocyclicaminosulfonyl, arylthio, alkylthio, phosphonate and alkylphosphonate;
Conv.9) conversion of a compound of formula (I) wherein X is defined in formula (I) except SO2 and -OSO2-, and R1 is an aryl, i.e. phenyl, substituted by -COOH, into the corresponding compound of formula (I) wherein R1 is an aryl, i.e. phenyl, substituted by -CONR"R"', where R" and R'" are as defined above, by treatment with an amine, of formula R"R"' -NH (XIII), in the presence of the appropriate condensing agents:
where Ra and Rb are independently halogen atom, hydrogen, nitro, cyano, C1 -C6 alkyl, polyfluorinated alkyl, polyfluorinated alkoxy, alkenyl, alkynyl, hydroxyalky1, aryl, arylalkyl, heterocyclic, C3-C7 cycloalkyl, hydroxy, alkoxy, aryloxy, heterocyclicoxy, methylenedioxy, alkylcarbonyloxy, arylcarbonyloxy, cycloalkenyloxy, heterocycliccarbonyloxy, alkylideneaminooxy, carboxy, alkoxycarbonyl, aryloxycarbonyl, cycloalkyloxycarbonyl, heterocyclicoxy-carbonyl, amino, ureido, alkylamino, dialkylamino, arylamino, arylamino, diarylaminocarbonyl, heterocyclic-carbonylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, arylaminocarbonyl, heterocyclic-aminocarbonyl, alkoxycarbonylamino, hydroxyaminocarbonyl, alkoxyamino, alkylsulfonylamino, arylsulfonylamino, heterocyclicsulfonylamino, formyl, alkylcarbonyl, arylcarbonyl, cycloalkylcarbonyl, arylcarbonyl, cycloalkylcarbonyl, minosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, arylaminosulfonyl, heterocyclicaminosulfonyl, arylthio, alkylthio, phosphonate and alkylphosphonate;
Conv.10) conversion of a compound of formula (I) wherein R1 is hydrogen and X is -NH- into the corresponding compound of formula (I) wherein R1 is iodine, and X is a single bond, by reaction with isoamylnitrite and diiodomethane or cesium iodide, in the presence of iodine and Cui:

Conv.11) conversion of a compound of formula (I) wherein R1 is iodine, and X is a single bond to the corresponding compound of formula (I) wherein X is -NH- and R1 is an optionally substituted aryl, by reaction with an optionally substituted arylamino of the formula o R1-NH2 (XVI), where R1 is as defined above, in the presence of Pd(OAc)2 θ BINAR:

Conv.12) conversion of a compound of formula (I) wherein R1 is iodine, and X is a single bond into the corresponding compound of formula (I) wherein X is a single bond and R1 is as defined in formula ( I), by reaction with a compound of formula (XVII):R1-Q(XVII)wherein R1 is as defined above and Q is an appropriate group, such as -B(OH)2, -B(OAlk.)2 , -Sn(Alk)4, ZnHàl, or MgHal, which can undergo palladium-mediated carbon bond formation:

Conv.13) conversion of a compound of formula (I) wherein R 1 is as defined in formula (I) and X is -S- to the corresponding compound of formula (I) wherein X is -SO 2 - under oxidative conditions:

Conv. 14) conversion of a compound of formula (I) wherein R1 is as defined in formula (I) and X is -SO2- to the corresponding compound of formula (I) wherein X is -NR'- by reaction of 5 sulfonyl group with an amine of formula R1-NHR1 (XVIa), where R1 and R' are as defined in formula (I):

Conv.15) conversion of a compound of formula (I) wherein R1 is as defined in formula (I) and X is -SO2- to the corresponding compound 10 of formula (I) wherein X is -O- via reaction of the sulfonyl group with a compound of formula R1-OH (XVIII) wherein R1 is as defined in formula I) except hydrogen:

Conv.16) conversion of a compound of formula (I) wherein 15 R 1 is methyl and X is -O- into the corresponding compound of formula (I) wherein R 1 is hydrogen and X is -0-:

Conv.17) conversion of a compound of formula (I) in which R1 is hydrogen and X is -O- into a compound of formula (I) in which R1 is trifluoromethyl and X -OS02- by reaction with an agent 5 of triflation:

Conv.18) converting a compound of formula (I) wherein R 1 is trifluoromethyl and X is -OSO 2 - to the corresponding compound of formula (I) wherein X is -O- and R 1 is as defined in formula 10 (I), by reaction with a compound of formula R1-OH (XVIII), where R1 is as defined above, except hydrogen:

Conv.19) conversion of a compound of formula (I) wherein R1 is trifluoromethyl and X is -OS02- to the corresponding compound of formula (I) wherein X is -NR'- and R1 is as defined in formula (I) except hydrogen, by reaction with a compound of the formula R1-NHR' (XVIa) where R1 is as defined above:

Conv.20) conversion of a compound of formula (I) wherein R1 is trifluoromethyl and X is -OSO2- to the corresponding compound of formula (I) wherein X is -S- and R1 is as defined in formula5 (I) except hydrogen , by reaction with a thiol of the formula RI-SH (XIX) where RI is as defined above except hydrogen:

Conv.21) the conversion of a compound of formula (I) in 10 which R1 is trifluoromethyl and X is -OS02- to the corresponding compound of formula (I) wherein X is a single bond and R1 is as defined in formula (I ), except hydrogen, by reaction with a compound of formula R1-Q (XVII), where R1 is as defined above, except hydrogen, and Q is an appropriate group, such as -B(OH)2, -B( OAIk)2, -Sn(Alk)4, ZnHal or MgHal, which can undergo palladium-mediated carbon bond formation:

Conv.22) the conversion of a compound of formula (I) wherein R 1 is methyl and X is -S- to the corresponding compounds of formula (I) where R 1 is an optionally substituted aryl and X 5 is a single bond, through of the reaction thereof with an optionally substituted aryl boronic acids of formula Rl, palladium:

Conv. 23) the conversion of a compound of formula (I) where such as -CH 2 -CH 2 - into the corresponding compound of formula (I) where A is a -CH=CH- group, by treatment with an oxidizing agent, or under operating conditions of dehydrogenation in the presence of a catalyst 15 Pd or Pt:
wherein X, R1, R2, R3 and R4 are defined in formula (I).
Conv. 24) the conversion of a compound of formula (I) wherein R4 is hydrogen and A is a divalent group, such as -CH2-5 CH2- into the corresponding compound of formula (I) wherein R4 is hydrogen and A is a group -CH=CH-, in the first conversion of the compound of formula (XX) with an excess of N-iodosuccinimide and thereafter removing the iodine in the presence of a palladium derivative:
where, X, R1, R2 and R3 are defined in formula (I) and R4 is hydrogen.
Conv. 25) removing any protecting groups or groups and, if desired, forming a salt.15 According to Step A of the process, an aldehyde of formula (II) is reacted with a phosphorane of formula (II) in a suitable solvent, such as such as, for example, toluene, xylene, THF or Et2O in a temperature range ranging from room temperature to reflux and for a time ranging from 1 to about 20 12 hours. Preferably, the above reaction is carried out in toluene at reflux to obtain a compound of formula (IV).
According to Step B, a compound of formula (IV) is reacted with TOSMIC, in the presence of a base such as KOH, NaH, LiN(TMS)2 in a suitable solvent, such as, for example, toluene, THF or Et2O at a temperature ranging from -78 °C to room temperature for a time ranging from 1 to about 12 hours. Preferably, the above reaction is carried out in the presence of LiN(TMS)2 in THF at -78°C to obtain a compound of formula (V).
According to Step C, a compound of formula (V) where R3 is hydrogen, R4 is hydrogen and A is defined in formula (I) except -CH=CH-, R2 is an optionally substituted alkoxy and R5 is a optionally substituted alkyl is converted to mono-carboxylic acid derivatives (VI) in the presence of a base such as KOH, NaOH, LiOH or Na2CO3 in a suitable solvent such as, for example, H2O, dioxane or adjuvants thereof at a temperature which ranges from 0°C to room temperature for a time ranging from 1 to about 24 hours. Preferably, the above reaction is carried out in the presence of LiOH in a dioxane/H2O mixture at room temperature to obtain a compound of formula (VI).
Alternatively, according to step Ca, a compound of formula (VII) is reacted with a compound of formula (VIII), in the presence of AcONa or sodium ethylate in a suitable solvent, such as, for example, H20, EtOH or AcOH at a temperature ranging from room temperature to reflux and for a time ranging from 1 to about 24 hours. Preferably, the above reaction is carried out in the presence of AcONa in refluxing H2O to obtain a compound of formula (VI) where R3 is hydrogen, R4 is as defined above, except hydrogen and R2 and A are as defined above.
According to Step D of the process, a compound of formula (VI) wherein R4 is defined in formula (I), can be converted to a compound of formula (IX) in the presence of TFAA or PPA in a suitable solvent thereof, such as asTFA, at a temperature ranging from room temperature to reflux and for a time ranging from 1 to 8 hours. Preferably, the above reaction is carried out in the presence of TFAA in TFA at room temperature to obtain a compound of formula (IX).
According to Step E of the process, a compound of formula (IX), where R3 is hydrogen atom, is reacted with a compound of formula (X), as defined above, where L is OH, in which case the conditions of Mitsunobu may be employed or a group which, optionally, upon activation may function as a leaving group, such as a halogen atom, tosylate, mesylate or triflate.
In the above case, that is, when a Mitsunobu protocol is employed, the reaction can be carried out using a dialkyl azodicarboxylate, such as diethylazodicarboxylate (DEAD), diisopropyl azodicarboxylate (DIAD) or the like, in the presence of a phosphine trialkyl or triaryl, preferably of triphenyl phosphine in a suitable solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, acetonitrile.
When L is a halogen or a group such as tosylate, mesylate or triflate or the conversion can be done using a suitable base such as, for example, NaH, K2CO3, CS2CO3, DBU, KO-t-Bu and the like, in a suitable solvent such as tetrahydrofuran, acetonitrile, N,N-dimethylformamide, N,N-dimethylacetamide and the like. Said reactions can be carried out at temperatures ranging from 0°C to reflux and for a time ranging from 30 minutes to about 48 hours.
According to Step F of the process, the compound of formula (IX) is reacted with an N,N-dimethylformamide derivative for example with an N,N-dimethylformamide derivative such as N,N-dimethylformamide-di-tert. -butylacetal, N,N-dimethylformamide-diisopropylacetal, N,N-dimethylformamide-dimethylacetal, N,N-dimethylformamide-diethylacetal or tris(dimethylamino)methane in a suitable solvent, such as, for example, DMF or toluene, at one temperature ranging from room temperature to reflux and for a time ranging from about 1 to about 48 hours. Preferably, the reaction is carried out in the presence of pure tris(dimethylamino)methane or in DMF at 90°C to obtain a compound of formula (XI).
According to Step G of the process, the compound of formula (XI) is reacted with a derivative of formula (XII) wherein X is a single bond or a selected divalent radical -NR'-, -O- and -S- wherein R' is as defined in formula (I), R1 is as defined in formula (I); so as to obtain a compound of formula (I) as defined above wherein X and R1 are as defined above, by pyrimidine ring formation optionally in the presence of a base such as AcOK, K2CO3, or NaaCCh in a suitable solvent, such as, for example, DMF, EtOH or toluene, at a temperature ranging from room temperature to reflux and for a time ranging from about 1 to about 48 hours. Preferably, the reaction is carried out in the presence of DMF at 120°C. As an alternative, microwave irradiation can be used instead of heating.
According to conversion 1 of the process, the compound of formula (I) in which R3 is a group selected from methoxymethylphenol or p-methoxybenzyl may be converted into another compound of formula (I) where R3 is hydrogen atom by reaction under acidic conditions, for example, with AcOH, TFA or HCl or under basic conditions, for example, NaOH and in the presence of a suitable solvent, such as MeOH, DCM or dioxane, at a temperature ranging from room temperature to reflux and by a time ranging from 1 to about 12 hours.
According to the conversion 2 process, a compound of Formula (I), where R3 is the hydrogen atom, can be converted to a compound of Formula (I), where R2 as defined above, except hydrogen atom, by the reaction with an appropriate compound of formula (X) as defined above, when L is OH, in which case Mitsunobu conditions can be employed or a group which, optionally, after activation can function as a leaving group, such as a halogen, tosylate, mesylate or triflate atom.
In the above case, that is, when a Mitsunobu protocol is employed, the reaction can be carried out using a dialkyl azodicarboxylate, such as diethylazodicarboxylate (DEAD), diisopropyl azodicarboxylate (DIAD) or the like, in the presence of a phosphine trialkyl or triaryl, preferably of triphenyl phosphine in a suitable solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, acetonitrile.
When L is a halogen or a group such as tosylate, mesylate or triflate or the conversion can be done using a suitable base such as, for example, NaH, K2CO3, CS2CO3, DBU, KO-t-Bu and the like, in a suitable solvent such as tetrahydrofuran, acetonitrile, N,N-dimethylformamide, N,N-dimethylacetamide and the like. Said reactions can be carried out at temperatures ranging from 0°C to reflux and for a time ranging from 30 minutes to about 48 hours.
According to conversion 3 of the process, a compound of formula (I) where R2 is OR5, where R5 is an optionally substituted alkyl can be converted to the corresponding carboxylic acid derivative of formula (I), where R2 is hydroxy or its salts corresponding to acidic or basic hydrolysis conditions widely known in the art. Preferably, the reaction is carried out in the presence of NaOH in dioxane/H2O at reflux.
According to conversion 4 of the process, the compound of formula (I), where R 2 is hydroxy or a corresponding salt, can be converted into a derivative of formula (I) where R 2 is an NR"R"' group or - N(OR"')R", where R" and R'" are defined in formula (I). The reaction is carried out in the presence of a compound of formula (XIII) or (XIV) as defined above in the presence of a base for example with DIPEA or TEA, in a suitable solvent such as DCM, DMF, THF or dioxane, and in the presence of a suitable condensing agent such as DCC, EDCI or TBTU; catalytic amount of PyBOP or HOBt may also be required. Preferably, the reaction is carried out in the presence of DIPEA and TBTU in DMF at room temperature.
Alternatively, the same conversion can be obtained by first reacting the compound of formula (I) where R2 is hydroxy or the corresponding salt with a chlorinating agent, e.g. to oxy dichloride or SOCl2 in a suitable solvent, e.g. , DCM, toluene, THF, dioxane or DMF, at a temperature ranging from room temperature to 100°C, to obtain the corresponding chloride derivative. Preferably, the reaction is carried out in the presence of SOCl2 in THF at reflux.
According to conversion 5 of the process, a compound of formula (I) wherein R2 is OR5, where R5 is an optionally substituted alkyl, is reacted with an appropriate compound of formula (XIII) or (XIV) as defined above, in the presence of a base such as NaH, NaN(TMS)2 or LiN(TMS)2 in a suitable solvent, for example Et2O, THF or dioxane, at a temperature ranging from -10°C to 40°C, and for a time ranging from about 10 minutes to about 12 hours, so as to obtain another compound of the formula (I) where R2 is an amino group of the formula -NR"R"' or -N(OR"')R" . Preferably, the reaction is carried out in the presence of LiN(TMS)2 in THF, at 0°C.
According to process conversion 6, replacement of bromine with the -NR"R"' moiety was achieved by reacting the starting material with an amine of formula (XIII) as defined above in a suitable solvent such as THF or dioxane and in the presence of the catalytic amount of Pd2(dba)3, 2-dicyclohexylphosphino-2'-(N,N-dimethylamino)-biphenyl and a base such as LiN(TMS)2 at a temperature ranging from room temperature at reflux and for a time ranging from 1 to about 24 hours.
According to the conversion 7 of the process, the compound of formula (I) as defined above is reacted with the compounds of formula (XV) as defined above according to conventional methods. As an example, the reaction may be carried out in a suitable solvent such as DMF, DME, dioxane or CH3CN and in the presence of an optionally substituted aryliodo of the formula (XV) as defined above, the catalytic amount of Pd2(dba)3, BINAP or 2-(dicyclohexylphosphino)-2',4',6'-triisopropyl-1,11-biphenyl(X-fos) and a base such as K2CO3, potassium phosphate or CS2CO3 over a varying temperature range from room temperature to 110 °C and for a time ranging from 2 to about 24 hours.
According to process conversion 8, deprotection of the carboxylic residue to the corresponding acid can be achieved using the procedure well known in the art under acidic conditions, for example, with HCl or TFA in a suitable solvent, for example, THF or dioxane, in a temperature range ranging from room temperature to 60°C and for a time ranging from about 1 to about 12 hours.
According to conversion 9 of the process, the transformation of the acid residue into corresponding amide derivatives CONR"R"', where R" and R'" are as defined above, can be achieved by reacting the acid derivatives with an amine of the formula (XIII), as defined above, under basic conditions, preferably with DIPEA or TEA, in a suitable solvent such as DCM, DMF, THF or dioxane and in the presence of a suitable condensing agent such as DCC, EDCI or TBTU ; the catalytic amount of PyBOP or HOBt may also be required, over a temperature range ranging from room temperature to 60°C and for a time ranging from about 1 to about 24 hours.
According to the conversion 10 of the process, compounds of formula (I), wherein R1 is iodine, and X is a single bond can be prepared by the corresponding compounds of formula (I), wherein R1 is hydrogen and X is - NH-; the reaction carried out using iso-amylnitrite and diiodomethane or cesium iodide, in the presence of iodine and Cul in a suitable solvent, such as THF, Et20 or DME, in a temperature range ranging from room temperature to about 70°C and for a time from about 8 hours to about 48 hours.
According to process conversion 11, replacement of iodine with an arylamine of formula R1-NH2 (XVI) can be carried out in a suitable solvent such as DMF, DME or CH3CN and in the presence of catalytic amounts of Pd(OAc) 2, BINAP or Xantphos and a base such as K2CO3, potassium phosphate or CS2CO3 over a temperature range from room temperature to 110°C and for a time from about 2 to about 24 hours.
According to conversion 12 of the process, the replacement of iodine with group of formula RI is carried out by exploiting any of the appropriate cross-coupling reactions for the formation of carbon-carbon bonds. Said reactions, which are well known in the art, involve coupling with a suitable reagent, such as, for example, organo-boron (Suzuki reaction), organotin (Stoke reaction), organomagnesium (Kumada reaction) or organozinc (Negishi Reaction) and the like. The preferred reaction is the Suzuki reaction where the appropriate aryl or heteroharylboronic derivative is used in the presence of a palladium based catalyst, such as PdCl2 (dppf) 2CH2C12 or d2(dba)3 or Pd (PPh3)4, in a solvent suitable, such as DMF, DCM, MeOH CH3CN, or in a mixture of solvents such as water, optionally in the presence of a base such as sodium and dimethoxyethane, cesium carbonate or cesium fluoride, at a temperature ranging from room temperature up to 100°C.
According to the process conversion 13, the transformation of the thio group into the sulfonyl group can be achieved by reaction with an oxidizing agent known to those skilled in the art, such as, for example, oxone in a suitable solvent, such as tetrahydrofuran, 1,4- dioxane, acetone, optionally in the presence of water, such as acid co-solvents or m-chloroperbenzoic acid in the presence of a suitable solvent preferably DCM at room temperature.
According to conversion 14 of the process, replacement of the sulfonyl group with an appropriate amino derivative is preferably carried out with an amine of formula R1-NHR' (XVI) in the presence of DMF, DME, dioxane, CH3CN, N-methyl- pyrrolidone or diqlime, in a temperature range from room temperature to about 100°C.
According to the process conversion 15, the substitution of the sulfonyl group can be easily obtained by reaction with an alcohol or phenol derivative of formula (XVIII). The reaction can be carried out in the presence of a base, such as K2CO3, or Na2C03, butyl lithium, LiN(TMS)2, NaH or the like, in a suitable solvent such as DMF or THF and working over a varying temperature range from room temperature to about 100°C.
According to process conversion 16, methyl residue removal can be achieved in the presence of sodium iodide and sodium trimethylsilylchloride. The reaction can be carried out in a suitable solvent such as CH3CN and working over a temperature range ranging from room temperature to reflux.
According to the conversion of the process compounds with a trifluoromethanesulfonyl group, this can be obtained by reacting the compounds of formula (I) where X is -0- and R1 is hydrogen with a triflating agent such as trifluoromethanesulfonic anhydride , trifluoromethanesulfonylchloride or N-phenyl-bis (trifluoromethanesulfonimide), optionally, in the presence of a base, such as TEA or DIPEA, in a suitable solvent, such as DCM, THF or dioxane in a temperature range ranging from -78°C at room temperature.
According to conversion 18 of the process, the reaction is carried out with an alcohol of the formula (XVIII), operating in a suitable solvent, such as dioxane, THF, DME, CH3CN, DMF or DMSO, in a temperature range that varies from room temperature to about 90°C, optionally, in the presence of a base such as K 2 CO 3 , potassium tert-butoxide or NaH.
Alternatively, the reaction can be carried out in a suitable solvent such as toluene, DMF, DME or CH3CN, in the presence of Pd(OAc)2, (±)-BINAR and a base such as potassium phosphate or K2CO3 or CS2CO3 at one temperature ranging from 0°C to 100°C.
According to conversion 19 of the process, compounds of formula (I), wherein R1 is as defined in formula (I), except hydrogen and X is -NR'- can be obtained from the corresponding trifluoromethanesulfonyl compounds with an amine of formula R1-NHR' (XVI). The reaction is usually obtained by operating in a suitable solvent, such as dioxane, THF, DME, CHgCN, DMF or DMSO, in a temperature range ranging from room temperature to 90°C, optionally, in the presence of a base, such as such as K2CO3 or TEA.
According to the process conversion 20, compounds of formula (I) wherein R1 is as defined in formula (I), except hydrogen, and X is -S-, can be obtained with the corresponding trifluoromethanesulfonyl compounds. The conversion is carried out by reaction with a thiol of formula RI-SH (XIX) where RI is as defined above in a suitable solvent, such as THF, DMF, DCM, MeOH, DME or CH3CN, at a temperature ranging from the temperature environment up to 100°C.
According to conversion 21 of the process, compounds of formula (I), wherein R1 is as defined above, can be obtained by the corresponding trifluoromethanesulfonyl. The conversion is carried out by reaction with derivatives of formula (XVII) in a suitable solvent, such as DMF, DCM, MeOH, DME or CH3CN, in the presence of Pd2(dba)3, PdCl2(dppf) or Pd(PPh3)4, optionally, in the presence of cesium fluoride, at a temperature ranging from room temperature to 100°C.
According to the conversion 22 of the process, compounds of formula (I), wherein R 1 is an optionally substituted aryl and X is a single bond, can be obtained by the corresponding compounds of formula (I) wherein X is -S - and RI is methyl. The conversion is carried out by reaction with boronic acid of formula (XVIIa) in a suitable solvent, such as DMF, THF, DCM, MeOH, DME or CH3CN, in the presence of CuTC and Pd2(dba>3 or Pd(PPh3)4, optionally , in the presence of cesium fluoride at a temperature ranging from room temperature to reflux.
According to process conversion 23, a compound of formula (I), wherein A is -(CH 2 ) 2 - may undergo dehydrogenation in the presence of optionally supported palladium or platinum or 2,3-dichloro-5,6- dicyano-1,4-benzoquinone (DDQ), so as to obtain the corresponding aromatic derivative of formula (I), operating in a suitable solvent, such as toluene, 1,4-dioxane, chlorobenzene, dichlorobenzene, at a varying temperature 90°C to reflux, for a time ranging from 2 hours to 8 hours.
According to the process conversion 24, a compound of formula (I) wherein R4 is hydrogen and A is -(CHz)2~ can be reacted with an excess of N-iodosuccinimide in DMF at room temperature to obtain a compound of formula (XX), which is further dehalogenated in the presence of a palladium catalyst, for example Tetrakis (triphenylphosphine)-palladium and sodium formate to obtain the corresponding aromatic derivative of formula (I), operating in a suitable solvent, such as N,N-dimethylformamide, at a temperature ranging from 90°C to reflux, for a time ranging between 2 hours and 8 hours.
According to the process conversion, the deprotection of the nitrogen atom of a compound of formula (I), where R' is a protecting group, can be carried out according to conventional methods, allowing selective hydrolysis of the groups protection of tert-butoxycarbonyl, benzyl, 4-methoxybenzyl, 2,4-dimethoxybenzyl and triphenylmethyl. Preferably, this reaction is carried out under acidic conditions, for example, in the presence of an organic or inorganic acid, such as hydrochloric, trifluoroacetic or methanesulfonic acid, in a suitable solvent, such as DCM, 1,4-dioxane, lower alcohol, such as methanol or ethanol, over a temperature range ranging from room temperature to reflux and for a period of time ranging from about 1 hour to about 48 hours.
According to any variant of the process for the preparation of compounds of formula (I), the starting material and any other reagent are known or easily prepared according to known methods. The compound of formula (II), wherein A is -CH2- is R5 is methyl is commercially available.
The compound of formula (II), wherein A is -(CH 2 ) 2 - and R 5 is methyl can be prepared as described in J. Org. Chem., 1998, 63(5), 1668.
The compound of formula (II), wherein A is -(OH2)3- and R5 is methyl can be prepared as described in the European Journal of Organic Chemestry, 2008, 23, 3917.
The compound of formula (II), wherein A is -C(CH 3 ) 2 -CH 2 - and R 5 is methyl, can be prepared as described in US5750769.
The compound of formula (II) wherein A is -CH 2 -C(CH 3 ) 2 - and R 5 is methyl can be prepared as described in J. org. Chem. , 1964, 29, 801. Compounds of formula (III), wherein R2 is methyl, ethyl and t-butyl are commercially available.
The compound of formula (VII) wherein A is -CH 2 CH 2 - can be prepared as described in US2010/160318. The compound of formula (VIII) wherein R 2 is ethoxy and R 4 is methyl is commercially available.
Compounds of the formula (X), (XII), (XIII), (XIV), (XV), (XVI), (XVIa), (XVII) and (XVIIa) are commercially available or can also be prepared by known methods . EXAMPLES
The synthetic preparation and some compounds of formula (I) of the invention are described in the examples below.
The compounds of the present invention, as prepared according to the examples below, were also defined by 1H NMR or by analytical HPLC/MS data; HPLC/MS data were collected following any of methods 1, 2, 3 and 4. Analytical Method 1 HPLC/MS
The HPLC equipment consisted of a WatersAcquity™ UPLC system equipped with a Waters 2996 PDA detector and a single quadruple mass spectrometer, model Micromass ZQ, equipped with an electrospray ion source (ESI). The control instrument, data acquisition and data processing were provided by Empower 2 and MassLynx 4.1 software.
HPCL was performed at 45°C at a flow rate of 0.7 ml/min using a Water Acquity™ BEH C18 column, 1.7 microm with 50 X 2.1 mm. Mobile phase A was 0.1% trifluoroacetic acid in H2O/CH3CN (95:5), and mobile phase B was H2O/CH3CN (5:95), the gradient was 5 to 95% B in 2 minutes then retained 95% B for 0.1 minutes. The injection volume was 0.8 microL. The mass spectrometer was operated in positive and negative ion mode, capillary voltage was set to 3 KV (ES+ and ES-), source temperature was 120°C; the cone at 30 V (ES+ and ES"), in full scan, the mass was adjusted ranging from 100 to 800 amu. Analytical Method 2 HPLC/MS
The HPLC equipment consisted of an HP Alliance Waters™ 2795 system equipped with a Waters 2996 PDA detector and a Micromass ZQ 2000 model single-mass quad spectrometer, equipped with an electrospray ion source (ESI). The control instrument, data acquisition and data processing were provided by Empower 2 and MassLynx 4.1 software.
HPCL was performed at 25°C at a flow rate of 1.0 ml/min using Phenomenex C18 column, 3 microm (50 X 4.6 mm). Mobile phase A was 5mM ammonium acetate buffer solution pH 5.2 with CH3CN 95:5), and Mobile phase B was H20/CH3CN (5:95); the gradient was from 10 to 90% B in 8 minutes and then rising to 100% in 1 minute. The injection volume was 10 microL. The mass spectrometer was operated in positive and negative ion modes, capillary voltage was set at 3.5 KV (ES+) and 28 V (ES-); the source temperature was 120°C; the cone at 14 V (ES+) and 2.8 kV (ES ); in full scan, the mass was adjusted ranging from 100 to 800 amu. HPLC/MS analytical method 3
The HPLC equipment consisted of an HP Alliance Waters™ 2795 system equipped with a Waters PDA detector and a model ZQ 2000 quad single mass spectrometer equipped with an electrospray ion source (ESI). Control instrument, data acquisition and data processing were provided by Empower 2 and MassLynx 4.1 software. HPCL was performed at 25°C at a flow rate of 1 mL/min using RP18 Waters x Terra (3 .0 x 20 mm) column. Mobile phase A was 0.05% buffer solution pH = 10 with CH3CN (95:5), and mobile phase B was H2O/CH3CN (5:95), gradient was 10 to 90% B in 4 minutes , then retained 90% B for 1 minute. The injection volume was 10 microL. The mass spectrometer was operated in positive and negative ion modes, capillary voltage was set to 2.5 KV; the source temperature was 120°C; the cone was at 10V; in full scan, the mass was adjusted ranging from 100 to 800 amu.
Various compounds of the invention of formula (I) were prepared according to the examples below, and purified by preparative HPLC. The operating conditions are defined below: Preparative Method 1 HPLC/MS
The HPLC equipment consisted of a Waters FractionLynx™ system equipped with a 2996 Waters PDA detector and Waters mod single quadrupole mass spectrometer. ZQ 2000, equipped with an electrospray ion source (ESI). Instrument control, data acquisition and data processing were provided by Empower 2 and MassLynx 4.1 software.
HPCL was carried out at 25°C at a flow rate of 20 ml/min using a Waters X Terra RP18, 10 microm (19 X 250 nm) column. Mobile phase A was 0.05% of the buffer solution formed by ammonium hydroxide pH = 10 with CH3CN (95:5), and mobile phase B was CH3CN; the gradient was from 10 to 90% B in 15 minutes, then retained 90% B for 3 minutes. The injection volume was 200 microL.
The mass spectrometer was operated in positive and negative ion modes, capillary voltage was set to 2.5 KV; the source temperature was 120°C; the cone was 10V; in full scan, in full scan, the mass was adjusted ranging from 100 to 800 amu. Preparative Method 2 HPLC/MS
The HPLC equipment consisted of a Waters FractionLynx™ system equipped with a 2996 Waters PDA detector and Waters mod single quadrupole mass spectrometer. ZQ 2000, equipped with an electrospray ion source (ESI). Instrument control, data acquisition and data processing were provided by Empower 2 and MassLynx 4.1 software.
HPCL was carried out at 25°C, with a flow rate of 20 ml/min, with a Waters X Terra RP18 column (19 x 250 mm). Mobile phase A was 0.1% TEA in H2O/CH3CN (95:5), and mobile phase B was CH3CN; the gradient was from 10 to 90% B in 15 minutes, then retained 90% B for 3 minutes. The injection volume was 200 microL.
The mass spectrometer was operated in positive and negative ion modes, capillary voltage was set at 2.5 KV; the source temperature was 120°C; the cone was 10V; in full scan, the mass was adjusted ranging from 100 to 800 amu.MS exact ESI exact mass data ( + ) was obtained on Waters Q-Tof Ultima directly connected to the Agilent 1100 HPLC micro as previously described (M. Colombo, F Riccardi-Sirtori, V. Rizzo, Rapid Commun. Mass Spectrom. 2004, 18, 511-517).
NMR spectra were recorded at a constant temperature of 28°C, on a Varian INOVA 400 spectrometer operating at 400.50 MHz and equipped with a 5 mm z-axis PFG indirect detection probe (:H {15N -31P}) .
Chemical changes were referenced to residual solvent signals (DMSO-d6: 2.50 ppm to :H, where not otherwise specified). Data are reported as follows: chemical shift (δ), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, br. s = 5 broad singlet, td = doublet triplet, dd = doublet doublet , ddd - double doublet of doublet, m = multiplet, spt = septet), coupling constants (J, Hz) and number of protons.
In the examples below, as well as throughout the report, the following 10 abbreviations have the following meanings.If not defined, the terms have their commonly accepted meanings.ABREVIATIONSAcOEt Ethyl acetateAcOHAcetic acidACONaSodium acetateBINAP (2,2'-Bis(diphenylphosphine) )-1,1'-binanaphthaleneCH3CN AcetonitrileCS2CO3 Cesium carbonateCuTc Copper(i) thiophenecarboxylateCul Copper (i) iodideDCC N,N'-dicyclohexylcarbodiimideDCM DichloromethaneDIPEA N,N'-diisopropylmethylamine N,N'-diisopropylethylamine DMEDM N-ethyl-N',N'-disopropyl carbodiimideEt2O Diethyl etherEtOH EthanolHC1 Hydrochloric acidHOBt lH-benzotriazol-1-olK2CO3 Potassium carbonateKH2PO4 Potassium hydrogen phosphateKOH Potassium hydrogen phosphateLiN(TMS)OH Sodium hydroxide Lithium 2 Lithium Na2(trimethyl) Sodium thiosulfateNa2S20s Sodium metabisulfiteNa2S2O4 Sodium sulfateNaH Sodium hydrideNaH2PO4 Monosodium phosphateNaHCOa Bi sodium carbonateNaOH Sodium hydroxidePd(OAc)2 Palladium acetatePd(PPh3}4 Tetrakis (Triphenylphosphine) palladiumPd2 (dba)3 Tris(dibenzylideneacetone)dipalladium(0)PdCl2(dppf) Palladium(II) chloride [1,1-bis (diphenylphosphine)ferrocene]PPA Polyphosphoric acidPyBOP Benzotriazol-l-yloxy-tripyrrolidinephosphonium hexafluorophosphateSOC12 Thionyl chlorideTBTU 0-(Benzotriazol-l-yl)-N,N,N,N-tetramethyluronium tetrafluoroborateTEA Triethylamine trifluoroacetic acid I-trifluoroacetic acid 4 trifluoroacetic acid trifluoroacetic acid ,5-Bis(diphenylphosphino)-9,9-dimethylxanthene Preparation A (step A)

A solution of methyl 5-oxopentanoate (1.9 g, 14.6 mmol) and triphenylphosphorane (carboethoxymethylene) (5.0 g, 14.9 mmol) in toluene (50 mL) was refluxed for 8 hours. The solvent was removed in vacuo and the crude was purified by flash chromatography on silica gel (eluent: AcOEt/hexane 2/8) to yield 1.32 g (48% yield) as colorless oil of the title compound.
NMR (401 MHz, DMSO-dβ) δ ppm 1.61-1.75 (m, 2H) 2.16-2.27 (m, 2H) 2.27-2.35 (m, 2H) 3.58 (s, 3H) 3.64 (s, 3H) 5.87 (dt, J = 15, 65, 1.56 Hz, 1H) 6.87 (dt, J = 15.65, 6.94 Hz, 1H)
According to this same methodology, but employing appropriate substituted derivatives, the following compounds were prepared: dimethyl (2Z)-5,5-dimethylhept-2-enedioate JH NMR (401 MHz, DMSO-d6) δ ppm 0.98 (s, 6H) 2.24 (s, 2H) 2.63 (dt, J = 7.75, 1.65Hz, 2H) ) 3.57 (m, 3H) 3.62 (s, 3H) ) 5.90 (dt, J=11.60, 1.65Hz, 1H) 6.38 (dt, J=11.60, 7.75Hz, 1H)dimethyl (2E)-5, 5-Dimethylhept-2-enedioate XH NMR (401 MHz, DMSO-d6) δ ppm 0.96 (s, 6H) 2.21 (s, 2H) 2.22-2.24 (m, 2H) 3 .58 (s, 3H) 3.65 (s, 3H) 5.90 (dt, J = 15.50, 5.85 Hz, 1H) 6.88 (dt, J = 15.50, 7. 80 Hz, 1 H)dimethyl (2E)-hex-2-enedioatodimethyl (2E)-oct-2-enedioatoÃH NMR (401 MHz, DMSO-d6) δ ppm 1.36-1.47 (m, 4H) 1 .37-1.57 (m, 2H) 2.20 (qd, J = 7.05, 1.60 Hz, 2H) 2.31 (t, J =7.32 Hz, 2H) 3.58 (s, 3H) 3.64 (s, 3H) 5.88 (dt, J = 15.65.1.60 Hz, 1H) 6.87 (dt, J = 15.65, 7.05 Hz , 1H)1-ethyl 8-methyl (2E)-oct-2-enedioateXH NMR (401 MHz, DMSO-d6) δ ppm 1.20 (t, J = 7.16 Hz, 3H) 1.36-1 .46 (m, 2H) 1.47-1.57 (m, 2H) 2.20 (qd, J = 7.10, 1.46 Hz, 2H) 2.31 (t, J = 7.14 Hz, 2H) 3.58 (s, 3H) 4.10 (q,J = 7.16 Hz , 2H) 5.86 (dt, J = 15.56, 1.46 Hz, 1H) 6.86 (dt, J = 15.56, 7.10 Hz, 1H) 1-ethyl 7-methyl (2E)-5,5-dimethylhept-2-enedioate NMR (401 MHz, DMSO-d6) δ ppm 0.96 (s, 6H) 1.21 (t, J = 7.08 Hz, 3H) 2.21 (s, 2H) 2.22 (dd, J = 7.87, 1.30Hz, 2H) 3.58 (s, 3H) 4.11 (q, J = 7.08Hz, 2H) 5.88 (dt, J = 15.47, 1.30 Hz, 1H) 6.86 (dt, J = 15.47, 7.87 Hz, 1H)1-ethyl 7-methyl (2E)- hept-2-enedioateXH NMR (401 MHz, DMSO-dβ) δ ppm 1.20 (t, J = 7.14 Hz, 3H) 1.68 (quin, J - 7.30 Hz, 2H) 2.15 -2.27 (m, 2H) 2.31 (t, J = 7.30 Hz, 2H) 3.58 (s, 3H) 4.11 (q, J = 7.14 Hz, 2H) 5 .85 (dt, J = 15.65, 1.59 Hz, 1 H) 6.86 (dt, J = 15.65, 6.94 Hz, 1 H) Preparation B (step B)

To a 1 M solution of LiN(TMS)2 in THF (5.9 mL, 5.9 mmol) cooled to -78°C under argon was added a solution of TOSMIC (1.15 g, 5.9 mmol) in THF (15 mL) dropwise. After 40 min at -78 °C, a solution of dimethyl (2E)-hept-2-enedioate (1.1 g, 5.9 mmol) in THF (15 mL) at -78 °C was added slowly. The solution was stirred for 10 minutes, then the cold bath was removed and the reaction was allowed to warm to room temperature. THF was evaporated and the residue partitioned between H 2 O (200ml) and DCM (200ml). The aqueous layer was extracted with DCM and the combined organic layers anhydrated in Na2SO4, filtered and concentrated to yield a residue which was chromatographed on silica gel (eluent: AcOEt/hexane 3/7) to give 633 mg (yield: 40% ) of the title compound as a white solid.
NMR (401 MHz, DMSO-d6) δ ppm 1.77 (quin, J = 7.45 Hz, 2 H) 2.28 (t, J = 7.45 Hz, 2 H) 2.62 (t, J = 7.45 Hz, 2H) 3.57 (s, 3H) 3.66 (s, 3H) 6.60 (t, J = 2.20 Hz, 1H) 7.32 (dd, J = 3 .17, 2.20 Hz, 1H) 11.15 (br.s., 1H)
According to this same methodology, but employing appropriate substituted derivatives, the following compounds were prepared:
Methyl 4-(4-methoxy-2,2-dimethyl-4-oxobutyl)-1H-pyrrole-3-carboxylate2H NMR (401 MHz, DMSO-d6) δ ppm 0.90 (s, 6H) 2.06 ( s, 2H) 2.74 (s, 2H) 3.65 (s, 3H) 6.60 (s, 1H) 7.33 (t, J = 2.56Hz, 1H) 11, 21 (br.s., 1H) 11.84 (br.s., 1H)Methyl 4-(3-methoxy-3-oxopropyl)-1H-pyrrole-3-carboxy-late:H NMR (401 MHz , DMSO-d6) δ ppm 2.52-2.58 (m, 2H) 2.83 -2.90 (m, 2H) 3.58 (s, 3H) 3.67 (s, 3H) 6.60 (t, J = 2.25 Hz, 1 H) 7.33 (dd, J = 3.17, 2.25 Hz, 1 H) 11.16 (br.s., 1 H) Methyl 4 -(5-methoxy-5-oxopentyl)-1H-pyrrole-3-carboxy-latoMS calculated: 240.1231; MS found: 240.1226Ethyl-4-(4-methoxy-2,2-dimethyl-4-oxobutyl)-1H-pyrrole-3-carboxylate ∑H NMR (401 MHz, DMSO-d6) δ ppm 0.89 (s) , 6H) 1.24 (t, J = 7.08Hz, 3H) 2.15 (s, 2H) 2.73 (s, 2H) 3.56 (s, 3H) 4.12 ( q, J = 7.08 Hz, 2 H) 6.59 (t, J = 2.30 Hz, 1 H) 7.31 (dd, J = 3.11, 2.30 Hz, 1 H) 11, 21 (br.s., 1 H) 5 Ethyl 4-(4-methoxy-4-oxobutyl)-1H-pyrrole-3-carboxylate∑H NMR (401 MHz, DMSO-dβ) δ ppm 1.24 (t, J = 7.14 Hz, 3H) 1.70-1.83 (m, 2H) 2.28 (t, J = 7.51 Hz, 2H) 2.61 (t, J = 7.51 Hz, 2H) 3.57 (s, 3H) 4.13 (q, J = 7.14 Hz, 1H) 6.59 (t, J = 2.20 Hz, 1H) 7.31 (dd, J = 3.17, 2.20 Hz, 1H) 11.13 10 (br.s. 1H) Preparation C (step C) 4-[4-(methoxycarbonyl)-1H-pyrrol-3-yl] acid butanoic
Methyl 4-(4-methoxy-4-oxobutyl)-1H-pyrrole-3-carboxylic acid (50 mg, 0.220 mmol) was suspended in anhydrous dioxane (2 mL) and H20 (0.5 mL) and LiOH (5.3 mg) , 0.220 mmol) were added. The reaction mixture was stirred at room temperature for 4 h. The reaction solution was acidified with IN HCL and AcOEt (50 mL)20 and H20 (20 mL) were added. The aqueous layer was extracted with AcOEt and the combined organic layers anhydrated in Na 2 SO 4 , filtered and concentrated to give 46 mg (quantitative yield) of the title compound as a white solid. MS calculated: 212.0918; MS found: 212.0917∑H NMR (401 MHz, DMSO-dβ) δ ppm 1.74 (quin, J = 7.50 Hz, 2H) 2.19 (t, J = 7.50 Hz, 2H) ) 2.62 (t, J = 7.50 Hz, 2H) 3.66 (s, 3H) 6.60 (t, J = 2.05 Hz, 1H) 7.32 (dd, J = 3 .10, 2.05 Hz, 1H) 11.14 (br.s., 1H) 11.93 (br.s., 1H)
According to this same methodology, but employing appropriate substituted derivatives, the following compounds were prepared: 4-[4-(methoxycarbonyl)-1H-pyrrol-3-yl]-3,3-dimethylbutanoic acid MS calculated: 240.1230; MS found: 240.1229∑H NMR (401 MHz, DMSO-d6) δ ppm 0.90 (s, 6H) 2.06 (s, 2H) 2.74 (s, 2H) 3.65 ( s, 3H) 6.60 (s, 1H) 7.33 (t, J = 2.56Hz, 1H) 11.21 (br.s., 1H) 11.84 (br.s. , 1 H) 3-[4-(methoxycarbonyl)-1H-pyrrol-3-yl]propanoic acid XH NMR (401 MHz, DMSO-dβ) δ ppm 2.45 (t, J = 7.50 Hz, 2 H) 2.84 (t, J = 7.50 Hz, 2H) 3.67 (s, 3H) 6.60 (t, J = 2.20 Hz, 1H) 7.33 (dd, J = 3, 17, 2.20 Hz, 1H) 11.15 (br.s., 1H) 11.96 (br.s., 1H) 5-[4-(methoxycarbonyl)-1H-pyrrol-3-yl ]pentanoic acid MS calculated: 248.0893; MS found: 248.0896XH NMR (401 MHz, DMSO-dβ) δ ppm 1.45-1.56 (m, 4 H) 2.20 (t, J = 6.90 Hz, 2 H) 2.60 ( t, J = 6.90 Hz, 2 H) 3.66 (s, 3 H) 6.59 (t, J = 2.20 Hz, 1 H) 7.31 (dd, J = 3.17, 2 .20 Hz, 1H) 11.11 (br.s., 1H) 11.92 (br.s., 1H) 4-[4-(ethoxycarbonyl)-1H-pyrrol-3-yl]-3 ,3-dimethylbutanoic acid co4-[4-(ethoxycarbonyl)-1H-pyrrol-3-yl]butanoic acid NMR (401 MHz, DMSO-d6) δ ppm 1.24 (t, J - 7.08 Hz, 3H ) 1.74 (quin, J = 7.50 Hz, 2 H) 2.19 (t, J = 7.50 Hz, 2 H) 5 2.61 (t, J = 7.50 Hz, 2 H) 4.14 (q, J = 7.08 Hz, 2 H) 6.59 (t, J = 2.20 Hz, 1 H) 7.31 (dd, J = 3.17, 2.20 Hz, 1 H) 11.12 (br.s., 1H) 11.92 (br.s. 1 H) Preparation D (Step Ca) 4-[4-(ethoxycarbonyl)-5-methyl-1H-pyrrole-3- il] acid
6-amino-5-oxotetradecanoic hydrochloric acid (9.73 g, 49.8 mmol) was dissolved in H 2 O (35 mL), and ethyl acetoacetate (5.51 g, 42.34 mmol) and AcONa (20, 3 g, 14.95 mmol) were added to the above-mentioned solution. The reaction solution was refluxed for 1h, cooled to room temperature and 0.5N HCl was added until a pH of about 5 was reached. The combined organic layers anhydrated in Na2SO4, filtered and concentrated to give 7.15g (yield: 60%) of the title compound as brown solid. Calculated MS: 240.1231; MS found: 240.1225*H NMR (401 MHz, DMSO-d6) δ ppm 1.25 (t, J = 7.14 Hz, 3H) 1.71 (quin, J = 7.50 Hz, 2H) 2.18 (t, J = 7.50 Hz, 2H) 2.36 (s, 3H) 2.56 (t, J = 7.50 Hz, 2H) 4.13 (q, J = 7. 14 Hz, 2 H) 6.39 (d, J = 2.32 Hz, 1 H) 10.91 (br.s., 1 H) 11.90 (br.S., 1 H) Preparation E (step D) Methyl 7-OXO-4,5,6,7,-teatrahydro-1H-indole-3-carboxy-late
4-[4-(methoxycarbonyl)-1H-pyrrol-3-yl]butanoic acid (500mg, 2.36mmol) was dissolved in TEA (3ml). TFAA (0.329 mL, 2.36 mmol) was added and the reaction was stirred at room temperature for 1 h. The organic solvent was evaporated to dryness and the residue suspended in Et20 (15 mL) and filtered to yield 320 mg (yield: 64%) of the title compound as a yellow solid.LH NMR (401 MHz, DMSO-d6) δ ppm 2 .02 (quin, J = 6.30 Hz, 2 H) 2.40 (t, J = 6.30 Hz, 2 H) 2.91 (t, J = 6.30 Hz, 2 H) 3.72 (s, 3H) 7.58 (d, J = 3.42 Hz, 1H) 12.38 (br.s., 1H)
According to this same methodology, but employing appropriate substituted derivatives, the following compounds were prepared: Methyl 5,5-dimethyl-7-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxylate XH NMR (401 MHz, DMSO-d6) δ ppm 0.97 (s, 6H) 2.30 (s, 2H) 2.82 (s, 2H) 3.72 (s, 3H) 7.60 (d, J = 3.42 Hz, 1 H) 12.38 (br.s., 1 H) Methyl 6-oxo-1,4,5,6-tetrahydrocyclopenta[b]pyrrole-3-carboxylate∑H NMR (401 MHz , DMSO-d6) δppm 2.71-2.80 (m, 2H) 2.87-2.93 (m, 2H) 3.74 (s, 3H) 7.85 (s, 1H) 12 .37 (br.s., 1H)Methyl 8-oxo-1,4,5,6,7,8-hexahydrocyclohepta[b]pyrrole-3-carboxylate XH NMR (401 MHz, DMSO-d6) δ ppm 1, 70-1.80 (m, 2H) 1.81-1.89 (m, 2H) 2.59-2.65 (m, 2H) 3.06-3.15 (m, 2H) 3.70 ( s, 3H) 7.51 (d, J = 3.66 Hz, 1H) 12.01 (br.s., 1H) Ethyl 5,5-dimethyl-7-oxo-4,5,6, 7-tetrahydro-1H-indole-3-carboxylate XH NMR (401 MHz, DMSO-d6) δ ppm 1.03 (s, 6H) 1.26 (t, J = 7.08 Hz, 3H) 2.30 ( s, 2H) 2.83 (s, 2H) 4.19 (q, J = 7.08 Hz, 2H) 7.57 (d, J = 3.42 Hz, 1H) 12.36 ( br.s., 1 H) Ethyl 7-OXO-4,5,6,7- tetrahydro-1H-indole-3-carboxylate 2 H NMR (401 MHz, DMS0-d6) δ ppm 1.24 (t, J = 7.08 Hz, 3H) 1.74 (quin, J = 7.50 Hz, 2H ) 2.19 (t, J = 7.50 Hz, 2 H) 2.61 (t, J = 7.50 Hz, 2 H) 4.14 (q, J = 7.08 Hz, 2 H) 6 .59 (t,J = 2.20 Hz, 1H) 7.31 (dd, J = 3.17, 2.20 Hz, 1H) 11.12 (br.5. , 1H) 11.92 (br. br. H)Ethyl 2-methyl-7-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxylate MS calculated: 222.1125; MS found: 222.1136∑H NMR (401 MHz, DMSO-d6) δ ppm 1.27 (t, J = 7.08 Hz, 3H) 1.99 (quin, J = 6.30 Hz, 2H) 2.36 (t, J = 6.30 Hz, 2 H) 2.43 (s, 3 H) 2.87 (t, J = 6.30 Hz, 2 H) 4.18 (q, J = 7 .08 Hz, 2H) 12.15 (br.s., 1H) Preparation F (step E)Methyl 1-methyl-7-oxo-4,5,6,7-tetrahydro-1H-indole-3- carboxylate

To a solution of methyl 7-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxylate (300 mg, 1.55 mmol) in dry DMF (5 mL) K2CO3 (429 mg, 3, 10 mmol) and methyl iodide (0.193 mL, 3.10 mmol) were added. The reaction was stirred at room temperature for 3 h, then H2O was added (100 mL) and the product extracted with DCM (3 x 30 mL). The organic fractions were dried over Na2SO4, filtered and concentrated in vacuo to give 305 mg (yield: 95%) as a pale yellow solid.
XH NMR (401 MHz, DMSO-d6) δ ppm 1.95-2.03 (m, 2H) 2.40 (t, J = 6.15 Hz, 2H) 2.91 (t, J = 6, 04 Hz, 2H) 3.72 (s, 3H) 3.85 (s, 3H) 7.71 (s, 1H)
According to this same methodology, but employing appropriate substituted derivatives, the following compounds were prepared:
Methyl-methyl-6-oxo-1,4,5,6-tetrahydrocyclopenta[b]pyrrole-3-carboxylate MS calculated: 194.0812; MS found: 194.0810∑H NMR (401 MHz, DMSO-dβ) δppm 2.72-2.81 (m, 2H) 2.83-2.92 (m, 2H) 3.73 (s, 3 H) 3.74 (s, 3H) 7.81-7.91 (m, 1H)Methyl 1,5,5-trimethyl-7-oxo-4,5,6,7-tetrahydro-1H-indole - 3-carboxylate MS calculated: 236.1281; MS found: 236.1281XH NMR (401 MHz, DMSO-dβ) δ ppm 1.02 (s, 6 H) 2.30 (s, 2 H) 2.83 (s, 2 H) 3.72 (s, 3H) 3.85 (s, 3H) 7.72 (s, 1H)Methyl 1-methyl-8-oxo-1,4,5,6,7,8-hexahydrocyclohepta[b]pyrrole-3-carboxylate} H NMR (401 MHz, DMSO-dβ) δ ppm 1.60-1.74 (m, 4H) 2.53-2.62 (m, 2H) 3.13 (t, J = 6.04 Hz, 2H) 3.68 (s, 3H) 3.78 (s, 3H) 7.66 (s, 1H)Ethyl 1,5,5-trimethyl-7-oxo-4,5,6,7- tetrahydro-1H-indole-3-carboxylate MS calculated: 250.1438; MS found: 250.1444rH NMR (401 MHz, DMSO-d6) δ ppm 1.02 (s, 6H) 1.26 (t, J = 7.08 Hz, 3H) 2.30 (s, 2H) 2.83 (s, 2H) 3.85 (s, 3H) 4.19 (q, J = 7.08 Hz, 2H) 7.70 (s, 1H) Ethyl 1-methyl-7-oxo -4,5,6,7-tetrahydro-1H-indole-3-carboxylate MS calculated: 222.1125; MS found: 222.1134:H NMR (401 MHz, DMSO-d6) δ ppm 1.26 (t, J = 7.16 Hz, 3H) 1.93-2.05 (m, 2H) 2.40 ( t, J = 6.10 Hz, 2 H) 2.92 (t, J = 6.10 Hz, 2 H) 3.86 (s, 3 H) 4.19 (q, J = 7.16 Hz, 2H) 7.70 (s, 1H)Ethyl 1-(methoxymethyl)-2-methyl-7-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxylate MS calculated: 266.1387; MS found: 266.1376XH NMR (401 MHz, DMSO-d6) δ ppm 1.29 (t, J - 7.12 Hz, 3H) 1.92-2.03 (m, 2H) 2.39-2, 45 (m, 2H) 2.53 (s, 3H) 2.93 (t, J = 6.16 Hz, 2H) 3.19 (s, 3H) 4.22 (q, J = 7. 12 Hz, 2H) 5.75 (s, 2H)Ethyl 1,2-dimethyl-7-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxylate MS calculated: 236.1281; MS found: 236.1283XH NMR (401 MHz, DMSO-d6) δ ppm 1.28 (t, J = 7.08 Hz, 3H) 1.95 (quin, J = 6.25 Hz, 2H) 2, 38 (t, J = 6.25 Hz, 2H) 2.48 (s, 3H) 2.90 (t, J = 6.25 Hz, 2H) 3.83 (s, 3H) 4.20 (q,J = 7.08 Hz, 2 H) Preparation G (Step F)Methyl (6E)-6-[(dimethylamino)methylidene]1-7-oxo-4,5,6,7-tetrahydro-1H- indole-3-carboxylate

Methyl 1-methyl-7-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxylate (288 mg, 1.39 mmol) was treated with tris(dimethylamino)methane (2.4 mL, 13) .9 mmol) and the reaction mixture was stirred at 90°C for 10 h. Volatile compounds were removed under reduced pressure and the residue used without further scrubbing.
According to this same methodology, but employing appropriate substituted derivatives, the following compounds were prepared: methyl (6E)-5,5-dimethyl-6-[(methylamino) methylidene]-7-oxo-4,5,6,7 -tetrahydro-1H-indole-3-carboxylate MS calculated: 263.1390; MS found: 263.1384NMR (401 MHz, DMSO-d6) δ ppm 1.15 (s, 6H) 2.74 (s, 2H) 2.97 (d, J = 5.05Hz, 3H) 3.64-3.73 (m, 3H) 6.91 (d, J = 12Hz, 1H) 7.40 (d, J = 3.30Hz, 1H) 9.58 (dd, J - 12.30, 5.05 Hz, 1H) 12.00 (br.s., 1H)methyl (7E)-7-[(dimethylamino)methylidene]-1-methyl-8-oxo-1,4 ,5,6,7,8-hexahydrocyclohepta[b]pyrrole-3-carboxylate MS calculated: 277.1547; MS found: 277.1554XH NMR (401 MHz, DMSO-d6) δ ppm 1.76 (quin, J = 6.80 Hz, 2 H) 2.32 (t, J = 6.80 Hz, 2 H) 2 .89 (t, J = 6.80 Hz, 2H) 3.07 (s, 6H) 3.69 (s, 3H) 3.74 (s, 3H) 7.36 (s, 1H) 7 .51 (s, 1 H)
Ethyl (6E)-6-[(dimethylamino)methylidene]-1-methyl-7-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxylate∑H NMR (401 MHz, DMSO-d6) δ ppm 1.25 (t, J = 7.14 Hz, 3H) 2.76-2.89 (m, 4H) 3.05 (s, 6H) 3.87 (s, 3H) 4. 17 (q, J = 7.14 Hz, 2H) 7.29 (s, 1H) 7.53 (s, 1H)(6E)-6-[(dimethylamino)methylidene]-2-methyl-7 -oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxylate MS calculated: 277.1547; MS found: 277.1544NMR (401 MHz, DMSO-d6) δ ppm 1.26 (t, J = 7.08 Hz, 3H) 2.41 (s, 3H) 2.77-2.83 (m, 2H) 2.85-2.91 (m, 2H) 3.04 (s, 6H) 4.16 (q, J = 7.08Hz, 2H) 7.26 (s, 1H) 11, 86 (br.s., 1H)Ethyl (6E)-6-[(dimethylamino)methylidene]-1-(methoxymethyl)-2-methyl-7-oxo-4,5,6,7-tetrahydro-1H-indole -3-carboxylateMethyl(6E)-6-[(dimethylamino)methylidene]-7-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxylate LC/MS (254nm) in HPLC method 2 at room temperature for 4.5 min.XH NMR (400 MHz, DMSO-d6) δ 2.80-2.84 (m, 2H) 2.88-2.92 (m, 2H) 3.06 (s, 6H) 3.70 (s, 3H) 7.31 (s, 1H) 7.41 (d, J = 2.75Hz, 1H) 12.06 (br.s., 1H).
Methyl (6E)-1-[1-(tert-butoxycarbonyl)piperidin-4-yl]-6-[(dimethylamino)methylidene]-7-oxo-4,5,6,7-tetrahydro-1H-indole-3 -carboxylate Preparation H (step E)
Methyl 1-[1-(tert-butoxycarbonyl)piperidin-4-yl]-7-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxylate
A mixture of methyl 7-oxo-4, 5,6,7-tetrahydro-1H-indole-3-carboxylate (100 mg 0.52 mmol), tert-butyl-4-hydroxypiperidine-1-carboxylate (105 mg, 0 .52 mmol) and triphenylphosphine (136 mg, 0.52 mmol) in anhydrous THF (5 ml) at room temperature, was added di-tert-butyl-diazadicarboxylate (DTAD) (120 mg, 0.52 mmol). The mixture was stirred at room temperature for 8 h. The HPLC/MS suggested 40% conversion and 60% SM remained. Reagents were added, triphenylphosphine (136mg, 0.52mmol) and DTAD (120mg, 0.52mmol), the mixture was stirred for 4 hours. HPLC/MS showed 80% conversion and 20% SM remained. Reagents were re-added TPP (136 mg, 0.52 mmol) and DTAD (120 mg, 0.526 mmol) and the solution stirred for more than 4 hours. Volatile compounds were removed in vacuo, the crude solid was purified by flash chromatography on silica gel (hexane/EtOAc 7/3) to yield 140 mg (70% yield) of the title compound as a white solid. Example 1 (step G )2-[(4-bromo-2-methoxyphenyl)amino]-9-methyl-β,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxylate [(I),R1=4- bromo-2-methoxyphenyl, X=-NH-, R2= -0-methyl, R3=methyl, R4=H, A=-CH2CH2-]

A suspension of methyl (6E)-6-[(dimethylamino)methylidene]-1-methyl-7-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxylate (365 mg, 1.39 mmol ) in DMF (5 mL) N -(4-bromo-2-methoxy-phenyl)-guanidine (340 mg, 1.39 mmol) was added. The mixture was stirred at 120°C for 3 hours. The resulting mixture was cooled to room temperature and evaporated to dryness. The crude solid was purified by flash chromatography on silica gel (eluent: AcOEt/hexane 4/6) to yield 306 mg (yield: 50%) of the title compound as a light orange solid. MS calculated: 443.0714; MS found: 443.0704NMR (401 MHz, DMSO-d6) δ ppm 2.76 (t, J = 7.81 Hz, 2H) 2.93 (t, J = 7.81 Hz, 2H) 3, 72 (s, 3H) 3.88 (s, 3H) 4.03 (s, 3H) 7.12 (dd, J = 8.60, 2.20 Hz, 1H) 7.20 (d, J = 2.20 Hz, 1 H) 7.65 (d, J = 0.49 Hz, 1 H) 7.91 (s, 1 H) 8.07 (dJ = 8.60 Hz, 1 H) 8.21 (s, 1 h)
According to this same methodology, but employing appropriate substituted derivatives, the following compounds were prepared: ethyl 2-[(4-bromo-2-methoxyphenyl)amino]-8-methyl-6,9-dihydro-5H-pyrrole[3 ,2-h]quinazoline-7-carboxylate [(I), R1= 4-bromo-2-methoxyphenyl), X= -NH-, R2= -0-ethyl, R3= H, R4= methyl, A= - CH2CH2-]
MS calculated: 457.087; MS found: 457.0868NMR (401 MHz, DMSO-d6) δ ppm 1.28 (t, J = 7.08 Hz, 3H) 2.51 (br.s., 3H) 2.75-2.83 (m, 2H) 2.91-2.98 (m, 2H) 3.92 (s, 3H) 4.19 (q, J = 7.08 Hz, 2H) 7.13 (dd, J = 8.65, 2.20 Hz, 1H) 7.20 (d, J = 2.20Hz, 1H) 7.60 (s, 1H) 8.17 (s, 1H) 8.50 ( d, J = 8.65 Hz, 1H) 12.07 (s, 1H)ethyl 9-methyl-2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-6,9- dihydro-5H-pyrrole[3,2-h]quinazoline-7-carboxylate [(I), R1 = 4-(4-methyliperazin-1-yl)phenyl, X= -NH-, R2 = -O-ethyl, R3=methyl, R4=H, A=-CH2CH2-]
MS calculated: 447.2503; MS found: 447.2485 NMR (401 MHz, DMSO-d6) δ ppm 1.27 (t, J = 7.08 Hz, 3H) 2.22 (s, 3H) 2.42-2.47 (m, 4H) 2.70-2.77 (m, 2H) 2.89-2.95 (m, 2H) 3.02-3.09 (m, 4H) 4.08 (s, 3H) 4. 19 (q, J = 7.08 Hz, 2H) 6.84-6.90 (m, 2H) 7.45-7.53 (m, 2H) 7.61 (s, 1H) 8.14 (s , 1H) 8.97 (s, 1H)ethyl 2-[(4-bromo-2-methoxyphenyl)amino]-9-methyl-6,9-dihydro-5H-pyrrole[3,2-h]quinazoline -7-carboxylate [(I), R 1 = 4-bromo-2-methoxyphenyl, X = -NH-, R 2 = -O-ethyl, R 3 = methyl, R 4 = H, A = -CH 2 CH 2 -]
MS calculated: 457.0870; MS found: 457.0876TH NMR (401 MHz, DMSO-d6) δ ppm 1.27 (t, J = 7.08 Hz, 3H) 2.71-2.83 (m, 2H) 2.89-2, 98 (m, 2H) 3.88 (s, 3H) 4.03 (s, 3H) 4.20 (q, J = 7.08 Hz, 2H) 7.12 (dd, J = 8. 60, 2.20Hz, 1H) 7.20 (d, J = 2.20Hz, 1H) 7.63 (s, 1H) 7.92 (s, 1H) 8.06 (dJ = 8.60 Hz, 1H) 8.20 (s, 1H)methyl 2-[(4-bromo-2-methoxyphenyl)amino]-10-methyl-5,6,7,10-tetrahydropyrrole[3', 2':6,7]cyclohepta[1,2-d]pyrimidine-8-carboxylate [(I),R1=4-bromo-2-methoxyphenyl, X=-NH-, R2=-0-methyl, R3- methyl, R4=H, A=-(CH2)3-]
MS calculated: 457.0870; MS found: 457.0851NMR (401 MHz, DMSO-d6) δ ppm 1.92-2.07 (m, 2H) 2.91 (t, J = 7.08 Hz, 2H) 3.71 (s, 3H) 3.85 (s, 3H) 3.86 (s, 3H) 7.13 (dd, J = 8.61, 2.20 Hz, 1H) 7.20 (d, J = 2, 20Hz, 1H) 7.66 (s, 1H) 7.93-8.08 (m, 2H) 8.30 (s, 1H)ethyl 2-amino-8-methyl-6,9-dihydro -5H-pyrrole[3,2-h]quinazoline-7-carboxylate [(I), R1=H, X=-NH-, R2= -0-ethyl, R3=H, R4=methyl, A=-CH2CH2 -]
ethyl 9-(methoxymethyl)-2-{[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]amino}-8-methyl-6,9-dihydro-5H-pyrrole[3,2-h ]ethyl quinazoline-7-carboxylate [(I), R1= 2-methoxy-4-(4-methylpiperazin-1-yl)phenyl, X= -NH-, R2= -0-ethyl, R3=methoxymethyl, R4 = methyl, A= -CH2CH2-]
Example 2 (conv, 3)2-[(4-bromo-2-methoxyphenyl)]-9-methyl-6,9-dihydro-5H-bromo-2-methoxyphenyl, X= -NH-, R2= -OH, R3=methyl, R4=H, A=CH2CH2-]
methyl 2-[(4-bromo-2-methoxyphenyl)amino]-9-methyl-6,9-dihydro-5H-pyrrole[3,2-h]quinazoline-7-carboxylate (300 mg, 0.68 mmol) was suspended in dioxane (10 mL) and treated with 2N NaOH solution (5.1 mL, 10.2 mmol) at reflux temperature for 3h. H2O (50 mL) was added and the solution was acidified with 2N HCL. The resulting precipitate was collected by filtration leaving 211 mg (72% yield) of the title compound as a white solid. MS calculated: 429.0557; MS found: 429.0566NMR (401 MHz, DMSO-d6) δ ppm 2.73 (t, J = 7.93 Hz, 2H) 2.93 (t, J = 7.93 Hz, 2H) 3, 88 (s, 3H) 4.03 (s, 3H) 7.12 (dd, J = 8.67, 2.20 Hz, 1H) 7.20 (d, J = 2.20 Hz, 1H) 7.57 (s, 1H) 7.88 (s, 1H) 8.08 (d, J = 8.67 Hz, 1H) 8.20 (s, 1H) 12.00 (br.s. ., 1 H)
According to this same methodology, but employing appropriate substituted derivatives, the following compounds were prepared: 2-[(4-bromo-2-methoxyphenyl)amino]-8,9-dimethyl-6,9-[(I), R1 = 4-bromo-2-methoxyphenyl, X= -NH-R2= -OH, R3= methyl, R4= methyl, A= -CH2CH2-]
MS calculated: 443.0714; MS found: 443.0703:H NMR (401 MHz, DMSO-d6) δ ppm 2.53 (s, 3H) 2.67-2.74 (m, 2H) 2.87-2.97 (m, 2H) 3.88 (s, 3H) 4.00 (s, 3H) 7.12 (dd, J = 8.54, 2.20 Hz, 1H) 7.20 (d, J = 2.20 Hz , 1H) 7.86 (s, 1H) 8.09 (d, J = 8.54Hz, 1H) 8.16 (s, 1H) 12.02 (br. sl H)2-amino -9-[1-<tert-butoxycarbonyl)piperidin-4-yl]-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxylic acid [(I), R1 = H, X = -NH-, R2= -OH, R3= 1-(tert-butoxycarbonyl)piperidin-4-yl, R4=H, A= -CH2CH2-]
Example 3 (conv. 4)2-[(4-bromo-2-methoxyphenyl)amino]-N-(2,6-diethylphenyl)-9-methyl-6,9-dihydro-5H-pyrrole[3,2- h]quinazoline-7-carboxamide diethylphenyl), R3=methyl, R4=H, A=-CH2CH2- (compound 8)
2-[(4-bromo-2-methoxyphenyl)]-9-methyl-6,9-dihydro-5H-pyrrole[3,2-h]quinazoline-7-carboxylic acid (206 mg, 0.48 mmol) was suspended in dry THF (10 mL) and SOC12 (0.7 mL, 9.6 mmol) was added under argon. The reaction mixture was refluxed to 2H, then all volatile compounds were removed under reduced pressure. The crude residue was dissolved in dry DCM (10 mL), then DIPEA (0.43 mL, 2.4 mmol) and 2,6-diethylaniline (143 mg, 0.96 mmol) were added and the reaction mixture it was refluxed for 2 h. DCM (100ml) was added and the organic phase extracted with H 2 O (3x25ml). The organic layer was dried over anhydrous Na 2 SO 4 and the solvent evaporated to dryness to give 190 mg (yield: 70%) of the title compound as a pale yellow solid. MS calculated: 560.1656; MS found: 560.1655NMR (401 MHz, DMSO-d6) δ ppm 1.11 (t, J = 7.57 Hz, 6h) 2.55 (q, J = 7.57 Hz, 4H) 2.72 -2.79 (m, 2H) 2.95-3.02 (m,2H) 3.89 (s, 4H) 4.08 (s, 3H) 7.08-7.16 (m, 3H) ) 7.16-7.24(m, 2H) 7.74 (s, 1H) 7.88 (s, 1H) 8.12 (d, J = 8.70Hz, 1H)
According to this same methodology, but employing appropriate substituted derivatives, the following compounds were prepared: 2-[(4-bromo-2-methoxyphenyl)]-8,9-dimethyl-6,9-dihydro-5H-5 pyrrolo[3,2-h]quinazoline-7-carboxamide [(I), R1= 4-bromo-2-methoxyphenyl, X= -NH-, R2= -NH2, R3=methyl, R4=methyl, A=- CH2CH2-J
Example 4 (conv. 5)2-[(4-bromo-2-methoxyphenyl)amino]-N-(2,6-diethylphenyl)-8,9-dimethyl-6,9-dihydro-5H-pyrrole[3, 2-h]quinazoline-7-carboxamides [(I), R 1 = 4-bromo-2-methoxyphenyl, X = -NH-, R 2 = -N-(2,6-diethylphenyl), R 3 = methyl, R 4 = methyl , A= -CH2CH2-]
For a solution of 2,6-diethylaniline (300 mg, 2.01 mmol) in dry THF (10 mL) under argon, lm in the THF solution of LiN(TMS)2 (4.02 mL, 4.02 mmmol) to 0°C was added dropwise. The mixture was stirred at 0°C for 10 minutes, then 2-[(4-bromo-2-methoxyphenyl)amino]-8,9-dimethyl-6,9-dihydro-5H-pyrrole[3,2- h]quinazoline-7-carboxylate (0.315 g, 0.67 mmol) in dry THF (10 mL) at 0°C was added dropwise. The ice bath was removed and the mixture was stirred at room temperature for 1 hour. H20 (20ml) was added and the mixture was extracted with AcOEt (2x30ml). The organic layer was dried over anhydrous Na2SO4 and the solvent evaporated to dryness. The crude solid was purified by flash chromatography on silica gel (eluent: AcOEt/cyclohexane 1/1) to yield 355 mg (92% yield) of the title compound as a yellow solid. MS calculated: 574.1812; MS found: 574.1818NMR (401 MHz, DMSO-d6) δ ppm 1.14 (t, J = 7.57 Hz, 6h) 2.44 (s, 3H) 2.58 (q, J = 7.57 Hz, 4H) 2.71-2.81 (m, 2H) 2.85-2.94 (m, 2H) 3.89 (s, 3H) 4.02 (s, 3H) 7.10-7 .16 (m, 3H) 7.18-7.23 (m, 2H) 7.85 (s, 1H) 8.13 (d, J = 8.67 Hz, 1H) 8.16 (8 , 1 H) 8.84 (s, 1 H) According to this same methodology, but employing appropriate substituted derivatives, the following compounds were prepared: N-(2,6-diethylphenyl)-9-(methoxymethyl)-2- {[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]amino}-8-methyl-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxamide [(I ), R 1 = 2-methoxy-4-(4-methylpiperazin-1-yl)phenyl, X = -NH-, R 2 = -N-(2,6-diethylphenyl), R 3 = methoxymethylphenol, R 4 = methyl, A = -CH2CH2-] 10 (compound 1)
MS calculated: 624.3657; MS found: 624.36602-[(4-Bromo-2-methoxyphenyl)amino]-N-(2,6-diethylphenyl)-10-methyl-5,6,7,10-tetrahydropyrrole[3',26.7 ] cyclohepta [1,2-d]15 pyrimidine-8-carboxamides [(I), R1 = 4-bromo-2-methoxyphenyl, X = -NH-, R2 = -N-(2,6-diethylphenyl), R3 = methyl, R4= H, A= -(CH2)3-] (compound 15)
MS calculated: 574.1812; MS found: 574.1797NMR (401 MHz, DMSO-d6) δ ppm 1.12 (t, J = 7.57 Hz, 6h) 1.94-2.05 (m, 2H) 2.55 (q, J = 7.57 Hz, 4H) 2.92 (t, J = 7.14Hz, 2H) 3.88 (s, 3H) 3.89 (s, 3H) 7.09-7.20 (m, 4H) 7.21 (d, J = 2.32 Hz, 1H) 7.69 (s, 1H) 7.98 (s, 1H) 8.10 (dJ = 8.54 Hz , 1H) 8.30 (s, 1H) 9.05 (s, 1H) Example 5 (conv. 6)N-(2,6-diethylphenyl)-2-{[2-methoxy-4-( 4-methylpiperazin-1-yl)phenyl]amino}-9-methyl-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxamide [(I), R1 = 2-methoxy-4 -(4-methylpiperazin-1-yl)phenyl, X= -NH-, R2= -N-(2,6-diethylphenyl), R3 = methyl, R4=H, A= -CH2CH2-] (compound 9)
Pd2(dba)3, (10mg, 0.010mmol), 2-dicyclohexylphosphino-2'-(N,N-dimethylamino)-biphenyl (10mg, 0.025mmol) and 2-[(4-bromo-2-methoxyphenyl) amino]-N-(2,6-diethylphenyl)-9methyl-6,9-dihydro-5H-pyrrole[3.2]quinazoline-7-carboxamide (100mg, 0.178mmol) in dry THF (5ml) was placed in a round bottom flask with argon. The flask was evacuated and refilled with argon. A solution of LiN(TMS)2 (1M in THF, 1.39 mL) and N-methylpiperazine (0.058 mL, 0.522 mmol) were added and the reaction mixture was heated at 85°C for 0.5 h. The reaction mixture was then allowed to cool to room temperature and the solvent evaporated to dryness. The crude solid was purified by flash chromatography on silica gel (eluent: DCM/MeOH 95/5) to yield 72 mg (70% yield) of the yellow solid title compound. MS calculated: 580.3395; MS found: 580.3373XH NMR (401 MHz, DMSO-d6) δ ppm 1.11 (t, J = 7.57 Hz, 6h) 2.25 (br.s., 3H) 2.54 (g, J = 7.57 Hz, 4H) 2.69-2.76 (m, 2H) 2.91-2.99 (m, 2H) 3.05-3.19 (m, 4H) 3.82 (s, 3H) 4.04 (s, 3H) 6.49 (dd, J = 8.67, J = 2.56 Hz, 1H) 6.63 (d, J = 2.56 Hz, 1H ) 7.08-7.14 (m, 2H) 7.16-7.23 (m, 1H) 7.66 (s, 1H) 7.69 (s, 1H) 7.76 (d, J = 8.67 Hz, 1 H) 8.10 (s, 1 H) 9.03 (s, 1 H)
According to this same methodology, but employing appropriate substituted derivatives, the following compounds were prepared: N-(2,6-diethylphenyl)-2-({2-methoxy-4-[4-(pyrrolidin-1-yl)piperidine -1-yl]phenyl}amino-8,9-dimethyl-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxamide [(I), R1 = 2-methoxy-4-[ 4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl, X=-NH-, R2=-N-(2,6-diethylphenyl), R3=methyl, R4=methyl, A=-CH2CH2-]
MS calculated: 648.4021; MS found: 648.4026XH NMR (401 MHz, DMSO-d6) δ ppm 1.13 (t, J = 7.57 Hz, 5 6h) 1.47-1.61 (m, 2H) 1.64 1, 76 (mm, 4H) 1.88-1.98 (m, 2H) 2.42 (s, 3H) 2.52-2.63 (m, 8H) 2.64-2.75 (m, 4H) 2.83-2.92 (m, 2H) 3.26-3.29 (m, 1H) 3.54-3.65 (m, 2H) 3.82 (s, 3H)3 .98 (s, 3H) 6.49 (dd, J = 8.65, 2.50 Hz, 1H) 6.63 (d, J =2.40 Hz, 1H) 7.08-7, 15 (m, 2H) 7.17-7.24 (m, 1H) 7.62 (s, 110H) 7.74 (d, J = 8.65Hz, 1H) 8.06 (s, 1H) 8.81 (s, 1H)N-(2,6-diethylphenyl)-2-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl)amino)-8, 9-dimethyl-6,9-dihydro-5H-pyrrole[3,2-h]quinazoline-7-carboxamide [(I), R1=4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl , X= -NH-, R 2 -N-(2,6-diethylphenyl), R 3 = methyl, R 4 = methyl, A = -CH 2 CH 2 -] (compound 4)
MS calculated: 622.3864; MS found: 622.3868XH NMR (401 MHz, DMSO-d6) δ ppm 1.13 (t, J = 7.57 Hz, 6h) 1.44-1.60 (m, 2H) 1.68-1, 90 (m, 2H) 2.23 (br., 6h) 2.42 (s, 3H) 2.58 (q, J = 7.57 Hz, 4H) 2.60-2.69 (m, 2H) ) 2.69-2.75 (m, 2H) 2.83-2.93 (m, 2H) 3.61-3.70 (m, 2H) 3.82 (s3H) 3.98 (s, 3 H) 6.49 (dd, J = 8.70, 2.50 Hz, 1H) 6.63 (d, J = 2.50 Hz, 1H) 7.06-7.16 (m, 2H) 7.17-7.24 (m, 1H) 7.62 (s, 1H) 7.74 (d, J = 8.70Hz, 1H) 8.06 (s, 1H) 8.81 (s, 1 H)N-(2,6-diethylphenyl)-2-{[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]amino}-8,9-dimethyl-6,9- dihydro-5H-pyrrole [3,2-h]quinazoline-7-carboxamides [(I), R1= 2-methoxy-4-(4-methylpiperazin-1-yl)phenyl, X= -NH-, R2= - N-(2,6-diethylphenyl), R3 = methyl, R4 = methyl, A = -CH2CH2-] (compound 5)
MS calculated: 594.3551; MS found: 594.3554XH NMR (401 MHz, DMSO-d6) δ ppm 1.13 (t, J = 7.57 Hz, 6h) 2.25 (s, 3H) 2.42 (s, 3H) 2 .58 (q, J = 7.57 Hz, 4H) 2 , 68-2.79 (m, 2H) 2.84-2.91 (m, 2H) 3.07-3.17 (m, 4 H) 3.82 (s, 3H) 3.99 (s, 3H) 6.49 (dd, J = 8.80, 2.45 Hz, 1 H) 6.63 (dJ = 2.45 Hz, 1 H) 7.06-7.17 (m, 2H) 7.17-7.24 (m, 1H) 7.62(s, 1H) 7.77 (d, J = 8.80 Hz, 1 H) 8.07 (s, 1H) 8.82 (s, 1H) N-(2,6-diethylphenyl)2({4-4-2-hydroxyethyl)piperazin-1-yl]-2-methoxyphenyl- 6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxamide [(I), R1 = 4-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methoxyphenyl, X = -NH-, R2= -N-(2,6-diethylphenyl), R3 = methyl, 5 R4=methyl, A= -CH2CH2-] (compound 6)
MS calculated: 624.3657; MS found: 624.3643NMR (401 MHz, DMSO-d6) δ ppm 1.13 (t, J = 7.57 Hz, 6h) 2.42 (s, 3H) 2.44-2.49 (m, 6 H) 2.58 (q, J = 7.57 Hz, 4H)10 2.73 (m, 2H) 2.88 (m, 2H) 3.06-3.20 (m, 4H) 3, 49-3.61 (m, 2H) 3.82 (s, 3H) 3.99 (s, 3H) 4.41 (br.s., 1H) 6.48 (ddJ = 8.70, 2 .35Hz, 1H) 6.63 (d, J = 2.35Hz, 1H) 7.04-7.16 (m, 2H) 7.17-7.23 (m, 1H) 7. 63 (s, 1H) 7.76 (d, J = 8.70 Hz, 1H) 8.06 (s, 1H) 8.82 (s, 1H)2-{[2-methoxy-4 -(4-methylpiperazin-1-yl)phenyl]amino)8,9-dimethyl-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxamide[(I), R1 = 2- methoxy-4-(4-methylpiperazin-1-yl)phenyl, X=-NH-,R2=-NH2, R3=methyl, R4-methyl, A=-CH2CH2-] (compound 7)
MS calculated: 462.2612; MS found: 462.2595XH NMR (401 MHz, DMSO-d6) 5ppm 2.22 (s, 3H) 2.38 (s, 3H) 2.43-2.47 (m, 4H) 2.61- 2.69 (m, 2H) 2.73-2.81 (m, 2H)5 3.06-3.13 (m, 4H) 3.80 (s, 3H) 3.93 (s, 3H) ) 6.47 (dd, J=8.70, 2.56Hz, 1H) 6.61 (d,J=2.56Hz, 1H) 6.89 (br.s.H2) 7.58 (s, 1H) 7.74 (d, J = 8.70 Hz, 1H) 8.04 (s, 1H)N-(2,6-diethylphenyl)—2 —({4 —[4 — (dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-9-methyl-6,9-dihydro-5H-pyrrole[3,2-h]10 quinazoline-7-carboxamide [(I), Rl= 4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl, X=-NH-, R2=-N-(2,6-diethylphenyl), R3=methyl, R4=H, A=-CHJCHJ -] (compound 10)
MS calculated: 608.3708; MS found: 608.371215 XH NMR (401 MHz, DMSO-d6) δ ppm 1.11 (t, J = 7.57 Hz, 6h) 1.41-1.61 (m, 2H) 1.77-1 2.92 (m, 2H) 2.17-2.32 (m, 7H) 2.54 (q, J = 7.57 Hz, H 46) 2.60-2.68 (m, 2H) 2. 69-2.77 (m, 2H) 2.90-3.01 (m, 2H) 3.59-3.64 (m, 2H) 3.82 (s, 3H) 4.03 (s, 3 H) 6.49 (dd, J = 8.80, 2.56 Hz, 1H) 6.63 (d, J = 2.56Hz, 1H) 7.05-7.16 (m, 2H) 7.16-7.23 (m, 1H) 7.66 (s, 1H) 7.69 (s, 1H) 7.74 (d, J = 8.80 Hz, 1H) 8.10 (s, 1H) 9.03 (s, 1H)N-(2,6-diethylphenyl)-2-({2-methoxy-4-[4-(pyrrolidin-1-yl)piperidin-1-yl ]phenyl}amino)-9-methyl-6,9-dihydro-5H-pyrrole[3,2-h]quinazoline-7-carboxamide [(I), R1=2-methoxy-4-[4-(pyrrolidine- 1-yl)piperidin-1-yl]phenyl, X=-NH-, R2=-N-(2,6-diethylphenyl), R3=methyl, R4=H, A=-CH2CH2-] (compound 11)
MS calculated: 634.3864; MS found: 634.3874;H NMR (401 MHz, DMSO-d6) δ ppm 1.11 (t, J = 7.57 Hz, 6h) 1.64 1.45-1.60 (m, 2H)- 1.74 (mm, 4H) 1.87-1.99 (m, 2H) 2.04-2.16 (m, 1H) 2.54 (q, J = 7.57 Hz, 4H) 2.65-2.81 (m, 4H) 2.90-3.03 (m, 2H) 3.50-3.66 (m, 2H) 3.50-3.66 (m, 2H) 3.82(s, 3H) 4.04 (s, 3H) 6.49 (dd, J = 8.70, 2.50 Hz, 1H) 6.63(d, J = 2.50 Hz, 1H) 7.04-7.15 (m, 2H) 7.15-7.29 (m, 1H) 7.65 (s, 1H) 7.69 (s, 1H) 7.74 ( d, J = 8.70 Hz, 1H) 8.10(s, 1H) 9.03 (s, 1H) N-(2,6-diethylphenyl)-2-[(4-{[3- (dimethylamino)propyl](methyl)amino}-2-methoxyphenyl)amino]-9-methyl-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxamide [(I), Rl= 4-{[3-(dimethylamino)propyl]methylamino}-2-methoxyphenyl, X= -NH-, R 2 = -N-(2,6-diethylphenyl), R 3 = methyl, R 4 = H, A = -CH 2 CH 2 - ] (compound12)
MS calculated: 596.3708; MS found: 596.3782NMR (401 MHz, DMSO-d6) δ ppm 1.11 (t, J = 7.51 Hz, 6h) 1.64 (quin, J = 6.80 Hz, 2H) 2.15 (s, 6H) 2.24 (t, J = 6.80 Hz, 2H) 2.54 (q, J = 7.51 Hz, 4H) 2.65-2.75 (m, 2H) 2.87 (s, 3H) 2.90-2.97 (m, 2H) 3.79 (s, 3H) 4.01 (s, 3H) 6.27 (ddj = 8.80, 2, 50Hz, 1H) 6.39 (d, J = 2.50Hz, 1H) 7.09-7.14 (m, 2H) 7.16-7.23 (m, 1H) 7.57 (d, J = 8.80 Hz, 1H) 7.62 (s, 1H) 7.67 (s, 1H) 8.06 (s, 1H) 9.02 (s, 1H)N -(2,6-diethylphenyl)-2-({4-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methoxyphenyl}amino)-9-methyl-6,9-dihydro-5H-pyrrole [3,2-h]quinazoline-7-carboxamide [(I), R1=4-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methoxyphenyl, X=-NH-, R2=-N -(2,6-diethylphenyl), R3 = methyl, R4=H, A= -CH2CH2-] (compound 13)
calculated MS: 610.3500; MS found: 610.3498:H NMR (401 MHz, DMSO-dβ) δ ppm 1.11 (t, J = 7.51 Hz, 6h) 2.45 (t, J = 6.10 Hz, 2H) 2.52-2.61 (m, 8H) 2.68-2.765 (m, 2H) 2.91-3.00 (m, 2H) 3.09-3.16 (m, 4H) 3. 54 (q, J = 6.10Hz, 2H) 3.82 (s, 2H) 4.04 (s, 2H) 4.37-4.45 (m, 1H) 6.48(ddJ = 8.79, 2.44 Hz, 1H) 6.62 (d, J = 2.44Hz, 1H) 7.097.13 (m, 2H) 7.15-7.23 (m, 1H) 7 .66 (s, 1H) 7.69 (s, 1H) 7.75 (d, J = 8.79Hz, 1H) 8.10 (s, 1H) 9.03 (s, 1H) )N-(2,6-diethylphenyl)-2-{[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]amino]-10-methyl-5,6,7,10-tetrahydropyrrole[3 ',2':6,7]cyclohepta[1,2-d]pyrimidine-8-carboxamide [(I), R1=2-methoxy-4-(4-methylpiperazin-1-yl)phenyl, X--NH -, R2= -N- (2,6-diethylphenyl), R3=methyl, R4=H, A=-(CH2)3-] (compound 16)
MS calculated: 594.3551; MS found: 594.3524NMR (401 MHz, DMSO-d6) δ ppm 1.11 (t, J = 7.57 Hz, 6h) 1.89-2.03 (m, 2H) 2.23 (s, 3H ) 2.43-2.48 (m, 4 H) 2.55 (q, J = 7.57 Hz, 4 H) 2.91 (t, J = 7.14 Hz, 2 H) 3.09- 3.15 (m, 4H) 3.80 (s, 3H) 3.81 (s, 3H) 6.49 (dd, J = 8.70, 2.50 Hz, 1H) 6.63 ( d, J = 2.50 Hz, 1H) 7.08-7.15 (m, 2H) 7.15-7.23 (m, 1H) 7.61-7.68 (m, 2H) 7 .79 (s, 1H) 8.19 (s, 1H) 9.01 (s, 1H)N-(2,6-diethylphenyl)-2-({4-[4-(dimethylamino)piperidin- 1-yl]-2-methoxyphenyl}amino)-10-methyl-5,6,7,10-tetrahydropyrrole [3',2':6,7]cyclohepta[1,2-d]pyrimidine-8-carboxamide [ (I), R 1 = 4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl, X = -NH-, R 2 = -N-(2,6-diethylphenyl), R 3 = methyl, R 4 = H, A=-(CH2)3_](compound 17)
MS calculated: 622.3864; MS found: 622.3876XH NMR (401 MHz, DMSO-d6) δ ppm 1.11 (t, J = 7.57 Hz, 6h) 1.42-1.58 (m, 2H) 1.76-1, 89 (m, 2H) 1.92-2.02 (m, 2H) 2.13-2.19 (m, 1H) 2.18-2.23 (m, 6H) 2.43-2, 48 (m, 2H) 2.55(q, J = 7.57Hz, 4H) 2.60-2.70 (mm, 2H) 2.92 (t, J = 7.08Hz2H) 3.62 -3.72 (m, 2H) 3.79 (s, 3H) 3.80 (s, 3H) 6.50 (dd,J = 8.75, 2.44 Hz, 1H) 6.62 (d, J = 2.44 Hz, 1H) 7.05-7.14 (m, 2H) 7.13-7.24 (m, 1H) 7.58-7.68 (m, 2H) 7.79 (s, 1H) 8.19 (s, 1H) 9.01 (s, 1H)N-(2,6-diethylphenyl)-2-({2-methoxy-4-[4- (pyrrolidin-1-yl)piperidin-1-yl]phenyl}amino)-10-methyl-5,6,7,10-tetrahydropyrrole[3',2':6,7]cyclohepta[1,2-d] pyrimidine-8-carboxamide [(I), R1 = 2-methoxy-4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl, X= -NH-, R2 = -N-(2, 6-diethylphenyl), R3=methyl, R4=H, A=~(CH2)3-](compound 18)
MS calculated: 648.4021; MS found: 648.4023NMR (401 MHz, DMSO-dβ) δ ppm 1.11 (t, J = 7.57 Hz, 6h) 1.42-1.59 (m, 2H) 1.63-1.76 (mm, 4H) 1.83-2.04 (m, 4H) 2.04-2.18 (m, 1H) 2.42-2.50 (m, 6H) 2.54 (q , J = 7.57 Hz, 4H) 2.65-2.77 (m, 2H) 2.92 (t, J = 7.14Hz, 2H) 3.51-3.65 (m, 2 H) 3.79 (s, 3H) 3.80 (s, 3H) 6.50 (dd, J = 8.85, 2.50 Hz, 1H) 6.62 (d, J = 2, 45Hz, 1H) 7.03-7.15 (m, 2H) 7.15-7.24 (m, 1H) 7.58-7.68 (m, 2H) 7.78 (s, 1 H) 8.19 (s, 1 H) 9.01 (s, 1 H) Example 6 (conv. 2) Ethyl-2[(4-bromo-2-methoxyphenyl)amino]-8,9-dimethyl-6 ,9-dihydro-5H-pyrrole[3,2-h]quinazoline-7-carboxylate [(I), R1=4-methyl, A=-CH2CH2-]
For a solution of ethyl 2-[(4-bromo-2-methoxyphenyl)amino]-8-methyl-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxylate (50mg, 0 .11 mmol) in DMF (1 mL), Cs 2 CO 3 (73 mg, 0.22 mmol) and methyl iodide (0.007 mL, 0.11 mmol) were added. The mixture was stirred at room temperature for 8 h, the solvent was removed under vacuum, then DCM (10 ml) was added and the organic phase washed with water (2 x 15 ml). The organic fraction was dried over Na2SO4, filtered and concentrated under vacuum. Purification by flash chromatography on silica gel (eluent: AcOEt/hexane 4/6) provided 40mg (yield: 80%) of the title compound as a pale yellow solid. MS calculated: 471.1027; MS found: 471.10311H NMR (401 MHz, DMSO-d6) δ ppm 1.28 (t, J = 7.08 Hz, 3H) 2.53 (s, 3H) 2.72 (t, J = 7 .63 Hz, 2H) 2.91 (t, J = 7.63Hz, 2H) 3.88 (s, 3H) 4.00 (s, 3H) 4.20 (q, J = 7.08 Hz , 2H) 7.12 (dd, J = 8.55, 2.14 Hz, 1 H) 7.20 (d, J = 2.14 Hz, 1 H) 7.89 (s, 1 H) 8 .07 (d, J = 8.55 Hz, 1 H) 8.17 (s, 1 H) According to this same methodology, but employing appropriate substituted derivatives, the following compound was prepared: Ethyl 2-amino-8, 9-dimethyl-6,9-dihydro-5H-pyrrole[3,2-h]quinazoline-7-carboxylate [(I), R1= -H, X= -NH-, R2= -O-ethyl, R3= methyl, R4=methyl, A=-CH2CH2-]
Example 7 (conv. 7) Ethyl 2-({2-Methoxy-4-[(1-methylpiperidin-4-yl)carbamoyl]phenylamino)-8,9-dimethyl-6,9-dihydro-5H-pyrrole[3 ,2-h]quinazoline-7-carboxylate [(I), R1=2-methoxy-4-[(1-methylpiperidin-4-yl)carbamoyl]phenyl, X=-NH-, R2=-O-ethyl, R3 = methyl, R4 = methyl, A = -CH2CH2-]
For a solution of ethyl 2-amino-8,9-dimethyl-6,9-dihydro-5H-pyrrole[3,2-h]quinazoline-7-carboxylate (87 mg, 0.280 mmol) in dioxane (2 mL), 4-iodo-3-methoxy-N-(1-methylpiperidin-yl)benzamide (112 mg, 0.254 mmol) and CS2CO3 (92 mg, 0.280 mmol) were added and the flask was evacuated and filled with argon. Pd2(dba)3 (4.7 mg, 0.005 mmol) and Xantphos (6.5 mg of 0.011 mmol) were then placed and the mixture was heated at 80°C under argon for 8 hours. After cooling to room temperature, the reaction mixture was concentrated, suspended in H 2 O (10 mL) and extracted with AcOEt (3 x 15 mL). The organic phase was anhydrated in Na2SO4, filtered and evaporated to dryness, the crude solid was purified by flash chromatography on silica gel (eluent: DCM/MeOH 9/2) to yield 100 mg (yield: 70%) of the title compound as a yellow solid. NMR (500 MHz, DMSO-dβ) δ ppm 1.29 (t, J = 7.00 Hz, 3H) 1.54-1.67 (m, 2H) 1.72-1.83 (m, 2H) 1.91-2.08 (m, 2H) 2.20(br.s., 3H) 2.55 (s, 3H) 2.70-2.76 (m, 2H) 2 .77.2.86 (m, 2H) 2.89-2.98 (m, 2H) 3.69-3.81 (m, 1H) 3.94 (s, 2H) 4.05 (s , 2H) 4.20 (q, J = 7.00 Hz, 2H) 7.40-7.54 (m, 2H) 7.97 (s, 1H) 8.12 (d, J = 7 .69 Hz, 1 H) 8.22 (s, 1 H) 8.29 (d, J = 8.24 Hz, 1 H) Example 8 (conv, 4) 2-[(4-Bromo-2-methoxyphenyl ) amino]-N-[(1s)-2-(1,3-dioxo-1,3-dihydro-2h-isoindol-2-yl)-1-phenyl-ethyl]-9-methyl-6,9-dihydro- 5H-pyrrole[3,2-h]quinazoline-7-carboxamide [(I), R1= 4-bromo-2-methoxyphenyl, X= -NH-, R2= N-[(IS)-2-(1, 3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-phenyl ethyl], R3=methyl, R4=H, A=
2-[(4-bromo-2-methoxyphenyl)]-9-methyl-6,9-dihydro-5H-pyrrole [3,2-h]quinazoline-7-carboxylic acid (50 mg, 0.116 mmol) in dry DMF (5.0 mL) was treated with DIPEA (0.056 mL, 0.033 mmol) and TBTU (65 mg, 0.200 mmol). The mixture was then treated with 2-[(2S)-2-amino-2-phenylethyl]-1H-isoindole-1,3(2H)-dione (3mg, 0.011mmol).
The reaction was stirred at room temperature for 4 h. The reaction was diluted with water and the resulting precipitate was collected by filtration to yield 35 mg (yield: 45%) of the yellow solid title compound. MS calculated: 677.1507; MS found: 677.1521 Example 9 (step G) Ethyl 8-methyl-2-(methylsulfanyl)-6,9-dihydro-5H-pyrrole15 [3,2-h]quinazoline-7-carboxylate[(I), Rl= methyl, X= -S-, R2= -O-ethyl, R3=H, R4=methyl, A= -CH2CH2-] and ethyl 2-(dimethylamino)-8-methyl-6,9-dihydro-5H-pyrrole [3,2-h]quinazoline-7-carboxylate [(I), R1=methyl, X=-N(Me)-, R2= -O-ethyl, R3=H, R4=methyl, A= -CH2CH2- ]
For a solution of ethyl (6E)-6-[(dimethylamino)methylidene]-2-methyl-7-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxylate, 2g (7.22 mmol ) in 20 mL of anhydrous DMF, 1.41 g (14.4 mmol) of anhydrous potassium acetate and 4.0 g (14.4 mmol) of methylisothiourea sulfate were added. The reaction was stirred at 100°C for 3 hours. The mixture was diluted with ethyl acetate, washed with H2O, dried over Na2SO4, filtered and evaporated. The crude was purified by silica gel chromatography (ethyl acetate: hexane 4:6) to give as main compounds 0.8 g of ethyl 8-methyl-2-(methylsulfanyl)-6,9-dihydro-5H-pyrrole[ 3,2-H]quinazoline-7-carboxylate (40%)LC/MS (254nm), HPLC method 2 at room temperature for 5.79 min.XH NMR (500 MHz, DMSO-d6) õ 1.28 (t , J = 7.05 Hz, 3H) 2.52 (s, 3H) 2.82 (t, J = 8.05Hz, 2H) 2.95 (t, J = 8.05Hz, 2H ) 3.33 (s, 3H) 4.18 (q, J = 7.05 Hz, 2H) 8.25 (s, 1H) 12.13 (br.s., 1H).HRMS (ESI ) calculated for C15H18N3O2S [M + H]+ 304.1114; found 304.1120; and as a by-product 0.2 g of ethyl 2-(dimethylamino)-8-methyl-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxylate (10%) LC/MS (254nm), HPLC method 2 at room temperature for 5.44 min.XH NMR (600 MHz, DMSO-d6) δ 1.27 (t, J = 7.08 Hz, 3H) 2.50 (s, 3H) 2.70 (t, J = 7.88 Hz, 2H) 2.89 (t, J = 7.88 Hz, 2H) 3.13 (s, 6H) 4.18 (q, J = 7.08 Hz, 2H) 7.99 (s, 1H) 11.78 (br.s., 1H).HRMS (ESI) calculated for C16H2iN4O [M + H]+ 301, 1659; found 301,1655. Applying the same method, the following compound was prepared:methyl 2-(methylsulfanyl)-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxylate [(I), R1 = methyl, X= -S-, R 2 = -O- methyl, R 3 = R 4 = H, A = -CH 2 CH 2 -]LC/MS (254nm), HPLC method 2 at room temperature for 5.02 min.XH NMR ( 600 MHz, DMSO-d6) δ 2.53 (s, 3 H) 2.86 (t, J = 8.06 Hz, 2 H) 2.99 (t, J = 8.06 Hz, 2 H) 3 .73 (s, 3H) 7.57 (s, 1H) 8.31 (s, 1H) 12.42 (br.s., 1H).HRMS (ESI) calcd for C13H14N3O2S [M + H] +276.0801; found 276.0799. Example 10 (conv. 2)ethyl 8-methyl-2-(methylsulfanyl)-9-(propan-2-yl)-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline -7-carboxylate [(I), R 1 = methyl, X = —S—, R 2 = O-ethyl, R 3 = H, R 4 = methyl, A = -CH 2 CH 2 -]
A solution of ethyl 8-methyl-2-(methylsulfanyl)-6,9-dihydro-5H-pyrrole[3,2-h]quinazoline-7-carboxylate (100 mg, 0.33 mmol) in dry DMF (2 mL) ), CS 2 CO 3 (160 mg, 0.495 mmol) and 2-iodo propane (0.08 ml, 0.825 mmol) were added. The reaction was stirred at 80°C for 8 h. HPLC/MS analysis showed 50% conversion, so an additional amount of reagents was added to the pot and stirred at the same temperature for more than 8 h. The mixture was poured into H 2 O (100ml) and the product extracted with AcOEt (3x30ml). The organic fractions were dried over Na2SO4, filtered and concentrated in vacuo. The crude solid was purified by flash chromatography on silica gel (eluent: AcOEt/hexane 1/9) to yield 75 mg (yield: 66%) of the title compound as an off-white solid.LC/MS (254nm) in HPLC method 2 in room temperature for 7.34 min.XH NMR (600 MHz, DMSO-d6) δ 1.28 (t, J = 7.08 Hz, 3H) 1.55 (d, J = 7.14 Hz, 6h) 2 1.51 (s, 3H) 2.66 (s, 3H) 2.70-2.74 (m, 2H) 2.87-2.91 (m, 2H) 4.20 (q, J = 7 .08 Hz, 2H) 5.90 (br.s., 1H) 8.28 (s, 1H).HRMS (ESI) calcd for C18H24N3O2S [M + H]+ 346, 1584; found 346,1595. Example 11 (cony. 2)methyl 9-[1-(tert-butoxycarbonyl)piperidin-4-yl]-2-(methylsulfanyl)-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7 - carboxylate [(I), R 1 = methyl, X = -S-, R 2 = -O-methyl, R 3 = 1-(tert-butoxycarbonyl)piperidin-4-yl, R 4 = H, A = -CH 2 CH 2 -]

A mixture of methyl 2-(methylsulfanyl)-6,9-dihydro-5H-pyrrole[3,2-h]quinazoline-7-carboxylate (60 mg 0.218 mmol), tert-butyl-4-hydroxypiperidine-1-carboxylate ( 88mg, 0.436mmol) and triphenylphosphine (120mg, 0.436mmol) in anhydrous THF (5ml) at room temperature, was added di-tert-butyldiazadicarboxylate (DTAD) (100mg, 0.436mmol). The mixture was stirred at room temperature for 18 h. HPLC/MS suggested 30% conversion and 70% SM remained, reagents were added, triphenylphosphine (120 mg, 0.436 mmol) and DTAD (100 mg, 0.436 mmol) in 5 mL of THF, the mixture was stirred for 6 hours. HPLC/MS showed 70% conversion and 30% SM remained. TPP reagents were re-added (120 mg, 0.436 mmol) and DTAD (100 mg, 0.436 mmol) in 5 mL of THF, the solution was stirred for a further 18 hours. Volatile compounds were removed in vacuo, the crude solid was purified by flash chromatography on silica gel (hexane/EtOAc 7/3) to yield 69 mg (70% yield) of the title compound.LC/MS (254nm) in HPLC method 2 at room temperature for 8.10 min. 5 Applying the same method, the following compound was prepared: Methyl 9-[1-(tert-butoxycarbonyl)piperidin-4-yl]-8-iodo-2-(methylsulfanyl)-9H -pyrrole[3,2-h]quinazoline-7-carboxylate[(I), R1=methyl, X=-S-, R2=-O-ethyl, R3=1-(tert-butoxycarbonyl)piperidin-4-yl , R4=I, A=-CH=CH-]
Example 12 (conv, 2)methyl-9-{cis-4-[(tert-butoxycarbonyl)amino]cyclohexyl}-2-(methylsulfanyl)-6,9-dihydro-5H-pyrrole[3,2-H]quinazoline -7-carboxylate [(I), R1=methyl, X=-S-, R2=O-methyl, R3=cis-4-[(tert-butoxycarbonyl)amino]cyclohexyl, R4=H, A=-CH2CH2- ]

A solution of methyl 2-(methylsulfanyl)-6,9-dihydro-5H-pyrrole[3,2-h]quinazoline-7-carboxylate (100mg 0.363mmol) in THF (5ml) trans-tert-butyl-4- hydroxycyclohexylcarbamate (156 mg 0.727 mmol), Ph3P (190 mg, 0.727 mmol) and DEAD (113 µL, 0.727 mmol) were added. The mixture was stirred at room temperature for 16 hours, HPLC/MS suggested non-reactive starting materials (80%) and the desired product (20%), then 190 mg Ph3P and 113 µL DEAD were added. After 5 h the solvent was removed by rotary evaporation to give an orange viscous oil. The mixture of SM (60%) and the desired product (40%) were isolated by flash chromatography on silica gel using 20:80 AcOEt-hexane as eluent. The mixture dissolved in THF (5 mL) was resubmitted with trans-tert-butyl-4-hydroxy-cyclohexylcarbamate (156 mg 0.727 mmol), Ph3P (190 mg, 0.727 mmol), DEAD (113 µL, 0.727 mmol) and stirred at room temperature for 16 h. HPLC/MS suggested non-reactive starting material (40%) and desired product (60%), then 95 mg Ph3P and 56 µL DEAD were added and stirred for 4h. The reaction required an additional five refreshes of the reagents before it came to an end. Volatile compounds were removed under vacuum and the crude purified by silica gel chromatography (hexane/EtOAc 8/2) to give the title compound as a yellow solid (93% yield 160 mg). HPLC method 2 at room temperature for 8.11 min. Example 13 (conv. 3) 8-methyl-2-(methylsulfanyl)-6,9-dihydro-5H-pyrrole[3,2-h]quinazoline-7-carboxylic acid [(I), R1=methyl, X= -S-, R2=OH, R3=H, R4=methyl, A=-CH2CH2-]
Ethyl 8-Methyl-2-(methylsulfanyl)-6,9-dihydro-5H-pyrrole [3,2-h]quinazoline-7-carboxylate (110 mg, 0.36 mmol) was suspended in dioxane (10 mL) and treated with 2N NaOH solution (4.0 ml, 8 mmol) at 95°C for 18 h. H2O (20ml) was added and the solution was acidified with 2N HCI. The mixture was partitioned between ethyl acetate and water, the organic layer was dried over Na2SO4, filtered and concentrated to furnish 95 mg (95%) of the title compound as an off-white solid.LC/MS (254nm) in HPLC method 2 at room temperature for 4.13 min.XH NMR (600 MHz, DMSO-d6) δ 2.48 (s, 3H) 2.52 (s, 3H) 2.77-2.83 (m, 2H) 2.92 -2.96 (m, 2H) 8.24 (s, 1H) 12.05 (br.s., 1 II).HRMS (ESI) calcd for C13H14N3O2S [M + H]+ 276.0801; found 276.0804. Working in an analogous way, the following compounds were prepared: 2-(methylsulfanyl)-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxylic acid [(I), Rl= methyl, X= -S-, R2= OH, R3 = R4= H, A= -CH2CH2-]
LC/MS (254nm) in HPLC method 2 at room temperature for 3.61 min.NMR (600 MHz, DMSO-d6) δ 2.53 (s, 3H) 2.85 (t, J= 7.75 Hz , 2H), 2.98 (t, J = 7.75Hz, 2H) 7.48-7.52 (m, 1H) 8.30 (s, 1H) 12.32 (br.s., 1 H).HRMS (ESI) calcd for C12H12N3O2S [M + H]+ 262.0645; found 262,0649.8-methyl-2-(methylsulfanyl)-9-(propan-2-yl)-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxylic acid [(I), R 1 = methyl, X = — S —, R 2 = OH, R 3 = is-propyl, R 4 = 1 from methamphetamine, A = -CH 2 CH 2 -]
LC/MS (254nm) in HPLC method 2 at room temperature for 5.43 min.NMR (600 MHz, DMSO-d6) δ 1.55 (d, J = 6.96 Hz, 6h) 2.48 (s, 3H) ) 2.66 (s, 3H) 2.71 (t, J = 7.78 Hz, 2H) 2.89 (t, J 7.75 Hz, 2H) 8.27 (s, 1H) 12.20 ( br.s., 1 H) HRMS (ESI) calcd for C 18 H 2 N302S [M + H] + 318.1271; found 318.1263.2-(dimethylamino)-8-methyl-6,9-dihydro-5H-pyrrole[3,2-h]quinazoline-7-carboxylic acid [(I), R1=methyl, X=-N(Me )-, 5 R2=OH, R3=H, R4=methyl, A=-CH2CH2-]
LC/MS (254nm) in HPLC method 2 at room temperature for 3.17 min.XH NMR (600 MHz, DMSO-d6) δ 2.54 (s, 3H) 2.79 (t, J =10 7.20 Hz, 2H) 2.98 (t, J = 7.20 Hz, 2H) 3.23 (s, 6H) 7.49(s, 1H) 7.91 (s, 1H) 12, 20 (br.s., 1 H).HRMS (ESI) calcd for CI4H17N4O2 [M + H]+ 273.1346; found 273.1346.9-[1-(tert-butoxycarbonyl)piperidin-4-yl]-2- (methylsulfanyl)-6,9-dihydro-5H-pyrrole[3,2-h]quinazoline-7-carboxylic acid [(I), R1=methyl, X=-S-, R2=OH, R3=1-( tert-butoxycarbonyl)piperidin-4-yl, R4=H, A=-CH2CH2-]
LC/MS (254nm) in HPLC method 2 at room temperature for 6.13 min.9-{cis4-[(tert-butoxycarbonyl)amino]cyclohexyl]-2-(methylsulfanyl)-6,9-dihydro-5H-pyrrole [3,2-h]quinazoline-7-carboxylic acid [(I), R1=methyl, X=-S-, R2=OH, R3=4 cis-[(tert-butoxycarbonyl)amino]cyclohexyl, R4=H , A= -CH2CH2-]
LC/MS (254nm) in HPLC method 2 at room temperature for 6.38 min.NMR (600 MHz, DMSO-dβ) δ 12.13 (br.s., 1 H), 8.31 (s, 1 H) ), 8.04 (s, 1H), 7.23 (d, J = 8.97 Hz, 1H), 5.45 (ddd, J = 4.03, 8.33, 12.00 Hz, 1H), 3.81 (br.s., 1H), 2.91-2.96 (m, 2H), 2.72-2.80 (IT., 2H), 2.00-2. 12 (m, 2H), 1.771.86 (m, 2H), 1.67-1.75 (m, 2H), 1.59 (m, 2H), 1.42 (s, 9H).HRMS( ESI) calculated for C23H3iN4O4S [M + H]+ 459.2061; found 459,2066.2-methyl-6,9-dihydro-5H-pyrrole[3,2-h]quinazoline-7-carboxylic acid [(I), R1=methyl, X=single bond, R2=OH, R3=H , R4=H, A=-CH2CH2-]
Example 14 (conv. 4) 8-methyl-2-(methylsulfanyl)-9-(propan-2-yl)-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxamide [( I), R1 = methyl, X = 5 ~S-, R2 = NH2, R3 = is-propyl, R4 = methyl, A = -CH2CH2-] (compound19)
8-methyl-2-(methylsulfanyl)-9-(propan-2-yl)-6,9-dihydro-10 5H-pyrrolo[3,2-h]quinazoline-7-carboxylic acid (100 mg, 0.363 mmol) in dry DMA (2.0 mL) was treated with NH 4 Cl (0.062 g, 0.108 mmol), D1PEA (0.253 mL, 0.14 mmol) and TBTU (175 mg, 0.544 mmol). The reaction was stirred at room temperature for 18 h.
The reaction was diluted with saturated NaHCO3 and the resulting precipitate was collected by filtration, washed with diethyl ether to yield 90 mg (yield: 90%) of the title compound as yellow solid.LC/MS (254nm) in HPLC method 2 at room temperature per 4.63 min. HRMS (ESI) calcd for C16H2iN4OS [M + H]+ 317.1431; found 317,1435. Working according to this method, the following compounds were prepared: 8-methyl-2-(methylsulfanyl)-6,9-dihydro-5H-pyrrole[3,2-h]quinazoline-7-carboxamide) [(I), R 1 = methyl, X = -S-, R 2 = NH 2 , R 3 = H, R 4 = methyl, A = -CH 2 CH 2 -] (compound 20)
LC/MS (254nm) in HPLC method 3 at room temperature for 4.63 min.:H NMR (500 MHz, DMSO-d6) δ 2.42 (s, 3H) 2.52 (s, 3H) 2, 79 (t, J = 8.05Hz, 2H) 2.87 (t, J = 8.05Hz, 2H) 6.53-7.04 (m, 2H) 8.21 (s, 1H) ) 11.79 (br.s., 1H)HRMS (ESI) calcd for C13Hi5N4OS [M + H]+ 275.0961; found 275.0968.2-(methylsulfanyl)-6,9-dihydro-5H-pyrrole[3,2-h]quinazoline-7-carboxamide, [(I), R1=methyl, X=-S-, R2=NH2, R3 = R4= H, A= -CH2CH2-] (compound 21)
LC/MS (254nm) in HPLC method 3 at room temperature for 5.43 min. ∑H NMR (500 MHz, DMSO-d6) δ 2.52 (s, 3H) 2.81 (t, J = 7.78 Hz, 2H) 3.00 (t, J = 7.78 Hz, 2H) 6.79 (br.s., 1H) 7.31 (br.s., 1H) 7.61 (d, J = 3.11 Hz, 1H) 8.27 (s, 1 H) 12.02 (br.s., 1 H)HRMS (ESI) calcd for C12H13N4OS [M + H]+ 261.0805; found 261,0814.2-(methylsulfanyl)-9-(propan-2-yl)-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxamide, [(I), R1 = methyl, X= -S-, R2=NH2, R3=is-propyl, R4=H, A=-CH2CH2-] (compound 22)
LC/MS (254nm) in HPLC method 3 at room temperature for 4.48 min.∑H NMR (600 MHz, DMSO-d6) δ 1.44 (d, J = 6.59 Hz, 6h) 2.75 ( t, J = 7.78 Hz, 2H) 2.98 (t, J = 7.78 Hz, 2H) 5.635.74 (m, 1H) 6.81 (br.s., 1H) 7 .30 (br.s., 1H) 7.88 (s, 1H) 8.28 (s, 1H)HRMS (ESI) calcd for C15H19N4OS [M + H]+ 303, 1274; found 303,1277.2-(dimethylamino)-8-methyl-6,9-dihydro-5H-pyrrole[3,2-h]quinazoline-7-carboxamide [(I), R1=methyl, X=-N(Me) -, R2=NH2, R3=H, R4=methyl, A=-CH2CH2_] (compound 23)
LC/MS (254nm) in HPLC method 3 at room temperature for 2.65 min.NMR (600 MHz, DMSO-dβ) δ 2.43 (s, 3H) 2.67 (t, J = 7.69 Hz, 2H) 2.81 (t, J = 7.69Hz, 2H) 3.13 (s, 6H) 6.505 6.95 (m, 2H) 7.96 (s, 1H) 11.45 ( br.s., 1H).HRMS (ESI) calcd for C14H18N5O [M + H]+ 272.1506; found 272,1509.tert-butyl 4-[7-carbamoyl-2-(methylsulfanyl)-5,6-dihydro-9H-pyrrolo[3,2-h]quinazolin-9-yl]piperidine-1-carboxylate [( I), 10 R 1 = methyl, X = -S-, R 2 = NH 2 , R 3 = 1-(tert-butoxycarbonyl)piperidin-4-yl, R 4 = H, A = -CH 2 CH 2 -]
LC/MS (254nm) in HPLC method 1 at room temperature 15 for 1.473 min. tert-butyl {cis-4-[7-carbamoyl-2-(methylsulfanyl)-5,6-dihydro-9H-pyrrole[3.2 -h]quinazolin-9-yl]cyclohexyl}carbamate [(I), R1 - methyl, X = -S-, R2 = NH2, R3 = 4 cis -[(tert-butoxycarbonyl)amino]cyclohexyl, R4 = H, A= -CH2CH2-]
LC/MS (254nm) in HPLC method 1 at room temperature for 1.501 min. 2-methyl-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxamide [(I), R1 = methyl , X= single bond, R2= NH2, R3=H, R4=H, A= -CH2CH2-] (compound 37)
HRMS (ESI) calcd for CI4 HI8N50 [M + H] 229.1084; found 229.1085. tert-butyl 4-(2-amino-7-carbamoyl-5,6-dihydro-9H-pyrrole[3.2-h) ]quinazolin-9-yl)piperidine-1-carboxylate [(I), R1=H, X=-NH-, R2=NH2, R3=4 -[(tert-butoxycarbonyl, R4=H, A=-CH2CH2- ]
ZH NMR (600 MHz, DMSO-dβ) ppm d 1.43 (s, 9H) 1.56-1.67 (m, 2H) 1.98-2.05 (m, 2H) 2.61 (t, J = 7.69 Hz, 2H) 2.92 (t, J = 7.69 Hz, 2H) 2.95-3.05 (m, 2H) 4.01-4.16 (m, 2H) 5.57- 5 5.68 (m, 1H) 6.37 (br.s., 2H) 6.75 (br.s., 2H) 7.80 (s, 1H) 7.95 ( s, 1 H)HRMS (ESI) calcd for C15H18N4O2S [M + H] + 413.2296; found 413,2296. Example 15 (conv. 2)9-(2-hydroxyethyl)-8-methyl-2-(methylsulfanyl)-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7- carboxamide [(I), R 1 = methyl, X = -S-, R 2 = NH 2 , R 3 = 2-hydroxyethyl, R 4 = methyl, A = -CH 2 CH 2 -] (compound 24)

For a solution of 8-methyl-2-(methylsulfanyl)-6,9-dihydro-5H-pyrrole[3,2-h]quinazoline-7-carboxamide (30 mg, 0.109 mmol) in dry dimethylformamide (2 mL), 2-iodine ethanol (37 µL, 0.437 mmol) and cesium carbonate (106 mg 0.327 mmol) were added. The resulting mixture was heated at 90°C for 8 hours. After cooling to room temperature, the mixture was poured into water and extracted with AcOEt. The organic layer is washed with brine, dried over Na2SO4 and concentrated. The crude was purified by chromatography on silica gel, eluting with DCM/MeOH 95/5 to give 8 mg of the title compound (25%).LC/MS (254nm) in HPLC method 2 at room temperature for 3.32 min.NMR (400 MHz, DMSO-dβ) δ 2.45 (s, 3H) 2.47 (s, 3H) 2.74 (t, J = 8.05 Hz, 2H) 2.83 (t, J = 8.05 Hz, 2 H) 3.68 (q,J = 5.90 Hz, 2 H) 4.54 (t, J = 5.90 Hz, 2 H) 4.86 (t, J = 5, 90Hz, 1H) 6.70-7.09 (m, 2H) 8.22 (s, 1H).HRMS (ESI) calcd for C15H18N4O2S [M + H]+ 319, 1223; found 319.1215. By working according to this method, the following compound was prepared: 9-(2-hydroxyethyl)-2-(methylsulfanyl)-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline- 7-carboxamide [(I), R 1 = methyl, X = -S-, R 2 = NH 2 , R 3 = 2-hydroxyethyl, R 4 = H, A = -CH 2 CH 2 -] (compound 25)
LC/MS (254nm) in HPLC method 2 at room temperature for 4.21 min.:H NMR (400 MHz, DMSO-dβ) δ 2.47 (s, 3H) 2.77 (t, J =7, 80 Hz, 2 H) 2.99 (t, J = 7.80 Hz, 2 H) 3.71 (q, J = 5.50 Hz, 2 H) 4.52 (t, J = 5.50 Hz , 2H) 4.90 (t, J = 5.50 Hz, 1H) 6.81 (br.s., 1H) 7.30 (br.s., 1H) 7.63 (s, 1H) 8.27 (s, 1H).HRMS (ESI) calcd for C14H17N4O2S [M + H]+ 305.1067; found 305,1062. Example 16 (conv. 23)methyl 2-(methylsulfanyl)-9H-pyrrole[3,2-h]quinazoline-7-carboxylate [(I), R1=methyl, X=-S-, R2 = - O-methyl, R3 = R4= H, A= -CH=CH-]

A solution of methyl 2-(methylsulfanyl)-6,9-dihydro-5H-pyrrole[3,2-h]quinazoline-7-carboxylate 250 mg (0.91 mmol) and 330 mg (1.82 mmol) of DDQ in chlorobenzene was heated to 140°C for 2 hours. Volatile compounds were removed in vacuo, the residue dissolved with ethyl acetate and washed with saturated aqueous NaHCO3 solution. The organic phase was dried with Na^SO, filtered and concentrated. The crude material was purified by chromatography on silica gel eluting with ethyl acetate and hexane (1:4), yielding 180 mg of the title compound (90%).LC/MS (254nm) in HPLC method 2 at room temperature for 5. 72 min.:H NMR (400 MHz, DMSO-d6) δ 2.73 (s, 3H) 3.86 (s, 3H) 7.74 (d, J = 8.61 Hz, 1H) 8 .20 (d, J = 8.61 Hz, 1H) 8.26 (d, J = 3.11 Hz, 1H) 9.37 (s, 1H) 13.23 (br.s., 1H) H).HRMS (ESI) calcd for C18H14NsC4S [M + H]+ 274.0645; found 274,065. Using the same method as described in the example above, the following analogues were also synthesized: Ethyl 8-methyl-2-(methylsulfanyl)-9H-pyrrole[3,2-h]quinazoline-7-carboxylate [(I) ), R 1 = methyl, X = -S-, R 2 = -O- methyl, R 3 = H, R 4 = methyl, A = -CH = CH-]
LC/MS (254nm) in HPLC method 2 at room temperature for 5.95 min. 1H NMR (400 MHz, DMSO-d6) δ 1.38 (t, J = 7.14 Hz, 3H) 2.73 (s , 3H) 2.77 (s, 3H) 4.33 (q, J = 7.14 Hz, 2H) 7.68 (d, J = 8.61 Hz, 1H) 8.15 (d, J = 8.61 Hz, 1H) 9.32 (s, 1H) 12.93 (br.s., 1H).HRMS (ESI) calculated for C15Hi6N3O2S [M + H]+ 302.0958; found 302.0957.2-(dimethylamino)-8-methyl-9H-pyrrole[3,2-h]quinazoline-7-carboxamide, R1=methyl, X=-S-, R2=NH2, R3=H, R4=methyl , A= -CH=CH-] (compound 26)
LC/MS (254nm) in HPLC method 2 at room temperature for 3.52 min.XH NMR (400 MHz, DMSO-d6) δ 2.67 (s, 3H) 3.30 (s, 6H) 7, 01 (s, 2 H) 7.35 (d, J = 8.61 Hz, 1 H) 7.67 (d, J = 8.61 Hz, 5 1 H) 9.04 (8, 1 H) 12 .08 (br.s., 1H). HRMS (ESI) calcd for C14H16N5O [M + H]+ 270.1350; found 270,1352. Example 17 (conv. 2)methyl 9-methyl-2-(methylsulfanyl)-9H-pyrrole[3,2-h]10 quinazoline-7-carboxylate [(I), R1=methyl, X= -S-, R2= -O- methyl, R3 - methyl, R4=H, A= ~CH=CH-]
To a solution of methyl 2-(methylsulfanyl)-9H-pyrrole15 [3,2-h]quinazoline-7-carboxylate (80mg 0.29mmol) in DMF (1.5ml), CS2CO3 (191mg, 0.58mmol) ) and methyl iodide (18μL, 0.29 mmol) were added. The mixture was stirred at room temperature for 8 h, the solvent was removed under vacuum, then DCM (10 ml) was added and the organic phase washed with water (2 x 15 ml). The organic fraction was dried over Na2SO4, filtered and concentrated in vacuo. Purification by flash chromatography on silica gel (eluent: AcOEt/hexane 4/6) provided 58 mg (yield: 70%) of the title compound as a pale yellow solid. LC/MS (254nm) in HPLC method 2 at room temperature for 6.4 min.NMR (400 MHz, DMSO-d6) δ 2.68 (s, 3H) 3.86 (s, 3H) 4.49 (s , 3H) 7.75 (d, J = 8.67 Hz, 1H) 8.21 (d, J = 8.67 Hz, 1H) 8.35 (s, 1H) 9.35 (s , Ih) .HRMS (ESI) calcd for C14H14N3O2S [M + H]+ 288.0801; found 288.0802. Example 18 (conv. 3) 9-methyl-2-(methylsulfanyl)-9H-pyrrole[3,2-h]quinazoline-7-carboxylic acid [(I), R1=methyl, X=- S-, R2= -OH, R3 = R4=H, A= -CH=CH-]
Methyl 9-methyl-2-(methylsulfanyl)-9H-pyrrole[3,2-h]quinazoline-7-carboxylate (50 mg, 0.174 mmol) was suspended in dioxane (5 mL) and treated with 2 N NaOH solution (2.0 mL, 4 mmol) at 95 °C for 2 h. H2O (20 mL) was added and the solution was acidified (pH ~6) with 2N HCl. The solid was filtered and washed with water and diethyl ether to provide 40 mg (85%) of the title compound as an off-white solid. LC/MS (254nm) in HPLC method 2 at room temperature for 4.13 min.∑H NMR (600nm) MHz, DMSO-d6) δ 2.68 (s, 3H) 4.48 (s, 3H) 7.71 (d, J = 8.61 Hz, 1H) 8.23 (d, J = 8 .61 Hz, 1H) 8.26 (s, 1H) 9.34 (s, 1H) 12.35 (br.s., 1H).HRMS (ESI) calcd for C13H12N3θ2S [M + H] +274.0645; found 274,064. According to the same working method, the following compounds were prepared: 8-methyl-2-(methylsulfanyl)-9H-pyrrolo[3,2-h]quinazoline-7-carboxylic acid [(I), Rl = methyl, X= -S-, R2= -OH, R3 = H, R4= methyl, A= -CH=CH-]
LC/MS (254nm) in HPLC method 2 at room temperature for 4.21 min.XH NMR (600 MHz, DMSO-d6) δ 2.73 (s, 3H) 2.76 (s, 3H) 7, 65 (d, J = 8.61 Hz, 1H) 8.18 (d, J = 8.61 Hz, 1H) 9.31 (s, 1H) 12.23 (br.s., 1H) ) 12.83 (br.s., 1H).HRMS (ESI) calcd for C13HI2N3O2S [M + H]+ 274.0645; found 274,065.9-[1-(tert-butoxycarbonyl)piperidin-4-yl]-2-(methylsulfanyl)-9H-pyrrolo[3,2-h]quinazoline-7-carboxylic acid [(I), R1 = methyl, X = -S-, R2= -OH, R3= 1-(tert-butoxycarbonyl)piperidin-4-yl, R4=H, A= -CH=CH-]
2-(methylsulfanyl)-9H-pyrrole[3,2-h]quinazoline-7-carboxylic acid [(I), R1 = methyl, X= -S-, R2 = -OH, R3 = H, R4 =5 methyl , A= -CH=CH-]
Example 19 (conv. 4)9-methyl-2-(methylsulfanyl)-9H-pyrrole[3,2-h]quinazoline-7-carboxamide) [(I), R1=methyl, X=-S-, R2= NH2, R3 = methyl, 10 R4=H, A= -CH=CH-(compound 27)
9-Methyl-2-(methylsulfanyl)-9H-pyrrole[3,2-h]quinazoline-7-carboxylic acid (30 mg, 0.109 mmol) in dry DMA (2.0 mL) was treated with NH4Cl (0.040 g) .74 mmol), DIPEA (0.120 ml, 0.6815 mmol) and TBTU (70 mg, 0.218 mmol). The reaction was stirred at room temperature for 3 h. The reaction was diluted with saturated NaHCO and the product extracted with AcOEt (3 x 30 mL). The organic fractions were dried over Na2SO4, filtered and evaporated in vacuo to yield 27 mg (yield: 93%) of the title compound as off-white solid.LC/MS (254nm) in HPLC method 2 at room temperature for 3.84 min.NMR (500 MHz, DMSO-d6) δ 2.68 (s, 3H) 4.46 (s, 3H) 7.01 (br.s., 1H) 7.58 (br.s., 1H) ) 7.64 (d, J = 8.61 Hz, 1H) 8.19 (s, 1H) 8.39 (d, J = 8.61 Hz, 1H) 9.31 (s, 1h) .HRMS (ESI) calcd for C13H3N4OS [M + H]+ 273.0805; found 273,0814. Working according to the same method, the following compounds were prepared: 8-methyl-2-(methylsulfanyl)-9H-pyrrole [3,2-h]quinazoline-7-carboxamide) R 1 = methyl, X = -S-, R2= NH2, R3 = H, R4= methyl, A= -CH=CH-] (compound 28)
LC/MS (254nm) in HPLC method 2 at room temperature for 3.54 min. JH NMR (600 MHz, DMSO-d6) δ 2.71 (s, 3H) 2.72 (s, 3H) 7.14 (s, 2 H) 7.58 (d, J = 8.61 Hz, 1 H) 8.04 (d, J = 8.61 Hz, 1 H) 9.29 (s, 1 H) 12.57 (s, lh).HRMS (ESI) calcd for C 3 H 3 N 3 O 2 S [M + H] + 273.0805; found 273.0807. tert-butyl 4-[7-carbamoyl-2-(methylsulfanyl)-9H-pyrrole[3,2-h]quinazolin-9-yl]piperidine-1-carboxylate [(I), R1=methyl, X=-S -, R2= -NH2, R3= 1-(tert-butoxycarbonyl)piperidin-4-yl, R4=H, A= -CH=CH-]
2-(methylsulfanyl)-9H-pyrrole[3,2-h]quinazoline-7-carboxamide [(I), R1=methyl, X= -S-, R2= -NH2, R3 = H, R4=H, A = -CH=CH-] (compound 36)
1H NMR (600 MHz, DMSO-d6) ppm d 2.72 (s, 3H) 6.98 (br.s., 1H) 7.62 (d, J = 8.61Hz, 1H) 7 .64 (br.s., 1H) 8.28(s, 1H) 8.37 (d, J = 8.61Hz, 1H) 9.33 (s, 1H) 12.80 (br .s., 1H)HRMS (ESI) calcd for C13H13N3O2S [M + H]+ 259.0648;15 found 259.0646. Example 20 (conv. 2)9-(2-hydroxyethyl)-8-methyl-2 -(methylsulfanyl)-9H-pyrrole[3,2-h]quinazoline-7-carboxamide [(I), R1=methyl, X=-S-, NH2, R3=2-hydroxyethyl, R4=methyl

For a solution of 8-methyl-2-(methylsulfanyl)-9H-pyrrole[3,2-h]quinazoline-7-carboxamide (20 mg 0.072 mmol) in DMF (mL 1.5), 2-iodo ethanol (24 µL, 0.288 mmol) and cesium carbonate (70 mg 0.216 mmol) were added. The resulting mixture was heated at 80°C for 8 hours. After cooling to room temperature, the reaction mixture was poured into water (10 ml) and partitioned with ethyl acetate. The organic layers were washed with brine, dried over Na2SO4 and concentrated. The crude was purified by silica gel chromatography (DCM/MeOH/acetone 85/0.5/1) to give 10mg of the title compound (45%) as a white solid.LC/MS (254nm) in HPLC method 2 at temperature ambient for 4.31 min.rH NMR (400 MHz, DMSO-d6) 2.62 (s, 3H) 2.73 (s, 3H) 3.85 (q, J = 5.50 Hz, 2H ) 4.92 (t, J = 5.50 Hz, 1H) 4.98 (t,J = 5.50 Hz, 2H) 7.29 (br.s., 2H) 7.62 (d , J = 8.61 Hz, 1H) 8.01 (d, J = 8.61 Hz, 1H) 9.28 (s, lh).HRMS (ESI) calculated for C15H17N4O2S [M + H] + 317, 1067; found 317,1064. Working in an analogous way, the following compounds were prepared: 8-methyl-2-(methylsulfanyl)-9-(propan-2-yl)-9H-pyrrole[3,2-h]quinazoline-7- carboxamide [(I), R1=methyl, X=-S-, R2=NH2, R3=is-propyl, R4=methyl, A=-CH=CH-(compound 30)
LC/MS (254nm) in HPLC method 2 at room temperature for 6.1 min.NMR (400 MHz, DMSO-d6) δ 1.54-1.93 (m, 6H) 2.63 (s, 3H) 2.79 (s, 3H) 4.96-5.10 (m, 1H) 7.35 (br.s., 2H) 7.57-7.68 (m, 1H) 7.90- 8.04 (m, 1H) 9.28 (s, 1H).HRMS (ESI) calcd for C16H19N4OS [M + H]* 315.1274; found 315.1281.9-ethyl-2-(methylsulfanyl)-9H-pyrrole[3,2-h]quinazoline-7-carboxamide [(I), R1=methyl, X=-S-, R2=NH2, R3=ethyl , R4=H, A=-CH=CH~] (compound 31)
LC/MS (254nm) in HPLC method 2 at room temperature for 4.13 min.XH NMR (600 MHz, DMSO-d6) δ 1.51 (t, J = 7.14 Hz, 3H) 2.66 (s , 3H) 4.94 (q, J = 7.14 Hz, 2H) 7.02 (br. (br.s., 1H) 7.65 (d, J = 8.61 Hz, 1H) ) 8.28 (s, 1H) 8.41 (d, J = 8.61 Hz, 1H) 9.32 (s, lh).HRMS (ESI) calculated for C14H15N4OS [M + H]+ 287, 0961; 287.0961. Example 21 (conv. 23) tert-butyl {cis-4-[7-carbamoyl-2-(methylsulfanyl)-9H-pyrrolo[3,2-h]quinazolin-9-yl]cyclohexyl]carbamate [ (I), R1=methyl, X=-S-, R2=NH2, R3=4 cis-[(tert-butoxycarbonyl)amino]cyclohexyl, R4=H, A=-CH=CH-]
A solution of tert-butyl {cis-4-[7-carbamoyl-2-(methylsulfanyl)-5,6-dihydro-9H-pyrrolo[3,2-H]quinazolin-9-yl]cyclohexyl}carbamate 15 mg ( 0.032 mmol) and 15 mg (0.064 mmol) of DDQ in chlorobenzene was heated at 140°C for 2 hours. Volatile compounds were removed in vacuo, the residue dissolved with ethyl acetate and washed with saturated aqueous NaHCOa solution. The organic phase was dried with Na2SO4, filtered and concentrated. The crude material was purified by silica gel column chromatography eluting with DCM/MeOH (97:3), yielding 10mg of the title compound (71%).LC/MS (254nm) in HPLC method 2 at room temperature for 5.72min .Example 22 (conv. 24)methyl 2-(methylsulfanyl)-9-(piperidin-4-yl)-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxylate hydrochloride [( I), R1=methyl, X=-S-, R2=-O-methyl, R3=piperidin-4-yl, R4=H, A=-CH2CH2-]
Methyl-9-[1-(tert-butoxycarbonyl)piperidin-4-yl]-2-(methylsulfanyl)-6,9-dihydro-5H-pyrrolo[3,2-H]quinazoline-7-carboxylate 10mg (0.021mmol ) were dissolved in 1,4-dioxane (2 ml) and 4 M HCl in 3 ml (3 mmol) 1,4-dioxane were added. The mixture was stirred at room temperature for 1 hour. Volatile compounds were removed in vacuo and the residue obtained was triturated with diethyl ether, filtered and dried to yield 8 mg of the title compound (97%).LC/MS (254nm) in HPLC method 2 at room temperature for 3.64 min.∑H NMR (600 MHz, DMSO-d6) δ 82.08-2.19 (m, 2H) 2.22-2.29 (m, 2H) 2.54 (s, 3H) 2.81 ( t, J = 7.88 Hz, 2H) 2.97 (t, J = 7.88 Hz, 2H) 2.99-3.03 (m, 2H) 3.44-3.51 (m, 2H) 3.75 (s, 3H) 5.51-5.59 (m, 1H) 7.71 (s, 1H) 8.38 (s, 1H) 8.78 (br.s.1H) H) 8.83 (br.s., 1H).HRMS (ESI) calcd for C18H24N4O2S [M + H]+ 359.1536; found 359.1531. Working analogously, the following compounds were prepared: 2-(methylsulfanyl)-9-(piperidin-4-yl)-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxamide chloride [(I), R1=methyl, X=-S-, R2=NH2, R3=piperidin-4-yl, R4=H, A=-CH2CH2-] (compound 32)
LC/MS (254nm) in HPLC method 2 at room temperature for 3.61 min.NMR (600 MHz, DMSO-d6) δ 1.91-2.11 (m, 2H) 2.23-2.32(m) , 2H) 2.53 (s, 3H) 2.76 (t, J = 7.60 Hz, 2H) 2.89-3.06 (m,4H) 3.45-3.56 (m, 2H) 5.40-5.50 (m, 1H) 6.89 (br.s., 1H) 7.45 (br.s., 1H) 7.83 (s, 1H) 8. 33 (s, 1H) 8.85 (br. s.2H) .HRMS (ESI) calcd for C17H23N5OS [M + H]+ 344.154; found 344,1544.9-(cis 4-aminocyclohexyl)-2-(methylsulfanyl)-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxamide chloride [(I), R1 = methyl, X= -S-, R2= NH2, R3= cis 4-aminocyclohexyl, R4=H, A= -
LC/MS (254nm) in HPLC method 2 at room temperature for 3.91 min.XH NMR (600 MHz, DMSO-d6) δ 1.72-1.86 (m, 2H) 1.89-2.01( m, 4H) 2.01-2.13 (m, 2H) 2.76 (t, J = 7.70 Hz, 2H) 2.94 (t,J = 7.70 Hz, 2H) 3 .43-3.54 (m, 1H) 5.31-5.44 (m, 1H) 6.93(br.s., 1H) 7.16 (br.s., 1H) 8 .00 (s, 1H) 8.08 (br. s.3H) 8.30 (s, 1H).HRMS (ESI) calcd for C18H24N5OS [M + H]+ 358.1696; found 358,1694.9-(cis-4-aminocyclohexyl)-2-(methylsulfanyl)-9H-pyrrole [3,2-h]quinazoline-7-carboxamide [(I), R1= methyl, X= -S-, R2 = NH2, R3 = cis 4-aminocyclohexyl R4= H, A= -CH=CH-] (compound 34)
LC/MS (254nm) in HPLC method 2 at room temperature for 3.15 min.XH NMR (600 MHz, DMSO-d6) δ 1.85-1.96 (m, 2H) 2.00-2.07 ( m, 2H) 2.07-2.14 (m, 2H) 2.17-2.29 (m, 2H) 2.68 (s, 3H) 3.51- 3.58 (m, 1H) 6 .01-6.11 (m, 1H) 7.11 (br.s., 1H) 7.54 (br.s., 1H) 7.67 (d, J = 8.61 Hz, 1 H) 8.13 (br.s., 3H) 8.38 (dJ = 8.61 Hz, 1H) 8.64 (s, 1H) 9.33 (s, Ih) .HRMS (ESI) calculated for C18H22N5OS [M + H]+ 356.1696; found 356,1694.9-(3-amino-2,2-dimethylpropyl)-2-{methylsulfanyl)-9H-pyrrolo[3,2-h]quinazoline-7-carboxamide hydrochloride [(I), R1 = methyl, X = -S-, R2= NH2, R3= 3-amino-2,2-dimethylpropyl, R4=H, A= -CH=CH-J (compound 38)
LC/MS (254nm) in HPLC method 2 at room temperature for 3.89 min.∑H NMR (600 MHz, DMSO-d6) δ 9.35 (s, 1H), 8.47 (d, J =8 .61 Hz, 1H), 8.28 (s, 1H), 7.83 (br.s., 4H), 7.69 (d, J =8.79 Hz, 1H), 7.08 (br.s., 1H), 5.11 (s, 2H), 2.76 (d, J =5.86Hz, 2H), 2.71 (s, 3H), 1.02-1 .07 (m, 6H).HRMS (ESI) calcd for C17H22N5OS [M + H]+ 344.1540; found 344,1544.9-(azepan-3-yl)-2-(methylsulfanyl)-9H-pyrrole[3,2-h] quinazoline-7-carboxamide hydrochloride [(I), R 1 = methyl, X = -S- , R2=NH2, R3=azepan-3-yl, R4=H, A- -CH=CH-] (compound 39)
LC/MS (254nm) in HPLC method 2 at room temperature for 3.82 min.NMR (600 MHz, DMSO-d6) δ (s, 1H), from 9.34 8.80-9.09 5 (m) , 2H), 8.50 (s, 1H), 8.43 (d, J = 8.61 Hz, 1H), 7.72-7.75(m, 1H), 7.67 (d , J = 8.61 Hz, 1H), 6.90-7.17 (m, 1H), 6.26 (br.s., 1H), 3.21 (m, 2H), 2. 69 (s, 3H), 2.32-2.46 (m, 3H), 2.07-2.11 (m, 2H), 1.91 (ml H).HRMS (ESI) calcd for C18H22N5OS [M + H]+ 356.1540; 10 found 356, 1538,2-amino-9-(piperidin-4-yl)-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxamide hydrochloride [(I), R1=H, X= -NH-, R2= NH2, R3 = piperidin-4-yl, R4=H, A= -CH2CH2-]
aH NMR (600 MHz, DMSO-d6) d ppm 1.95-2.11 (m, 2H) 2.22-2.33 (m, 2H) 2.53 (s, 3H) 2.76 (t, J = 7.60 Hz, 1H) 2.89-3.06 (m, 4H) 3.45-3.55 (m, 2H) 5.40-5.50 (m, 1H) 6, 89 (br.s., 1H) 7.45 (br.s., 1H) 7.83 (s, 1H) 8.33 (s, 1H) 8.85 (br.s. 2H) HRMS (ESI) calcd for CigH22N5O [M + H] + 344.1540; found 344,1544.2-(methylsulfanyl)-9-(piperidin-4-yl)-9H-pyrrole[3,2-h]quinazoline-7-carboxamide [(I), R1=methyl, X=-S-, R2 = NH2, R3 = piperidin-4-yl, R4=H, A= -CH=CH-] (compound 35)
1H NMR (600 MHz, DMS0-d6) d ppm 1.80-1.94 (m, 2H) 2.112.19 (m, 2H) 2.71 (s, 3H) 2.72 - 2-80 (m , 2H) 3.15-3.24 (m,2H) 6.07 - 6-17 (m, 1H) 7.01 (br.s., 1H) 7.63 (br.s., 1H) H) 7.66 (d, J = 8.61 Hz, 1 H) 8.45 (d, J = 8.61 Hz, 1 H) 8.55 (s, 1 H) 9.32 (s, 1 H)HRMS (ESI) calcd for C18H22N5O [M + H]+ 245.1033; found 245,1041. Example 23 (step G)methyl 2-methyl-6,9-dihydro-5H-pyrrole[3,2-h]quinazoline-7-carboxylate [(I), R1=methyl, X=single bond , R2=-O-methyl, R3=H, R4=H, A=-CH2CH2-]
For a solution of methyl (6E)-6-[(dimethylamino)methylidene]-7-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxylate (50 mg, 0.2 mmol DMF ( 4 mL) acetamidine hydrochloride (190 mg, 2.0 mmol)) and K 2 CO 3 (275 mg, 2.0 mmol) were added and the mixture was heated at 180°C for 1h under microwave irradiation. Volatile compounds were removed in vacuo, the residue was dissolved with DCM and washed with H20. The organic phase was dried with Na2SO4, filtered and concentrated. The crude material was purified by silica gel chromatography eluting with DCM/MeOH (10:1), yielding 20 mg of the title compound (40%) as a dark yellow solid.NMR (600 MHz, DMSO-d6) ppm d 2 .55 (s, 3H) 2.85-2.90 (m, 2H) 2.96-2.99 (m, 2H) 3.72 (s, 3H) 7.50 (s, 1H) 8 .35 (s, 1H) 12.40 (br.s., 1H)HRMS (ESI) calcd for C18H22N5O [M + H]+ 244.1081; found 244,1087. Example 24 (step G) methyl 2-amino-9-[1-(tert-butoxycarbonyl)piperidin-4-yl]-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline -7-carboxylate [(I), R 1 = H, X = -NH-, R 2 = -O-methyl, R 3 = 1-(tert-butoxycarbonyl)piperidin-4-yl, R 4 = H, A = -CH 2 CH 2 - ]

For a solution of methyl (6E)-1-[1-(tert-butoxycarbonyl)piperidin-4-yl]-6-[(dimethylamino)methylidene]-7-oxo-4,5,6,7-tetrahydro-1H -indole-3-carboxylate (10mg, 0.023mmol) in DMF (1ml) was added guanidine carbonate (10mg, 0.055mmol). The mixture was stirred at 110°C for 8 hours. The resulting mixture was cooled to room temperature and evaporated to dryness. The crude solid was purified by flash chromatography on silica gel (eluent: AcOEt) to yield 8 mg (yield: 80%) of the title compound as a brown solid. MS calculated: 428.2293; MS found: 428.2292NMR (401 MHz, DMSO-d6) ppm d 1.43 (s, H 9) 1.66-1.84 (m, 2H) 1.92-2.04 (m, 2H) 2 2.62-2.69 (m, 2H) 2.86-2.92 (m, 2H) 2.92-3.10 (m, 2H) 3.71 (s, 3H) 3.98-4, 07 (m, 2H) 5.59-5.72 (m, 1H) 6.28 (s, 2H) 7.72 (s, 1H) 7.99 (s, 1H) Working in a similar way , the following compound was prepared: methyl 2-amino-6,9-dihydro-5H-pyrrole[3,2-h]quinazoline-7-carboxylate [(I), R1=H, X=-NH-, R2= -0-methyl, R3=H, R4=H, A=-CH2CH2-]
MS calculated: 245.1033; MS found: 245.1041 NMR (600 MHz, DMS0-d6) ppm d 2.71 (t, J = 7.78 Hz, 2 H) 2.91 (t, J = 7.78 Hz, 2 H) 3 .71 (s, 3H) 6.08 (br. 7.44 (d, J = 2.93 Hz, 1H) 7.98 (s, 1H) 12.09 (br.s., 1H) ) Preparation Imethyl 2-(methylsulfanyl)-8-iodo-9H-pyrrole[3,2-h]quinazoline-7-carboxylate [(I), R1=methyl, X=-S-, R2=-Q-methyl, R3=H, R4=I, A=-CH=CH-]

To a solution of methyl 2-(methylsulfanyl)-6,9-dihydro-5H-pyrrole[3,2-h]quinazoline-7-carboxylate (100mg, 0.363mmol) in DMF (5ml) was added N-iodosuccinimide (3.25 mg, 1.44 mmol) and the mixture was stirred at room temperature for 24 h. Volatile compounds were removed in vacuo, the residue was dissolved with DCM and washed with H20. The organic phase was dried with NazSO4, filtered and concentrated. The crude material was purified by silica gel chromatography eluting with hexane/EtOAc (4:2) yielding the title compound 85 mg (60%) as a yellow solid. ÃH NMR (600 MHz, DMSO-d6) ppm d 2.75 (s, 3H) 3.89 (s, 3H) 7.69 (d, J = 8.79 Hz, 1H) 8.15 (d, J = 8.79 Hz, 1H) 9.35 (s, 1H) 13.75 (s, 1H) MS calculated: 399.9611; MS found: 399.9610 Example 25 (conv. 23)methyl 9-[1-(tert-butoxycarbonyl)piperidin-4-yl]-2-(methylsulfanyl)-9H-pyrrolo[3,2-h]quinazoline-7- carboxylate[(I), R1=methyl, X= -S-, R2= -O-methyl, R3= 1-(tert-butoxycarbonyl)piperidin-4-yl, R4=H, A= -CH=CH-]

For a solution of methyl 9-[1-(tert-butoxycarbonyl)piperidin-4-yl]-8-iodo-2-(methylsulfanyl)-9H-pyrrolo[3,2-h]quinazoline-7-carboxylate (30mg , 0.05mmol) in DMF (2ml) were added sodium formate (7mg, 10mmol) and Pd(PPH 3 )4 (50mg, 0.004mmol) and the mixture was heated at 120°C for 3 hours. Volatile compounds were removed in vacuo. The crude material was purified by silica gel column chromatography eluting with DCM/MeOH (95:5), yielding 15 mg of the title compound (65%) as a white solid. -(methylsulfanyl)-9H-pyrrole[3,2-h]quinazoline-7-carboxylate [(I), R1=methyl, X=-S-, R2=-O-methyl, R3=H, R4=H, A= -CH=CH-]

The compounds of formula (I) are active as protein kinase inhibitors and are therefore useful, for example, to restrict the unregulated proliferation of tumor cells.
In therapy, they can be used in the treatment of various tumors such as, for example, as defined above, as well as in the treatment of other cell proliferative diseases, such as benign prostatic hyperplasia, familial adenomatosis polyposis, neuro-fibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis, glomerulonephritis and postsurgical stenosis and restenosis.
The inhibiting activity of the putative MPS1 inhibitors and the potency of selected compounds were determined by the assay described below.
The short forms and abbreviations used in this document have the following meaning:Ci CurieDMSO dimethylsulfoxideID identity KDa kiloDaltonmicroCi microCuriemg milligrammicrog microgramml millilitermicroL microliterM molarmM millimolarmicroM micromolarnM nanomolarEt ethyl Cloning, expression and purification of the total length protein color of recombinant MPS1 20 residues -857 of the full-length sequence, see Swiss-Prot accession number P33981) was PCR amplified from the present full-length human MPS1 gene, acquired internally, as clone pGEX4t_MPS1. Amplification was performed using forward oligonucleotide:5'GGGGACAAGTTTGTACAAAAAAGCAGGCTTATTCGAAAACCTGAGTATTGCTGGCGCCCTTTso oligonucleotide:5'GGGGACAAGTTTGTACAAAAAAGCAGGCTTATTCGAAAACCTGAGTATTGCTGGCGCCCTA :5'GGGGACCACTTTGTACAAGAAAGCTGGGTTTCACTATTTATTGAGGACTGTGAGGGGCTT-3'Both oligonucleotides are described in WO2009/156315 published December 30, 2009.
For cloning purposes, the oligonucleotides included attB sites in order to obtain a suitable flanked attB PCR product for cloning using Gateway® technology (Invitrogen). Furthermore, for purification purposes, the forward primer including a TEV® cleavage site (Amersham Biosciences). The resulting PCR product was cloned into plasmid pDONR221 and then transferred to the modified baculovirus expression vector pVL1393 (Invitrogen) Gateway®. For purification and expression purposes, the His tag was added at the N-terminus to the PLK kinase domain. Cloning was performed according to the protocols described in the Gateway® manual.
Baculovirus was generated by transfections of Sf9 insect cells and with the viral DNA expression vector using the BaculoGold® transfection kit (Pharmingen). Viral supernatant was recovered after 5 days and subjected to 3 cycles of amplification to increase viral titer. Recombinant protein was produced by transfections of High5 insect cells. After 72 hours of infection at 21°C, cells were recovered, pelleted and frozen at -80°C. For purification of the recombinant protein, the pellet was thawed, resuspended in lysis buffer (PBS, 150 mM NaCl, 0.1% CHAPS, 20 mM DTT, 10% glycerol, protease inhibitors) and lysed by Gaulin. The lysate was cleaned by centrifugation and loaded onto a GST affinity column. After extensive washing, the recombinant protein was cleaved by a specific protease and eluted by incubation.
To obtain a fully activated enzyme, the protein was then subjected to autophosphorylation in the presence of 1 mM ATP at 25°C for 2 hours in the kinase buffer (Hepes pH 7.5 50mm, 2.5 mM MgCl2, 1 mM MnC12, 1mM DTT, phosphatase inhibitors); the ATP was then removed with a desalting column. Biochemical Assay for MPS1 Kinase Activity Inhibitors
The inhibitory activity of putative kinase inhibitors and the potency of selected compounds were determined through a trans-phosphorylation assay.
Specific peptide or protein substrates are trans-phosphorylated by their serine-threonine or tyrosine kinase specificity, in the presence of 33P-y_ATP-traceable ATP, and in the presence of their own ideal buffer and cofactors.
At the end of the phosphorylation reaction, more than 98% cold ATP and radioactive ATP were captured by an excess of Dowex ion exchange resins. The resin was seated at the bottom of the gravity reaction wells.
The supernatant, containing phosphorylated substrate, was subsequently removed and transferred to a counting plate, and then evaluated by β counting. Reagent/assay conditions. Preparation of Dowex resin 500 g of wet resin (SIGMA, prepared Dowex resin 1x8 200 to 400 mesh, 2.5 kg) was weighed, and diluted to 2L in 150 mM sodium formate, pH 3.00.
The resin was left for several hours and then the supernatant was discarded.
After three washes as above over two days, the resin has settled, the supernatant is discarded and two volumes of 150 mM sodium formate buffer are added per volume of pellet. The pH is then measured and should be around 3.00. The resin is washed and stabilized for more than a week, the stored resin is kept at 4°C before use.ii. Kinase Buffer (KB)
The kinase buffer was composed of 50 mM HEPES pH 7.5, with 2.5 mM MgCls, 1 mM DTT, 3 microM Na3V04, 2 mM β-glycerophosphate and 0.2 mg/ml BSA.iii . Test conditions
The kinase assay was performed with a final MPS1 enzyme concentration of 5 nM, in the presence of 15 microM ATP and 1.5 nM 33P-y-ATP; the substrate was P38-βtide, used in 200 microM. Robotized Dowex Assay1) 3x enzyme mix (made in 3X kinase buffer), 5 microL/well2) 3x substrate and ATP mix (made in ddH2O), together with 33P-y-ATP , 5_microL/well3) 3x test compounds (diluted in ddH2O - 3% DMSO) - 5 microL/well
Compound dilution and test scheme are reported below. The dilution of compounds
Test compounds are received as 1 mM solution in 100% DMSO, distributed in 96 or 384 well plates: a) for Percent Inhibition (HTS) studies, individual 1 mM dilution plates are diluted to a concentration of 3X (30 microM) in ddH2O (3% DMSO = final concentration) using a Beckman NX automated pipetting platform. The same instrument is used to distribute the diluted motherboards onto test plates. b) for IC50 determination (KSS platform), 100 microL of each compound in 1 mM in 100% DMSO is transferred from the original plate into the first column of another 96-well plate (A1 to Gl); well HI is empty for the internal standard inhibitor, usually staurosporine.
An automated serial dilution station (Biomek FX, Beckman) is used to produce 1:3 dilutions in 100% DMSO, from line Al to A10 and for all seven compounds in the column. In addition, 4 to 5 copies of the daughter plates are prepared for 5 microL reformation of this first set of 100% DMSO dilution plates into 384 deep well plates: one copy of the daughter plates with the serial dilutions of test compounds will be frozen on the day of the experiments, reconstituted in a concentration of 3X with water and used in the IC50 determination tests. In a standard experiment, the highest (3x) concentration of all compounds is 30 microM, while the lowest is 1.5 nM.
Each 384-well plate will contain reference wells (total enzyme activity vs. no enzyme activity) for Z' and signal for background assessment.
384-well V-bottom assay plates (test plates) are prepared with 5 microL of compound dilution (3x) and then placed on a PlateTrak 12 robotic station (Perkin Elmer robot has 384-tip pipetting tips for start the assay plus 96 tips to dispense resin), along with a reservoir for the enzyme mix (3x) and one for the ATP mix (3X). In the beginning, the robot aspirates 5 microL of the ATP mixture, leaves an air gap in the tip (3 microL) and aspirates 5 microL of the PLK1 mixture. The following dispenses on the plates allow the kinase reaction to start after 3 cycles of mixing, made by the robot itself.
At this point, the correct concentration is restored by all reagents.
The robot incubates the plates for 60 minutes at room temperature and then stops the reaction by pipetting 70 microL of the Dowex resin suspension into the reaction mix.
Three mixing cycles are done immediately after resin addition.
Another mixing cycle is carried out after all the plates are stopped, this time using normal tips: the plates then rest for about an hour, to maximize the ATP capture. At this point, 22 microL of the supernatant is transferred to 384-Optiplates (Perkin-Elmer), with 50 microL of Microscint 40 (Perkin-Elmer), after 5 min of orbital shaking the plates were read in a Perkin-Elmer Top radioactivity counter Count.iii. Data analysis
Data is analyzed by an in-house customized version of the SW package "Assay Explorer", which provides both % inhibition for primary assays and ten-dilution sigmoidal curve fitting for IC50 determination for confirmation/secondary assay routines.Assay Assay in vitro cell proliferation Human ovarian A2780 and MCF7 breast cancer cells (1250 cells/well) were seeded in white 384-well plates in complete medium (RPMI 1640 or EMEM plus 10% fetal bovine serum) and treated with compounds dissolved in DMSO 0.1% after 24h sowing. Cells were incubated at 37 °C and 5% CO2 and after 72 hours the plates were processed using the CellTiter-Glo test (Promega), following the manufacturer's instructions. CellTiter Glo is a homogeneous method based on the quantification of ATP present, an indicator of metabolically active cells. ATP is quantified using a system based on luciferase and D-luciferin resulting in light generation. The luminescent signal is proportional to the number of cells present in the culture.
Briefly 25 microL of the reagent solution is added to each well and after 5 minutes the microplates are red by a luminometer. The luminescent signal is proportional to the number of cells present in the culture.
Inhibitory activity was assessed by comparing treated versus control data using the Assay Explorer (MDL) assay program. IC50 was calculated using the sigmoidal interpolation curve.
In view of the above inhibition assays, the compounds of formula (I) of the invention have been shown to possess good MPS1 inhibitory activity, typically with an IC50 in the range between 0.001 and 5 microM.
Furthermore, the compounds of formula (I) of the invention show good cell proliferation inhibitory activity, typically with an IC50 in the range of 0.010 to 5 µM in A2780 cells.
Biochemical Assay for PIM-1 Kinase Activity Inhibitors
The inhibitory activity of putative kinase inhibitors and the potency of selected compounds were determined through a trans-phosphorylation assay.
Specific peptide or protein substrates are trans-phosphorylated by their serine-threonine or tyrosine kinase specificity, in the presence of P-y-ATP-screened ATP, and in the presence of their own ideal cap and cofactors.
At the end of the phosphorylation reaction, more than 98% cold ATP and radioactive ATP were captured by an excess of Dowex ion exchange resins. The resin was seated at the bottom of the gravity reaction wells.
The supernatant containing phosphorylated substrate was then removed and transferred to a counting plate, and then evaluated by β counting. Reagents/assay conditions
Preparation of Dowex resin 500 g of wet resin (SIGMA, prepared Dowex resin 1x8 200 to 400 mesh, 2.5 kg) were weighed, and diluted to 2L in 150 mM sodium formate, pH 3.
The resin was left for several hours and then the supernatant was discarded.
After three washes as above, over two days, the resin has settled, and two volumes of 150 mM sodium formate buffer are added. The pH is measured and then it should be around 3. Kinase Buffer (KB)
The kinase buffer was composed of 50 mM HEPES pH 7.5 containing 10 mM MgCl 2 , 1 mM DTT, 3 microM NaVCh, and 0.2 mg/ml BSA.
Full length human PIM-1 was expressed and purified as described in Bullock, et al., J. Biol Chem. 2005, 280, 41675-82.
The enzyme showed linear kinetics after a step of
preactivation by autophosphorylation under the following conditions: 1.7 microM PIM1 was incubated for 1 hour at room temperature at 28°C in the presence of 125 microM ATP. Test conditions
ATP Concentration: 200 microM33P-Y-ATP: 6 nMEnzyme Concentration: 1 nMAktide Substrate Concentration (Chemical Summary Service Registration Number 324029-01-8): 25 Robotized Dowex MicroMassay1) 3x Enzyme Mixes (Made in Kinase Buffer 3X), 5 microL/well2) 3x substrate and ATP mix (made in ddH2O) together with 33P-Y~ATP, 5 microL/well3) 3x test compounds (diluted in ddH2O - 3% DMSO) - 5 microL/well
Compound dilution and testing scheme are reported below. For compound dilution and testing, see the following. Dilution of compounds
For IC50 determination, test compounds are received as a 1 mM solution in 100% DMSO and distributed in 96-well plates: compounds are then plated in the first column of a new 96-well plate (Al aGl) , 100 microL/well.
An automated station (Biomek FX, Beckman) is used for serial dilutions, producing 1:3 dilutions in 100% DMSO, from line Al to A10, for all compounds in the column. In addition, 4-5 copies of daughter plates are prepared by microL 5 reformatting this first set of 100% DMSO dilution plates into 384-deep well plates: one copy of these serial dilution plates with test compounds is thawed on the day of study, reconstituted working concentration (3 times final concentration) with 162 microL/well of water and used for IC50 determination assays. In a standard experiment, the highest (3x) concentration of compounds is typically 30 microM, while the lowest is typically 1.5 nM.
Each plate of 384 generates at least one standard staurosporine inhibitor curve and reference wells (total enzyme activity vs. no enzyme activity) for evaluation of 71 and signal to background ratio (S/B). Assay SchemeBackground Assay Plates in V-shaped 384 wells (test plates) are prepared with 5 microL of the compound dilution (3x) and then placed on a PlateTrak 12 robotic station (Perkin Elmer, the robot has 384-pipetting tips to begin the assay over 96 tips for dispensing resin), together with a reservoir for enzyme mix (3X) and one for ATP mix (3X) and one for ATP mix (3X). sigmoidal fits of ten-dilution curves for IC50 determination for confirmation/secondary assay routines.5 Method for PIM-2 Kinase Inhibition Assay: Dowex Technique Kinase Buffer (KB)
The buffer for the PIM-2 assay was composed of 50 mM HEPES pH 7.5 containing 10 mM MgCl2, 1 mM DTT, 3 microM 10 NaVCú, and 0.2 mg/ml BSA
Full length PIM-2 was expressed and purified as described in Fedorov O, et al., PNAS 2007 104, 51, 20523-28. Assay conditions (final concentrations) Enzyme concentration = 1.5 nMAktide substrate concentration ( chemistry summary service registration number 324029-01-8): 5 microMATP = 4 microM33p-Y-ATP = 1 nM20 Robotic Dowex AssaySee above: same procedure as described for PIM-1.
Table A reports the following experimental data of some representative compounds of the invention of formula (I) being tested on MPS1, PIM-1 and PIM-2 enzymes in the 25 specific in vitro kinase assays described above (IC5omicroM).
Table A also reports the inhibitory activity of some of the closest prior art compounds.
The reference compounds 1, 2, 3 and 4 correspond, respectively, to the compounds coded M3, N9, N4 and N10 of the patent application W02008/065054 cited above; these compounds correspond, respectively, to the third, fifth, seventh and sixth compound just mentioned in the present invention.

权利要求:
Claims (15)
[0001]
1. Compound, CHARACTERIZED by having the formula (I):
[0002]
2. A compound of formula (I), as defined in claim 1, CHARACTERIZED by the fact that: X is a -NR'- group and R2 is a -NHR- group, wherein R" is hydrogen or a linear group or branched, optionally substituted, selected from C1-C6 alkyl, C3-C7 cycloalkyl, cycloalkyl-alkyl, aryl, arylalkyl.
[0003]
3. Compound of formula (I), as defined in claims 1 or 2, CHARACTERIZED by the fact that: X is a -NR'- group; R2 is an -NHR" group, wherein R" is hydrogen or a linear or branched, optionally substituted group selected from a C1-C4 alkyl and aryl group.
[0004]
4. A compound of formula (I), as defined in claim 1, CHARACTERIZED by the fact that: X is a -0- group and R2 is a -NHR group".
[0005]
5. Compound of formula (I), as defined in claims 1 or 4, CHARACTERIZED by the fact that: X is an -O- group; R2 is an -NHR" group, wherein R" is hydrogen or a linear or branched, optionally substituted group selected from C1-C4 alkyl and aryl.
[0006]
6. A compound of formula (I), as defined in claim 1, CHARACTERIZED by the fact that: X is an -S- group and R2 is a -NHR group".
[0007]
7. Compound of formula (I), as defined in claims 1 or 6, CHARACTERIZED by the fact that: X is an -S- group; R2 is an -NHR" group, wherein R" is hydrogen or a linear or branched, optionally substituted group selected from C1-C4 alkyl and aryl.
[0008]
8. A compound of formula (I), as defined in claim 1, CHARACTERIZED by the fact that: X is a single bond and R2 is a -NHR group".
[0009]
9. A compound of formula (I), as defined in claim 1 or 8, CHARACTERIZED by the fact that: X is a single bond; R2 is an -NHR" group, wherein R" is hydrogen or a linear or branched, optionally substituted group selected from C1-C4 alkyl and aryl.
[0010]
10. A compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined in claim 1, CHARACTERIZED by the fact that it is selected from the group consisting of: N-(2,6-diethylphenyl)-9-(methoxymethyl)-2 -{[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]amino}-8-methyl-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxamide,2 -[(4-bromo-2-methoxyphenyl)amino]-N-(2,6-diethylphenyl)-8,9-dimethyl-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7- carboxamide,N-(2,6-diethylphenyl)-2-({2-methoxy-4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl}amino)-8,9-dimethyl-6 ,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxamide,N-(2,6-diethylphenyl)-2-({4-[4-(dimethylamino)piperidin-1-yl]- 2-methoxyphenyl}amino)-8,9-dimethyl-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxamide,N-(2,6-diethylphenyl)-2-{[2 -methoxy-4-(4-methylpiperazin-1-yl)phenyl]amino}-8,9-dimethyl-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxamide,N-( 2,6-diethylphenyl)-2-({4-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methoxyphenyl}amino)-8,9-dimethyl-6,9-dihydro-5H- pyrrolo[3,2-h]quinazoline-7-carboxamide,2-{[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]amino}-8,9-dimethyl-6,9-dihydro- 5H-pyrrole[3,2-h]quinazoline-7-carboxamide,2-[(4-bromo-2-methoxyphenyl)amino]-N-(2,6-diethylphenyl)-9-methyl-6,9-dihydro -5H-pyrrole[3,2-h]quinazoline-7-carboxamide,N-(2,6-diethylphenyl)-2-{[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]amino} -9-methyl-6,9-dihydro-5H-pyrrole[3,2-h]quinazoline-7-carboxamide,N-(2,6-diethylphenyl)-2-({4-[4-(dimethylamino)piperidine - 1-yl]-2-methoxyphenyl}amino)-9-methyl-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxamide,N-(2,6-diethylphenyl)-2 -({2-methoxy-4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl}amino)-9-methyl-6,9-dihydro-5H-pyrrole[3,2-h] quinazoline-7-carboxamide,N-(2,6-diethylphenyl)-2-[(4-{[3-(dimethylamino)propyl](methyl)amino}-2-methoxyphenyl)amino]-9-methyl-6, 9-dihydro-5H-pyrrole[3,2-h]quinazoline-7-carboxamide,N-(2,6-diethylphenyl)-2-({4-[4-(2-hydroxyethyl)piperazin-1-yl] -2-methoxyphenyl}amino)-9-methyl-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxamide,2-[(4 -bromo-2-methoxyphenyl)amino]-N-[(1S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-phenylethyl]-9-methyl- 6,9-dihydro-5H-pyrrole[3,2-h]quinazoline-7-carboxamide,2-[(4-bromo-2-methoxyphenyl)amino]-N-(2,6-diethylphenyl)-10-methyl -5,6,7,10-tetrahydropyrrole[3',2':6,7]cyclohepta[1,2-d]pyrimidine-8-carboxamide,N-(2,6-diethylphenyl)-2-{[2 -methoxy-4-(4-methylpiperazin-1-yl)phenyl]amino}-10-methyl-5,6,7,10-tetrahydropyrrole [3',2':6,7] cyclohepta [1,2-d ] pyrimidine-8-carboxamide,N-(2,6-diethylphenyl)-2-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-10-methyl-5,6 ,7,10-tetrahydropyrrole [3',2':6,7]cyclohepta[1,2-d]pyrimidine-8-carboxamide,N-(2,6-diethylphenyl)-2-({2-methoxy-4 -[4-(pyrrolidin-1yl-)piperidin-1-yl]phenyl}amino)-10-methyl-5,6,7,10-tetrahydropyrrole[3',2':6,7] cyclohepta [1,2 -d]pyrimidine-8-carboxamide, 8-methyl-2-(methylsulfanyl)-9-(propan-2-yl)-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxamide ,8-methyl-2-(methylsulfanyl)-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxamide) 2-(methyls ulfanyl)-6,9-dihydro-5H-pyrrole[3,2-h]quinazoline-7-carboxamide,2-(methylsulfanyl)-9-(propan-2-yl)-6,9-dihydro-5H-pyrrole [3,2-h]quinazoline-7-carboxamide,2-(dimethylamino)-8-methyl-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxamide,9-(2- hydroxyethyl)-8-methyl-2-(methylsulfanyl)-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxamide,9-(2-hydroxyethyl)-2-(methylsulfanyl)-6 ,9-dihydro-5H-pyrrole[3,2-h]quinazoline-7-carboxamide,2-(dimethylamino)-8-methyl-9H-pyrrolo[3,2-h]quinazoline-7-carboxamide,9-methyl -2-(methylsulfanyl)-9H-pyrrole[3,2-h]quinazoline-7-carboxamide)8-methyl-2-(methylsulfanyl)-9H-pyrrole[3,2-h]quinazoline-7-carboxamide)9 -(2-hydroxyethyl)-8-methyl-2-(methylsulfanyl)-9H-pyrrole[3,2-h]quinazoline-7-carboxamide,8-methyl-2-(methylsulfanyl)-9-(propan-2- yl)-9H-pyrrole[3,2-h]quinazoline-7-carboxamide,9-ethyl-2-(methylsulfanyl)-9H-pyrrole[3,2-h]quinazoline-7-carboxamide,2-(methylsulfanyl) -9-(piperidin-4-yl)-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-7-carboxamide,9-(cis 4-aminocyclohexyl)-2-(methylsulfanion l)-6,9-dihydro-5H-pyrrole[3,2-h]quinazoline-7-carboxamide, 9-(cis-4-aminocyclohexyl)-2-(methylsulfanyl)-9H-pyrrole[3.2 -h]quinazoline-7-carboxamide,2-(methylsulfanyl)-9-(piperidin-4-yl)-9H-pyrrole[3,2-h]quinazoline-7-carboxamide,2-(methylsulfanyl)-9H-pyrrole [3,2-h]quinazoline-7-carboxamide,2-methyl-6,9-dihydro-5H-pyrrole[3,2-h]quinazoline-7-carboxamide,9-(3-amino-2,2- dimethylpropyl)-2-(methylsulfanyl)-9H-pyrrole[3,2-h]quinazoline-7-carboxamide hydrochloride, e9-(azepan-3-yl)-2-(methylsulfanyl)-9H-pyrrole[3.2 -h]quinazoline-7-carboxamide hydrochloride.
[0011]
11. Process for preparing a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof, CHARACTERIZED in that the process comprises the following steps: Step A) reacting a compound of formula (II).
[0012]
12. Pharmaceutical composition, CHARACTERIZED in that it comprises one or more compounds of formula (I) or a pharmaceutically acceptable salt thereof, as defined in claim 1, and at least one pharmaceutically acceptable excipient, carrier and/or diluent.
[0013]
13. Product or kit, CHARACTERIZED by the fact that they comprise a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined in claim 1, or pharmaceutical compositions thereof, as defined in claim 12, and one or more chemotherapeutic agents, such as a combined preparation for simultaneous, separate or sequential use in anticancer therapy.
[0014]
14. A compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined in claim 1, CHARACTERIZED by the fact that they are used as a medicine.
[0015]
15. Use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined in claim 1, CHARACTERIZED in that it is for preparing a medicament for the treatment of cancer.

类似技术:

---

公开号 | 公开日 | 专利标题

---

JP6118383B2|2017-04-19|Tricyclic pyrrolo derivatives, their preparation and their use as kinase inhibitors

---

EP2668188B1|2016-05-18|Tricyclic derivatives, process for their preparation and their use as kinase inhibitors

---

JP5976778B2|2016-08-24|Pyrazolyl-pyrimidine derivatives as kinase inhibitors

---

KR100597505B1|2006-07-10|4-Amino-6-Phenyl-Pyrrolo[2,3-d]pyrimidine Derivatives

---

BR112019012217B1|2021-08-10|COMPOUNDS, CRYSTALLINE FORMS, PHARMACEUTICAL COMPOSITION AND USE OF A COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT

---

RU2652638C2|2018-04-28|Substituted pyrazolo-quinazoline derivatives as kinase inhibitors

---

US9333205B2|2016-05-10|Isoxazolo-quinazolines as modulators of protein kinase activity

---

KR20190020104A|2019-02-27|N- | -sulfonamide derivatives as kinase inhibitors

---

AU2005211493B2|2008-08-07|Pyrrolo pyrimidine derivatives useful for treating proliferative diseases

同族专利:

---

公开号 | 公开日

---

HK1189229A1|2014-05-30|

---

EP2668190B1|2016-08-17|

---

CN103339134A|2013-10-02|

---

US20150141408A1|2015-05-21|

---

WO2012101032A1|2012-08-02|

---

US8975267B2|2015-03-10|

---

EP2668190A1|2013-12-04|

---

RU2013139353A|2015-03-10|

---

JP5925809B2|2016-05-25|

---

JP6118383B2|2017-04-19|

---

BR112013018515A2|2016-10-18|

---

ES2602791T3|2017-02-22|

---

US20130296305A1|2013-11-07|

---

CN103339134B|2015-12-23|

---

JP2016053042A|2016-04-14|

---

US9309253B2|2016-04-12|

---

RU2591191C2|2016-07-10|

---

JP2014503567A|2014-02-13|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

IL115833A|1994-11-25|1998-10-27|Zeneca Ltd|6,6-Dihalo-3,3-dimethyl-5-hydroxy-7,7,7-trifluoroheptanoic acids and their alkyl esters useful as intermediates for insecticides and their preparation|

---

MY125533A|1999-12-06|2006-08-30|Squibb Bristol Myers Co|Heterocyclic dihydropyrimidine compounds|

---

MXPA04008130A|2002-02-19|2004-11-26|Pharmacia Corp|Tricyclic pyrazole derivatives for the treatment of inflammation.|

---

EA010904B1|2003-05-22|2008-12-30|НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л.|Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors|

---

CN1897950A|2003-10-14|2007-01-17|惠氏公司|Fused-aryl and heteroaryl derivatives and methods of their use|

---

EP2118102B1|2006-11-28|2013-06-12|Nerviano Medical Sciences S.r.l.|Tricyclic indoles and indoles|

---

AT547411T|2006-12-04|2012-03-15|Jiangsu Simcere Pharmaceutical R & D Co Ltd|3-PYRROLO-CYCLOHEXYLENE-2-DIHYDROINDOLINO DERIVATIVES AND APPLICATIONS THEREOF|

---

US8614220B2|2006-12-21|2013-12-24|Nerviano Medical Sciences S.R.L.|Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors|

---

CN101687869A|2007-07-16|2010-03-31|诺瓦提斯公司|Tetracyclic lactam derivatives as the MK2 inhibitor|

---

WO2009089305A1|2008-01-07|2009-07-16|Synta Pharmaceuticals Corp.|Compounds for inflammation and immune-related uses|

---

WO2009137492A1|2008-05-05|2009-11-12|Abbott Laboratories|Heteroaryl-fused macrocyclic pyrimidine derivatives|

---

HUE027527T2|2008-06-26|2016-10-28|Servier Lab|Pyrazolo-quinazolines as protein kinase activity modulators|

---

EP2320903B1|2008-07-29|2017-01-18|Nerviano Medical Sciences S.r.l.|THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT|

---

ES2532732T3|2008-07-29|2015-03-31|Nerviano Medical Sciences S.R.L.|Use of a CDK inhibitor for the treatment of glioma|

---

JP2012509859A|2008-11-24|2012-04-26|ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ|CDK inhibitors for the treatment of mesothelioma|

---

WO2010106028A1|2009-03-20|2010-09-23|Nerviano Medical Sciences S.R.L.|Use of a kinase inhibitor for the treatment of thymoma|

---

EP2424868B1|2009-04-29|2018-01-10|Nerviano Medical Sciences S.r.l.|Cdk inhibitor salts|

---

AR076784A1|2009-05-26|2011-07-06|Nerviano Medical Sciences Srl|THERAPEUTIC COMBINATION UNDERSTANDING A PLK1 INHIBITOR AND AN ANTINEOPLASTIC AGENT|

---

JP5851990B2|2009-07-29|2016-02-03|ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ|PLK inhibitor salt|

---

EP2598508B1|2010-07-30|2015-04-22|Nerviano Medical Sciences S.r.l.|Isoxazolo-quinazolines as modulators of protein kinase activity|

---

RU2652638C2|2010-12-17|2018-04-28|НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л.|Substituted pyrazolo-quinazoline derivatives as kinase inhibitors|

---

WO2012101032A1|2011-01-26|2012-08-02|Nerviano Medical Sciences S.R.L.|Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors|AR077468A1|2009-07-09|2011-08-31|Array Biopharma Inc|PIRAZOLO COMPOUNDSPYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS|

---

RU2652638C2|2010-12-17|2018-04-28|НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л.|Substituted pyrazolo-quinazoline derivatives as kinase inhibitors|

---

WO2012101032A1|2011-01-26|2012-08-02|Nerviano Medical Sciences S.R.L.|Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors|

---

GB201216017D0|2012-09-07|2012-10-24|Cancer Rec Tech Ltd|Inhibitor compounds|

---

GB201216018D0|2012-09-07|2012-10-24|Cancer Rec Tech Ltd|Pharmacologically active compounds|

---

WO2014110574A1|2013-01-14|2014-07-17|Incyte Corporation|Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors|

---

MX2015009057A|2013-01-15|2015-10-05|Incyte Corp|Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors.|

---

MX2016002367A|2013-08-23|2016-10-28|Incyte Corp|Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors.|

---

GB201403536D0|2014-02-28|2014-04-16|Cancer Rec Tech Ltd|Inhibitor compounds|

---

RU2692479C2|2014-04-07|2019-06-25|Недерлэндс Транслэшинал Рисерч Сентер Б.В.|pyrimido[4,5-e]indolysines|

---

US9822124B2|2014-07-14|2017-11-21|Incyte Corporation|Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors|

---

US9580418B2|2014-07-14|2017-02-28|Incyte Corporation|Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors|

---

WO2016166255A1|2015-04-17|2016-10-20|Netherlands Translational Research Center B.V.|Prognostic biomarkers for ttk inhibitor chemotherapy|

---

ITRM20150212A1|2015-05-15|2016-11-15|Univ Degli Studi Di Palermo|4,5,6,9-TETRAHYDROPYRROL [2 ', 3': 3,4] CICLOEPTA [1,2-D] ISOXAZOLES, PROCEDURE FOR THEIR PRODUCTION AND THEIR USE AS ANTI-CANCER|

---

WO2016196244A1|2015-05-29|2016-12-08|Incyte Corporation|Pyridineamine compounds useful as pim kinase inhibitors|

---

KR20180041135A|2015-07-16|2018-04-23|어레이 바이오파마 인크.|A pyrazolo [1,5-a] pyridine compound substituted as a RET kinase inhibitor|

---

TWI734699B|2015-09-09|2021-08-01|美商英塞特公司|Salts of a pim kinase inhibitor|

---

CN105130980B|2015-09-09|2018-05-22|沈阳药科大学|N-3- benzimidazole thiazole amines derivatives and preparation method and application|

---

TW201718546A|2015-10-02|2017-06-01|英塞特公司|Heterocyclic compounds useful as PIM kinase inhibitors|

---

RU2744852C2|2015-10-26|2021-03-16|Локсо Онколоджи, Инк.|Point mutations in trk inhibitor-resistant malignant tumors and related methods|

---

TN2018000335A1|2016-04-04|2020-01-16|Loxo Oncology Inc|Liquid formulations of -n--2--pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide|

---

WO2017176744A1|2016-04-04|2017-10-12|Loxo Oncology, Inc.|Methods of treating pediatric cancers|

---

US10045991B2|2016-04-04|2018-08-14|Loxo Oncology, Inc.|Methods of treating pediatric cancers|

---

PL3458456T3|2016-05-18|2021-04-19|Loxo Oncology, Inc.|Preparation of -n--2-pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide|

---

CR20190224A|2016-10-10|2019-09-30|Array Biopharma Inc|Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors|

---

TWI704148B|2016-10-10|2020-09-11|美商亞雷生物製藥股份有限公司|Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors|

---

MA45802A1|2017-06-26|2019-12-31|Loxo Oncology Inc|Process for the preparation of pyrazolo [1,5-a] pyrimidines and salts thereof|

---

WO2018136661A1|2017-01-18|2018-07-26|Andrews Steven W|SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS|

---

WO2018136663A1|2017-01-18|2018-07-26|Array Biopharma, Inc.|Ret inhibitors|

---

TN2019000263A1|2017-03-16|2021-01-07|Array Biopharma Inc|Macrocyclic compounds as ros1 kinase inhibitors|

---

JP2020513034A|2017-04-01|2020-04-30|晟科薬業（江蘇）有限公司Ｓｈｅｎｇｋｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ （Ｊｉａｎｇｓｕ） Ｌｔｄ．|1H-imidazo [4,5-H] quinazoline compounds as protein kinase inhibitors|

---

GB201709840D0|2017-06-20|2017-08-02|Inst Of Cancer Research: Royal Cancer Hospital|Methods and medical uses|

---

TW201922252A|2017-10-10|2019-06-16|美商絡速藥業公司|Formulations of 6--4-methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile|

---

TW201922741A|2017-10-10|2019-06-16|美商亞雷生物製藥股份有限公司|Crystalline forms|

---

WO2019113487A1|2017-12-08|2019-06-13|Incyte Corporation|Low dose combination therapy for treatment of myeloproliferative neoplasms|

---

CA3087354A1|2018-01-18|2019-07-25|Array Biopharma Inc.|Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors|

---

US20200339579A1|2018-01-18|2020-10-29|Array Biopharma Inc.|Substituted pyrazolyl[4,3-c]pyridine compounds as ret kinase inhibitors|

---

CA3108065A1|2018-07-31|2020-02-06|Loxo Oncology, Inc.|Spray-dried dispersions and formulations of -5-amino-3-methyl)phenyl)-1--1h-pyrazole-4-carboxamide|

---

JP2022500383A|2018-09-10|2022-01-04|アレイ バイオファーマ インコーポレイテッド|Condensed heterocyclic compound as a RET kinase inhibitor|

---

CN113490666A|2018-12-19|2021-10-08|奥瑞生物药品公司|Substituted pyrazolo [1,5-A ] pyridine compounds as inhibitors of FGFR tyrosine kinases|

---

US20220041579A1|2018-12-19|2022-02-10|Array Biopharma Inc.|Substituted quinoxaline compounds as inhibitors of fgfr tyrosine kinases|

---

WO2021023104A1|2019-08-02|2021-02-11|成都赛诺希亚生物科技有限公司|1h-[1, 2, 3]triazolo[4, 5-h] quinazoline compounds acting as protein kinase inhibitors|

---

WO2021134004A1|2019-12-27|2021-07-01|Schrodinger, Inc.|Cyclic compounds and methods of using same|

法律状态:
2018-01-16| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|

---

2018-04-03| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|

---

2019-03-19| B07E| Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |

---

2019-05-21| B06T| Formal requirements before examination [chapter 6.20 patent gazette]|

---

2021-06-01| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|

---

2021-06-29| B16A| Patent or certificate of addition of invention granted|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/01/2012, OBSERVADAS AS CONDICOES LEGAIS. |

优先权:

---

申请号 | 申请日 | 专利标题

---

EP11152190|2011-01-26|

---

EP11152190.2|2011-01-26|

---

PCT/EP2012/050773|WO2012101032A1|2011-01-26|2012-01-19|Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors|

---